5-Pyrimidinecarboxamide derivatives and methods of use thereof
Novel small molecule splicing modulators target RNA transcripts to regulate splicing, offering therapeutic benefits for genetic diseases like Huntington's and myotonic dystrophy by improving upon existing treatment limitations.
Patent Information
- Application Number
- JP2024532768
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-03
- Filing Date
- 2022-12-02
- Publication Date
- 2024-11-15
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for genetic diseases caused by splicing dysregulation, such as Huntington's disease and myotonic dystrophy, face challenges with unfavorable pharmacokinetics and delivery issues, particularly affecting the brain, and there is a need for additional small molecule splicing modulators (SMSMs) that can effectively target RNA transcripts to regulate splicing.
Development of novel small molecule splicing modulators (SMSMs) that target cis elements in RNA transcripts, including splice sites, branch points, splicing enhancers, and silencers, to regulate alternative splicing and potentially treat a variety of diseases, including neurodegenerative and repeat expansion diseases.
The SMSMs can alter the sequence or amount of mature transcripts, providing therapeutic benefits for a range of genetic disorders by modulating splicing processes and addressing the limitations of existing treatments.
Smart Images

Figure 2024542743000001_ABST
Abstract
Description
[Technical Field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to and the benefit of U.S. Provisional Application No. 63 / 285,629, filed December 3, 2021, the contents of which are incorporated herein by reference in their entirety. [Background technology]
[0002] More than 90% of human genes produce multiple mature transcripts through alternative splicing. This process is essential for generating distinct transcripts in different cell and tissue types during development and in response to internal and external signals. Alternative splicing is common not only for protein-coding genes but also for most other types of genes, including microRNA genes and long non-coding genes. Splicing is carried out by the spliceosome. Small nuclear RNAs (snRNAs) are essential components of the spliceosome. The main spliceosome, containing U1, U2, U4, U5, and U6 snRNAs, catalyzes the removal of approximately 95% of human introns. The remaining introns (called U12-type introns) are removed by smaller spliceosomes containing U11, U12, U4atac, U5, and U6atac snRNAs. These snRNAs form complexes with their respective protein partners to form the functional units of small nuclear ribonucleoproteins (snRNPs).
[0003] Splicing is a highly regulated process, regulated by both cis- and trans-factors. Cis-elements recognized by snRNAs include 5' splice sites, 3' splice sites, and branch points, each of which is associated with sequence motifs recognized by components of the spliceosome. Additionally, there are intronic splicing enhancers (ISEs), intronic splicing silencers (ISSs), exonic splicing enhancers (ESEs), and exonic splicing enhancers (ESSs), which are recognized by numerous trans-factors, commonly known as RNA-binding proteins (RBPs). Some of these RBPs directly bind to cis-elements in a sequence-specific manner, while others recognize RNA structures (e.g., RNA duplexes or unpaired loop regions), and still others function through protein-protein interactions. Approximately 1,600 RBPs have been annotated in the human genome, which are expressed in a cell-type-specific manner and form an extensive regulatory network for splicing regulation.
[0004] Dysregulation of splicing is involved in approximately half of human diseases. Some diseases are caused by mutations in spliceosome components or RBPs, while others are caused by mutations in cis-elements such as splice sites, branch points, or various splicing enhancers and silencers. Current approaches to treat these diseases, such as CRISPR-based genome editing, viral-assisted gene therapy, or various oligonucleotide-based technologies, continue to improve, but they still suffer from significant technical and clinical challenges. In particular, oligonucleotide-based therapeutics exhibit unfavorable pharmacokinetics, cannot be administered orally, and cannot be effectively delivered to many tissues, particularly the brain. Small molecule drugs, with excellent pharmacokinetics, effective delivery, and bioavailability, have only recently become available to modulate RNA splicing. However, currently available molecules represent a limited number of chemical series. Therefore, there is a great need to develop additional small molecule splicing modulators (SMSMs).
[0005] Nearly 50 genetic disorders in humans result from an increase in the number of copies of a single repeat in genomic DNA. These DNA repeats appear prone to such expansions because they have abnormal structural properties that disrupt cellular replication, repair, and recombination mechanisms. The presence of expanded DNA repeats alters gene expression in human cells, leading to disease.
[0006] One of these genetic disorders is Huntington's disease (HD). HD is a fatal neurodegenerative disorder with no cure, accompanied by cognitive impairment, dementia, and loss of motor coordination. It is characterized by a progressive and heritable increase in the length of CAG trinucleotide repeats, which encode polyglutamine expansions, in the Huntington gene (HTT) coding region. These repeats can increase from one generation to the next. Normal alleles of the HTT gene contain fewer than 36 CAG repeats, while mutant alleles contain more than 36 repeats. Most HD patients have one normal allele and one mutant allele that cause the disease. Functionally, the abnormal accumulation of CAG repeats is thought to result in a deleterious gain of function in the mutant HD protein, leading to aggregation, the formation of protein deposits (i.e., inclusion bodies), and the induction of cell death. The severity of the disease generally reflects the extent of the repeat expansion in the mutant HTT protein.
[0007] Myotonic dystrophy type 1 (DM1) and type 2 (DM2) are associated with long poly-CUG and poly-CCUG repeats in the 3'-UTR and intron 1 regions of the transcripts of myotonic dystrophy protein kinase (DMPK) and zinc finger protein 9 (ZNF9), respectively. Normal individuals have up to 30 CTG repeats, while DMI patients have higher repeat numbers, ranging from 50 to several thousand. Disease severity and age of onset correlate with the number of repeats. Adult-onset patients exhibit mild symptoms and have fewer than 100 repeats, while juvenile-onset DM1 patients have up to 500 repeats, and congenital cases typically have approximately 1,000 CTG repeats. Expanded transcripts containing CUG repeats form secondary structures, accumulate as nucleoli in the nucleus, and sequester RNA-binding proteins (RNA-BPs).
[0008] In addition to the extra copy of the repeat inherited at birth, in many repeat expansion disorders, the repeats are highly unstable, and the repeat number continues to expand throughout the patient's lifetime. Experimental studies have shown that this repeat instability is mediated by proteins in the DNA mismatch repair (MMR) process, including PMS1, MLH1, and MSH3. Human genetic data from genome-wide association studies have shown that variants in MMR proteins are associated with clinically relevant HD symptoms, including age at onset, progression rate, and somatic instability. Knockdown and knockout of MMR genes has been shown to halt or slow somatic repeat expansion in various preclinical models of repeat expansion disorders. Therefore, small molecule splicing modulators of MMR genes may be useful therapeutic agents for treating various repeat expansion disorders. Summary of the Invention [Means for solving the problem]
[0009] Here, we describe a series of novel small molecule splicing modulators (SMSMs) that can be used to treat a wide variety of diseases, including neurodegenerative and repeat expansion disorders. These SMSMs target regions of primary RNA transcripts that are cis-elements, such as splice sites, branch points, splicing enhancers, or splicing silencers. These regions may contain unpaired nucleotides in the RNA duplex, called bulges. Bulges can occur naturally or be caused by disease. When SMSMs contact an RNA transcript, they can be bound by spliceosomes or other trans-factors, most notably RNA-binding proteins (RBPs). The SMSMs reported herein can cause changes in the sequence or abundance of the mature transcript, which can result in differences in the sequence or abundance of a functional protein if the transcript is protein-coding, or in the sequence or abundance of a functional RNA if the transcript is non-coding.
[0010] In some aspects, the present disclosure provides, inter alia, a compound of formula (I): [ka] or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein: A is a saturated or partially unsaturated monocyclic, bicyclic, or tricyclic 4-14 membered heterocycloalkyl or NRR, where the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R; R1 is a -(CH2) group of 4 to 14 ring atoms, including at least one nitrogen ring atom and 0 to 2 additional ring heteroatoms independently selected from N, O, and S; 0-2 -heterocycloalkyl, and R 1 is optionally substituted with 1, 2, 3, or 4 R6; R2 is hydrogen, C 1-7 Alkyl, or C 3-8 is cycloalkyl, R3, Halo, C 1-7 Alkyl, OR5, N(R5)2, C 3-8 cycloalkyl, or heterocycloalkyl; R4 is an aryl or bicyclic 9-membered heteroaryl containing 2, 3, or 4 heteroatoms independently selected from N, O, and S, and R4 is optionally substituted with 1, 2, or 3 R7; Each R5 is independently C 1-7 Alkyl, C 1-7 Haloalkyl, C 3-8 cycloalkyl, or heterocycloalkyl; Each R6 is independently selected from hydroxy, halogen, C 1-7 Alkyl, -(CH2) 0-3 -NR a R b , C 1-7 Heteroalkyl, -(CH2) 0-3 -C 3-8 Cycloalkyl, -NR'-(CH2) 0-3 -C 3-8 Cycloalkyl, -(CH2)0-3 -heterocycloalkyl, -C(O)-heterocycloalkyl, or -O-heterocycloalkyl, wherein alkyl is selected from 1 to 4 independently selected halogen, OH, or C 1-7 cycloalkyl and heterocycloalkyl are optionally substituted with 1 to 4 independently selected C 1-7 optionally substituted with alkyl, halogen, or OH; Or two R6 together form an oxo (=O), Or two R6s together, C 1-7 alkylene to form a ring, Each R' is hydrogen or C 1-7 is alkyl, Each R7 is independently halo, cyano, C 1-7 Alkyl, C 1-7 Haloalkyl, C 1-7 Alkoxy, C 1-7 Haloalkoxy, or C 3-8 is cycloalkyl, C 1-7 alkyl is optionally substituted with OH; Each R a However, independently, H, C 1-7 Alkyl, C 1-7 Haloalkyl, or C 3-8 is cycloalkyl, Each R b However, independently, H, C 1-7 Alkyl, C 1-7 Haloalkyl, or C 3-8 or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein:
[0011] In some aspects, the disclosure provides compounds obtainable by or obtained by a method for preparing a compound described herein (e.g., a method comprising one or more steps described herein).
[0012] In some aspects, the present disclosure provides a pharmaceutical composition comprising a compound of the present disclosure, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, and a pharmaceutically acceptable diluent or carrier.
[0013] In some aspects, the present disclosure provides intermediates described herein that are suitable for use in the methods for preparing the compounds described herein (e.g., the intermediates are selected from the intermediates described herein).
[0014] In some aspects, the present disclosure provides a method of treating or preventing a disease or disorder disclosed herein in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt, solvate, or prodrug thereof, or a pharmaceutical composition of the present disclosure.
[0015] In some aspects, the present disclosure provides a method of treating a disease or disorder disclosed herein in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt, solvate, or prodrug thereof, or a pharmaceutical composition of the present disclosure.
[0016] In some aspects, the present disclosure provides a compound of the present disclosure, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, for use in the treatment or prevention of a disease or disorder disclosed herein.
[0017] In some aspects, the present disclosure provides a compound of the present disclosure, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, for use in treating a disease or disorder disclosed herein.
[0018] In some aspects, the present disclosure provides the use of a compound of the present disclosure, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, for treating or preventing a disease or disorder disclosed herein.
[0019] In some aspects, the present disclosure provides the use of a compound of the present disclosure, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, for treating a disease or disorder disclosed herein.
[0020] In some aspects, the present disclosure provides the use of a compound of the present disclosure, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, in the manufacture of a medicament for treating or preventing a disease or disorder disclosed herein.
[0021] In some aspects, the present disclosure provides the use of a compound of the present disclosure, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, in the manufacture of a medicament for treating a disease or disorder disclosed herein.
[0022] In some aspects, the disclosure provides methods of preparing the compounds of the disclosure.
[0023] In some aspects, the disclosure provides methods of preparing compounds comprising one or more of the steps described herein.
[0024] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of this disclosure, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. Additionally, the materials, methods, and examples are merely illustrative and are not intended to be limiting.
[0025] Other features and advantages of the present disclosure will become apparent from the following detailed description and claims. DETAILED DESCRIPTION OF THE INVENTION
[0026] The compounds described herein are generally designed to treat the diseases and disorders disclosed herein.
[0027] definition Unless otherwise stated, the following terms used in the specification and claims have the following meanings, as set forth below.
[0028] As used herein, "alkyl," "C1, C2, C3, C4, C5, C6, or C7 alkyl," or "C1-C7 alkyl" is intended to include C1, C2, C3, C4, C5, C6, or C7 straight-chain (straight-chain) saturated aliphatic hydrocarbon groups and C3, C4, C5, C6, or C7 branched saturated aliphatic hydrocarbon groups. For example, C1-C7 alkyl is intended to include C1, C2, C3, C4, C5, C6, and C7 alkyl groups. Examples of alkyl include moieties having 1 to 6 carbon atoms, such as, but not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, i-pentyl, or n-hexyl. In some embodiments, a straight chain or branched chain alkyl has 6 or fewer carbon atoms (e.g., C1-C7 for straight chain, C3-C7 for branched chain), and in other embodiments, a straight chain or branched chain alkyl has 4 or fewer carbon atoms.
[0029] As used herein, the term "optionally substituted alkyl" refers to an unsubstituted alkyl or an alkyl having specified substituents replacing one or more hydrogen atoms on one or more carbons of the hydrocarbon backbone. Such substituents may include, for example, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonate, phosphinate, amino (including alkylamino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl, and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfate, alkylsulfinyl, sulfonate, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocycloalkyl, alkylaryl, or aromatic or heteroaromatic moieties.
[0030] Other optionally substituted moieties (such as optionally substituted cycloalkyl, heterocycloalkyl, aryl, or heteroaryl) include both unsubstituted moieties and moieties with one or more of the specified substituents. For example, substituted heterocycloalkyls include those substituted with one or more alkyl groups, such as 2,2,6,6-tetramethyl-piperidinyl and 2,2,6,6-tetramethyl-1,2,3,6-tetrahydropyridinyl.
[0031] As used herein, the term "cycloalkyl" refers to a group having 3 to 30 carbon atoms (e.g., C3-C 12 , C3-C 10, or C3-C8), a saturated or partially unsaturated hydrocarbon monocyclic or polycyclic (e.g., fused, bridged, or spirocyclic) system. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, 1,2,3,4-tetrahydronaphthalenyl, and adamantyl. In the case of polycyclic cycloalkyl, only one of the rings in the cycloalkyl need be non-aromatic.
[0032] As used herein, the term "heterocycloalkyl" or "heterocyclyl," unless otherwise specified, refers to a saturated or partially unsaturated 3-8 membered monocyclic, 7-12 membered bicyclic (fused, bridged, or spirocyclic), or 11-14 membered tricyclic (fused, bridged, or spirocyclic) ring system having one or more heteroatoms (such as O, N, S, P, or Se) independently selected from the group consisting of nitrogen, oxygen, and sulfur, e.g., 1, or 1-2, or 1-3, or 1-4, or 1-5, or 1-6 heteroatoms, or e.g., 1, 2, 3, 4, 5, or 6 heteroatoms.Examples of heterocycloalkyl groups include piperidinyl, piperazinyl, pyrrolidinyl, dioxanyl, tetrahydrofuranyl, isoindolinyl, indolinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, triazolidinyl, oxiranyl, azetidinyl, oxetanyl, thietanyl, 1,2,3,6-tetrahydropyridinyl, tetrahydropyranyl, dihydropyranyl, pyranyl, morpholinyl, tetrahydrothiopyranyl, 1,4-diazepanyl, 1,4-Oxazepanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, 2,5-diazabicyclo[2.2.1]heptanyl, 2-oxa-6-azaspiro[3.3]heptanyl, 2,6-diazaspiro[3.3]heptanyl, 1,4-dioxa-8-azaspiro[4.5]decanyl, 1,4-dioxaspiro[4.5]decanyl, 1-oxaspiro[4.5]decanyl, 1-azaspiro[4.5]decanyl, 3'H-spiro[cyclohexane-1,1'-isobenzofuran]-yl , 7'H-spiro[cyclohexane-1,5'-furo[3,4-b]pyridin]-yl, 3'H-spiro[cyclohexane-1,1'-furo[3,4-c]pyridin]-yl, 3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[3.1.0]hexan-3-yl, 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazolyl, 3,4,5,6,7,8-hexahydropyrido[4,3-d]pyrimidinyl, 4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridinyl Examples of heterocycloalkyls include, but are not limited to, 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidinyl, 2-azaspiro[3.3]heptanyl, 2-methyl-2-azaspiro[3.3]heptanyl, 2-azaspiro[3.5]nonanyl, 2-methyl-2-azaspiro[3.5]nonanyl, 2-azaspiro[4.5]decanyl, 2-methyl-2-azaspiro[4.5]decanyl, 2-oxa-azaspiro[3.4]octanyl, 2-oxa-azaspiro[3.4]octan-6-yl, and the like. For polycyclic heterocycloalkyls, only one of the rings in the heterocycloalkyl must be non-aromatic (e.g., 4,5,6,7-tetrahydrobenzo[c]isoxazolyl).
[0033] As used herein, the term "aryl" refers to the radical of a monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 π electrons shared in a cyclic arrangement) having 6 to 14 ring carbon atoms and zero heteroatoms provided in the aromatic ring system. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, and the like. For convenience, aryl is phenyl.
[0034] As used herein, the term "heteroaryl" is intended to include a stable 5-, 6-, or 7-membered monocyclic or 7-, 8-, 9-, 10-, 11-, or 12-membered bicyclic heteroaromatic ring consisting of carbon atoms and one or more heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, e.g., 1, 1-2, 1-3, 1-4, 1-5, or 1-6 heteroatoms, or e.g., 1, 2, 3, 4, 5, or 6 heteroatoms. The nitrogen atom may be substituted or unsubstituted (i.e., N or NR, where R is H or other defined substituent). The nitrogen and sulfur heteroatoms may optionally be oxidized (i.e., N→O and S(O)). p , where p=1 or 2). Note that the total number of S and O atoms in the aromatic heterocycle is not more than 1. Examples of heteroaryl groups include pyrrole, furan, thiophene, thiazole, isothiazole, imidazole, triazole, tetrazole, pyrazole, oxazole, isoxazole, pyridine, pyrazine, pyridazine, pyrimidine, and the like. Heteroaryl groups can also be fused or bridged with alicyclic or heterocyclic rings that are not aromatic so as to form a polycyclic system (e.g., 4,5,6,7-tetrahydrobenzo[c]isoxazolyl).
[0035] Furthermore, the terms "aryl" and "heteroaryl" include polycyclic aryl and heteroaryl groups, e.g., tricyclic, bicyclic, such as naphthalene, benzoxazole, benzodioxazole, benzothiazole, benzimidazole, benzothiophene, quinoline, isoquinoline, naphtholidine, indole, benzofuran, purine, benzofuran, deazapurine, indolizine.
[0036] A cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring can have one or more ring positions (e.g., a ring-forming carbon or heteroatom such as N) bearing a substituent as described above, e.g., alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminocarbonyl, aralkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, aralkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, aminocarbonyl, The aryl and heteroaryl groups may be substituted with carboxyl, alkylthiocarbonyl, phosphate, phosphonate, phosphinate, amino (including alkylamino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl, and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfate, alkylsulfinyl, sulfonate, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocycloalkyl, alkylaryl, or aromatic or heteroaromatic moieties. Aryl and heteroaryl groups may also be fused or bridged with alicyclic or heterocyclic rings that are not aromatic so as to form polycyclic systems (e.g., tetralin, methylenedioxyphenyl such as benzo[d][1,3]dioxol-5-yl).
[0037] As used herein, the term "substituted" means that any one or more hydrogen atoms on the designated atom are replaced with a selection from the designated group, provided that the replacement does not exceed the normal valence of the designated atom, and that the substitution results in a stable compound. When the substituent is oxo or keto (i.e., =0), two hydrogen atoms on the atom are replaced. Keto substituents are not present in aromatic moieties. As used herein, a ring double bond is a double bond formed between two adjacent ring atoms (e.g., C=C, C=N, or N=N). "Stable compound" and "stable structure" are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture and formulation into an effective therapeutic agent.
[0038] When a bond to a substituent is shown to cross the bond joining two atoms in a ring, then such substituent may be bonded to any atom in the ring. When a substituent is recited without indicating the atom through which it is bonded to the remainder of the compound of a given formula, then such substituent may be bonded through any atom in such formula. Combinations of substituents and / or variables are permissible, but only if such combinations result in stable compounds.
[0039] When any variable (e.g., R) occurs more than one time in any constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown to be substituted with 0 to 2 R moieties, that group may be optionally substituted with up to 2 R moieties, and R at each occurrence is selected independently of the definition of R. Also, combinations of substituents and / or variables are permissible, but only if such combinations result in stable compounds.
[0040] As used herein, the term "hydroxy" or "hydroxyl" refers to an -OH or -O - The group includes a group having the formula:
[0041] As used herein, the term "cyano" refers to the group --CN.
[0042] As used herein, the term "halo" or "halogen" refers to fluoro, chloro, bromo, and iodo.
[0043] As used herein, the term "optionally substituted" refers to an unsubstituted group having specified substituents replacing one or more hydrogen atoms. Such substituents may include, for example, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonate, phosphinate, amino (including alkylamino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl, and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfate, alkylsulfinyl, sulfonate, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocycloalkyl, alkylaryl, or aromatic or heteroaromatic moieties.
[0044] As used herein, the term "haloalkyl" refers to an alkyl group having independently selected halogens replacing one or more hydrogen atoms. For example, C 1-7 Haloalkyl includes straight and branched chain hydrocarbons of 1 to 7 carbons with halogens replacing one or more hydrogens. Haloalkyl groups include, but are not limited to, CF, CHF, CH-CF, CHClCF, CFCF, CF(CH), CHBrCHF, and CHCHICHBr.
[0045] As used herein, the term "haloalkoxy" refers to an alkoxy structure substituted with one or more halo groups or combinations thereof. For example, the terms "fluoroalkyl" and "fluoroalkoxy" include haloalkyl and haloalkoxy groups, respectively, in which the halo is fluorine.
[0046] As used herein, the term "heteroalkyl" refers to straight-chain and branched hydrocarbons having one or more carbons replaced with heteroatoms independently selected from N, O, and S. The hydrogens bonded to the heteroatoms are adjusted according to the available valence of the substituted heteroatom. CH3 can be replaced with NH2, OH, or SH. CH2 can be replaced with NH, O, or S. CH can be replaced with N. For example, C 1-7 Heteroalkyl includes straight-chain and branched hydrocarbons of 1 to 7 carbons with one or more carbons replaced by a heteroatom independently selected from N, O, and S. Thus, a C7 heteroalkyl has fewer than 7 carbons because at least one carbon is replaced by a heteroatom. Heteroalkyl groups include, but are not limited to, alkoxy groups such as methoxy, ethoxy, and isopropoxy; mono- and dialkylamino groups such as methylamino, N,N-dimethylamino, and N-ethyl-N-methylamino; alkylthio groups such as methylthio and isopropylthio; and various other groups such as -CHOCH, -CHNH, -CHOCHCHOCH, -CHNHCHCH, -CH(OH)CHCH, -CHNHCHCHOCH, and -CHOCH(CH)CHSCH.
[0047] As used herein, "alkylene," "C, C, C, C, C, C, or C alkylene," or "C-C alkylene" is a divalent branched or straight-chain alkyl group having two open valences connecting the alkylene to two other groups. Examples of alkylene include -CH-, -CHCH-, -CHCHCH-, and -CH(CHCH)-CH-. When an alkylene connects its open valences to the same atom or to separate atoms that are already part of a chain or ring, the alkylene forms a ring together with the atom or atoms to which it is attached.
[0048] As used herein, the term "alkoxy" refers to the group -OR, where R is alkyl. Particular alkoxy groups are methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, and 1,2-dimethylbutoxy. Particular alkoxy groups are lower alkoxy, i.e., having 1 to 6 carbon atoms.
[0049] As used herein, phrases such as "one or more of A, B, or C," "one or more of A, B, and C," "one or more of A, B, and C," "one or more of A, B, and C," "one or more of A, B, and C," "selected from the group consisting of A, B, and C," "selected from A, B, and C," and the like are used interchangeably and all refer to a selection from the group consisting of A, B, and / or C, i.e., one or more A, one or more B, one or more C, or any combination thereof, unless otherwise indicated.
[0050] It is to be understood that the present disclosure provides methods for the synthesis of any compound of the formula described herein. The present disclosure also provides detailed methods for the synthesis of the various disclosed compounds of the present disclosure according to the following schemes, as well as those shown in the Examples.
[0051] It should be understood that throughout this specification, when a composition is described as having, including, or comprising particular components, it is contemplated that the composition also consists essentially of, or consists of, the recited components. Similarly, when a method or process is described as having, including, or comprising particular process steps, the process also consists essentially of, or consists of, the recited process steps. Furthermore, it should be understood that the order of steps or order for performing certain actions is immaterial so long as the invention remains operable. Moreover, two or more steps or actions may be conducted simultaneously.
[0052] It will be understood that the synthetic processes of the present disclosure can tolerate a wide variety of functional groups, and thus variously substituted starting materials can be used. The processes generally provide the desired final compound at or near the end of the overall process, although in some cases it may be desirable to further convert the compound to a pharmaceutically acceptable salt thereof.
[0053] It will be understood that the compounds of the present disclosure can be prepared in a variety of ways using commercially available starting materials, compounds known in the literature, or readily preparable intermediates by employing standard synthetic methods and procedures that are known to those skilled in the art or that will be apparent to those skilled in the art in light of the teachings herein. Standard synthetic methods and procedures for the preparation of organic molecules and functional group transformations and manipulations can be obtained from the relevant scientific literature or from standard textbooks in the field. See, for example, but not limited to, any one or more sources, Smith, MB, March, J., March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 5 th edition, John Wiley & Sons: New York, 2001, Greene, TW, Wuts, PGM, Protective Groups in Organic Synthesis, 3 rdedition, John Wiley & Sons: New York, 1999; R. Larock, Comprehensive Organic Transformations, VCH Publishers (1989); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994); and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995), are classic texts incorporated herein by reference and are useful and recognized reference texts in organic synthesis known to those skilled in the art.
[0054] Those skilled in the art will note that the order of certain steps, such as the introduction and removal of protecting groups, may be varied during the reaction sequences and synthetic schemes described herein. Those skilled in the art will recognize that certain groups may require protection from the reaction conditions through the use of protecting groups. Protecting groups may also be used to distinguish between similar functional groups in a molecule. A list of protecting groups and methods for introducing and removing these groups can be found in Greene, T.W., Wuts, P.G.M., Protective Groups in Organic Synthesis, 3 rd edition, John Wiley & Sons: New York, 1999.
[0055] Unless otherwise specified, any description of a method of treatment will be understood to include the use of the compounds to provide treatment or prophylaxis as described herein, as well as the use of the compounds to prepare a medicament for treating or preventing such conditions. Unless otherwise specified, any description of a method of treatment will be understood to include the use of the compounds to provide treatment or prophylaxis as described herein, as well as the use of the compounds to prepare a medicament for treating such conditions. Treatment includes the treatment of humans or non-human animals, including rodents and other disease models.
[0056] As used herein, the term "subject" is interchangeable with the term "subject in need thereof," and both refer to a subject having a disease or at high risk of developing a disease. "Subject" includes mammals. A mammal can be, for example, a human or a suitable non-human mammal, such as a primate, mouse, rat, dog, cat, cow, horse, goat, camel, sheep, or pig. A subject can also be a bird or poultry. In one embodiment, the mammal is a human. A subject in need thereof can be a subject previously diagnosed or identified as having a disease or disorder disclosed herein. A subject in need thereof can also be a subject suffering from a disease or disorder disclosed herein. Alternatively, a subject in need thereof can be a subject at high risk of developing such a disease or disorder compared to the general population (i.e., a subject who is prone to developing such a disorder compared to the general population). A subject in need thereof can have a refractory or resistant disease or disorder disclosed herein (i.e., a disease or disorder disclosed herein that does not respond or has not yet responded to treatment). The subject may be resistant to treatment at the beginning or may become resistant during treatment. In some embodiments, the subject in need thereof has undergone and failed all known effective treatments for the diseases or disorders disclosed herein. In some embodiments, the subject in need thereof has undergone at least one prior treatment.
[0057] As used herein, the term "treating" or "treat" describes the management and care of a subject for the purpose of combating a disease, condition, or disorder, and includes the administration of a compound of the present disclosure, or a pharmaceutically acceptable salt or solvate thereof, to alleviate the symptoms or complications of the disease, condition, or disorder, or to eliminate the disease, condition, or disorder. The term "treat" can also include the treatment of a cell in vitro or in an animal model.
[0058] It should be understood that references to "treating" or "treatment" include the alleviation of established symptoms of a condition. Thus, "treating" or "treatment" of a health condition, disorder, or condition includes (1) delaying the onset of clinical symptoms of the health condition, disorder, or condition that develop in a person who may be suffering from or predisposed to the health condition, disorder, or condition but who has not yet experienced or exhibited clinical or subclinical symptoms of the health condition, disorder, or condition; (2) inhibiting the health condition, disorder, or condition, i.e., preventing, alleviating, or delaying the onset or recurrence of the disease (in the case of maintenance treatment) or at least one clinical or subclinical symptom thereof; or (3) palliating or attenuating the disease, i.e., causing regression of the health condition, disorder, or condition, or at least one of its clinical or subclinical symptoms.
[0059] It is to be understood that the compounds of the present disclosure, or pharmaceutically acceptable salts or solvates thereof, can also be or can be used to prevent associated diseases, conditions, or disorders, or to identify suitable candidates for such purposes.
[0060] As used herein, the terms "preventing," "prevent," or "protecting against" describe reducing or eliminating the onset of symptoms or complications of such disease, condition, or disorder.
[0061] It should be understood that those skilled in the art may refer to general reference texts for detailed descriptions of known techniques described herein or equivalent techniques. These texts include Ausubel et al., Current Protocols in Molecular Biology, John Wiley and Sons, Inc. (2005); Sambrook et al., Molecular Cloning, A Laboratory Manual (3 rd edition), Cold Spring Harbor Press, Cold Spring Harbor, New York (2000), Colligan et al., Current Protocols in Immunology, John Wiley & Sons, NY, Enna et al., Current Protocols in Pharmacology, John Wiley & Sons, NY, Fingl et al., The Pharmacological Basis of Therapeutics (1975), Remington's Pharmaceutical Sciences, Mack Publishing. Co.,Easton,PA,18 th Edition (1990), which texts may, of course, be referenced when making or using aspects of the present disclosure.
[0062] It should be understood that the present disclosure also provides pharmaceutical compositions comprising any of the compounds described herein in combination with at least one pharmaceutically acceptable excipient or carrier.
[0063] As used herein, the term "pharmaceutical composition" refers to a formulation containing a compound of the present disclosure in a form suitable for administration to a subject. In one embodiment, the pharmaceutical composition is in bulk or unit dosage form. The unit dosage form may be in any of a variety of forms, including, for example, a capsule, an IV bag, a tablet, a single pump on an aerosol inhaler, or a vial. The amount of active ingredient (e.g., a formulation of the disclosed compound or its salt, hydrate, solvate, or isomer) in a unit dose composition is an effective amount and varies according to the specific treatment involved. Those skilled in the art will understand that routine variations in dosage may be necessary depending on the age and condition of the subject. Dosage also varies depending on the route of administration. Various routes are contemplated, including oral, pulmonary, rectal, parenteral, transdermal, subcutaneous, intravenous, intramuscular, intraperitoneal, inhalation, buccal, sublingual, intrapleural, intrathecal, intranasal, etc. Dosage forms for topical or transdermal administration of a compound of this disclosure include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches, and inhalants. In one embodiment, the active compound is mixed under sterile conditions with a pharmaceutically acceptable carrier, and any required preservatives, buffers, or propellants.
[0064] As used herein, the term "pharmaceutically acceptable" refers to compounds, anions, cations, materials, compositions, carriers, and / or dosage forms that are suitable for use in contact with the tissues of human beings and animals without undue toxicity, irritation, allergic response, or other problem or complication, and that are within the scope of sound medical judgment and commensurate with a reasonable benefit / risk ratio.
[0065] As used herein, the term "pharmaceutically acceptable excipient" means an excipient that is generally safe, non-toxic, and not biologically or otherwise undesirable and is useful in preparing pharmaceutical compositions, and includes excipients that are acceptable for veterinary use as well as for human pharmaceutical use. As used in the specification and claims, "pharmaceutically acceptable excipient" includes both one and more than one such excipient.
[0066] It should be understood that the pharmaceutical compositions of the present disclosure are formulated to be compatible with their intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., ingestion), inhalation, transdermal (topical), and transmucosal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application may contain the following components: a sterile diluent such as water for injection, saline, fixed oils, polyethylene glycol, glycerin, propylene glycol, or other synthetic solvents; an antimicrobial agent such as benzyl alcohol and methylparaben; an antioxidant such as ascorbic acid and sodium bisulfite; a chelating agent such as ethylenediaminetetraacetic acid; a buffer such as acetate, citrate, and phosphate; and an agent for adjusting osmolality such as sodium chloride or dextrose. pH can be adjusted with acids or bases such as hydrochloric acid or sodium hydroxide. Parenteral preparations can be enclosed in glass or plastic ampoules, disposable syringes, or multiple-dose vials.
[0067] It should be understood that the compound or pharmaceutical composition of the present disclosure can be administered to a subject by many of the well-known methods currently used in chemotherapy treatment.For example, the compound of the present disclosure can be injected into the bloodstream or body cavity, can be taken orally, or can be applied through the skin with a patch.The selected dose should be sufficient to constitute effective treatment, but not so high as to cause unacceptable side effects.The disease state (e.g., the disease or disorder disclosed herein) and the subject's health condition should be closely monitored during and for a reasonable period after treatment.
[0068] As used herein, the term "therapeutically effective amount" refers to an amount of a pharmaceutical agent that treats, ameliorates, or prevents a specified disease or condition, or that exhibits a detectable therapeutic or inhibitory effect. This effect can be detected by any assay method known in the art. The precise effective amount for a subject will vary depending on the subject's weight, size, and health, the nature and extent of the condition, and the therapeutic agent or combination of therapeutic agents selected for administration. The therapeutically effective amount for a given situation can be determined by routine experimentation, which is within the skill and judgment of the clinician.
[0069] A "therapeutically effective amount" means the amount of a compound that, when administered to a subject for treating a disease, is sufficient to effect such treatment for the disease. The "therapeutically effective amount" will vary depending on the compound, the disease and its severity, and the age, weight, etc., of the subject being treated.
[0070] It is understood that for any compound, the therapeutically effective amount can be initially estimated either in cell culture assays, e.g., tumor cells, or in animal models, usually rats, mice, rabbits, dogs, or pigs. Animal models can also be used to determine appropriate concentration ranges and routes of administration. Such information can then be used to determine useful doses and routes for administration in humans. Therapeutic / prophylactic efficacy and toxicity can be determined using standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED 50 (the dose therapeutically effective in 50% of the population) and LD 50 (the dose lethal to 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index, which can be expressed as the ratio LD 50 / ED 50 Pharmaceutical compositions that exhibit large therapeutic indices are preferred. The dosage can vary within this range depending on the dosage form used, the sensitivity of the subject, and the route of administration.
[0071] Dosage and administration are adjusted to provide sufficient levels of the active agent(s) or to maintain the desired effect. Factors that may be taken into consideration include the severity of the disease state, the subject's general health, the subject's age, weight, and sex, diet, time and frequency of administration, drug combination(s), reaction sensitivity, and tolerance / response to therapy.
[0072] The pharmaceutical composition containing the active compound of the present disclosure can be prepared by a generally known method, for example, by conventional mixing, dissolving, granulating, dragee making, suspending, emulsifying, encapsulating, encapsulating or lyophilizing process.The pharmaceutical composition can be formulated by a conventional method using one or more pharmaceutically acceptable carriers, including excipients and / or auxiliary agents that facilitate the processing of active compound into pharmaceutically usable preparations.Of course, the appropriate formulation depends on the selected route of administration.
[0073] Pharmaceutical compositions suitable for injection include sterile aqueous solutions (where water soluble) or dispersions, and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, NJ), or phosphate-buffered saline (PBS). In all cases, the composition must be sterile and fluid to the extent that easy syringability exists. The composition should be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), and suitable mixtures thereof. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it is preferable to include isotonic agents, for example, sugars, polyalcohols (such as mannitol and sorbitol), and sodium chloride in the composition. Prolonged absorption of injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, aluminum monostearate and gelatin.
[0074] Sterile injectable solution can be prepared by incorporating the required amount of active compound into a suitable solvent with one or a combination of the above-listed ingredients as needed, and then sterilize by filtration.Generally, dispersion is prepared by incorporating active compound into a sterile vehicle that contains a basic dispersion medium and other ingredients required from the above-listed ingredients.For the preparation of sterile powder for sterile injectable solution, the preparation method is vacuum drying and freeze-drying, which produces a powder containing active compound and any additional desired ingredients from its previously sterile-filtered solution.
[0075] Oral compositions generally contain an inert diluent or an edible pharmaceutically acceptable carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with an excipient and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, in which the compound in the fluid carrier is orally applied, allowed to flow in the mouth, and then expectorated or swallowed. Pharmaceutically compatible binders and / or adjuvants can be included as part of the composition. Tablets, pills, capsules, troches, etc. may contain any of the following ingredients: a binder such as microcrystalline cellulose, gum tragacanth, or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetener such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring, or compounds of a similar nature.
[0076] For administration by inhalation, the compounds can be delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, eg, a gas such as carbon dioxide, or a nebulizer.
[0077] Systemic administration can also be via transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art and include, for example, detergents, bile salts, and fusidic acid derivatives for transmucosal administration. Transmucosal administration can be achieved by using nasal sprays or suppositories. For transdermal administration, the active compound is formulated into ointments, salves, gels, or creams, as generally known in the art.
[0078] The active compounds can be prepared in pharmaceutically acceptable carriers that prevent the compound from being rapidly removed from the body, such as controlled-release formulations, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid, can be used. Methods for preparing such formulations will be apparent to those skilled in the art. Materials are also commercially available from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells using monoclonal antibodies against viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.
[0079] For ease of administration and dosage uniformity, it is particularly advantageous to formulate oral or parenteral compositions in dosage unit form.The unit dosage form used herein refers to a physically separate unit that is suitable as a unitary dosage for treating a subject; each unit contains a predetermined amount of active compound, calculated to produce desired therapeutic effect in association with required pharmaceutical carrier.The specification of the unit dosage form of the present disclosure is determined and directly depends on the unique characteristics of active compound and the specific therapeutic effect that is to be achieved.
[0080] In therapeutic applications, dosages of pharmaceutical compositions used in accordance with the present disclosure will vary depending on, among other factors, the agent, the age, weight, and clinical condition of the recipient subject, and the experience and judgment of the clinician or medical professional administering the treatment, which will affect the selected dosage. Generally, the dose should be sufficient to alleviate, preferably cause regression, and preferably cause complete regression of the symptoms of the diseases or disorders disclosed herein. An effective amount of a pharmaceutical agent is one that provides an objectively identifiable improvement as noted by a clinician or other qualified observer. Improved survival and growth indicate regression. As used herein, the term "dosage effective manner" refers to the amount of active compound to achieve a desired biological effect in a subject or cell.
[0081] It will be appreciated that the pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.
[0082] For compounds of the present disclosure that are capable of further forming salts, it should be understood that all of these forms are also contemplated within the scope of the claimed disclosure.
[0083] As used herein, the term "pharmaceutically acceptable salts" refers to derivatives of the compounds of the present disclosure, where the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, inorganic or organic acid salts of basic residues such as amines, alkali or organic salts of acidic residues such as carboxylic acids, etc. Pharmaceutically acceptable salts include conventional non-toxic salts or quaternary ammonium salts of the parent compound, formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include 2-acetoxybenzoic acid, 2-hydroxyethanesulfonic acid, acetic acid, ascorbic acid, benzenesulfonic acid, benzoic acid, bicarbonate, carbonic acid, citric acid, edetic acid, ethanedisulfonic acid, 1,2-ethanesulfonic acid, fumaric acid, glucoheptonic acid, gluconic acid, glutamic acid, glycolic acid, glycollyarsanilic acid, hexylresorcinic acid, hydrabamic acid, hydrobromic acid, hydrochloric acid, hydroiodic acid, hydroxymaleic acid, hydroxynaphthoic acid, and the like. The preferred carboxylic acids include, but are not limited to, those derived from inorganic and organic acids selected from acetic acid, isethionic acid, lactic acid, lactobionic acid, laurylsulfonic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, napsylic acid, nitric acid, oxalic acid, pamoic acid, pantothenic acid, phenylacetic acid, phosphoric acid, polygalacturonic acid, propionic acid, salicylic acid, stearic acid, subacetic acid, succinic acid, sulfamic acid, sulfanilic acid, sulfuric acid, tannic acid, tartaric acid, toluenesulfonic acid, and commonly occurring amino acids such as glycine, alanine, phenylalanine, arginine, and the like.
[0084] In some embodiments, the pharmaceutically acceptable salt is a sodium salt, a potassium salt, a calcium salt, a magnesium salt, a diethylamine salt, a choline salt, a meglumine salt, a benzathine salt, a tromethamine salt, an ammonia salt, an arginine salt, or a lysine salt.
[0085] Other examples of pharmaceutically acceptable salts include hexanoic acid, cyclopentanepropionic acid, pyruvic acid, malonic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo-[2.2.2]-oct-2-ene-1-carboxylic acid, 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, muconic acid, etc. The present disclosure also encompasses salts formed when an acidic proton present in the parent compound is replaced by a metal ion, e.g., an alkali metal ion, alkaline earth ion, or aluminum ion, or when coordinated with an organic base, e.g., ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, etc. It is understood that in the salt form, the ratio of the compound to the cation or anion of the salt can be 1:1, or any ratio other than 1:1, for example, 3:1, 2:1, 1:2, or 1:3.
[0086] It should be understood that all references to pharmaceutically acceptable salts include the solvent addition forms (solvates) of the same salt as defined herein.
[0087] The compound, or a pharmaceutically acceptable salt thereof, may be administered orally, nasally, transdermally, pulmonary, inhalation, buccal, sublingually, intraperitoneally, subcutaneously, intramuscularly, intravenously, rectally, intrapleurally, intrathecally, and parenterally. In one embodiment, the compound is administered orally. Those skilled in the art will recognize the advantages of certain routes of administration.
[0088] Salts can be formed, for example, between an anion and a positively charged group (e.g., amino) on a substituted compound disclosed herein. Suitable anions include chloride, bromide, iodide, sulfate, bisulfate, sulfamate, nitrate, phosphate, citrate, methanesulfonate, trifluoroacetate, glutamate, glucuronate, glutarate, malate, maleate, succinate, fumarate, tartrate, tosylate, salicylate, lactate, naphthalenesulfonate, and acetate (e.g., trifluoroacetate).
[0089] As used herein, the term "pharmaceutically acceptable anion" refers to an anion suitable for forming a pharmaceutically acceptable salt. Similarly, salts can also be formed between a cation on a substituted compound disclosed herein and a negatively charged group (e.g., a carboxylate). Suitable cations include sodium, potassium, magnesium, calcium, and ammonium cations such as tetramethylammonium or diethylamine. The substituted compounds disclosed herein also include salts thereof containing a quaternary nitrogen atom.
[0090] It should be understood that the compounds of the present disclosure, for example, salts of the compounds, can exist in either hydrated or non-hydrated (anhydrous) form, or as solvates with other solvent molecules. Non-limiting examples of hydrates include monohydrates, dihydrates, etc. Non-limiting examples of solvates include ethanol solvates, acetone solvates, etc.
[0091] As used herein, the term "solvate" refers to a solvent addition form that contains either stoichiometric or non-stoichiometric amounts of solvent.Some compounds have the tendency to trap a certain molar ratio of solvent molecules in the crystalline solid state, thereby forming a solvate.When the solvent is water, the solvate formed is a hydrate, and when the solvent is alcohol, the solvate formed is an alcoholate.A hydrate is formed by the combination of one or more water molecules with one molecule of a substance, where water retains its molecular state as HO.
[0092] As used herein, the term "analog" refers to a compound that is structurally similar to another but differs slightly in composition (such as the replacement of one atom with an atom of a different element or the presence of a particular functional group, or the replacement of one functional group with another). Thus, an analog is a compound that is similar or equivalent in function and appearance, but not in structure or origin, to the reference compound.
[0093] As used herein, the term "derivative" refers to compounds that have a common core structure and are substituted with various groups as described herein.
[0094] As used herein, the term "bioisostere" refers to a compound resulting from the exchange of an atom or group of atoms with another, broadly similar atom or group of atoms. The goal of bioisostere replacement is to create a new compound with similar biological properties as the parent compound. Bioisostere replacement can be physicochemically or topologically based. Examples of carboxylic acid bioisosteres include, but are not limited to, acylsulfonamides, tetrazoles, sulfonates, and phosphonates. See, e.g., Patani and LaVoie, Chem. Rev. 96, 3147-3176, 1996.
[0095] It is also to be understood that a particular compound of any one of the formulas disclosed herein can exist in solvated, e.g., hydrated, and unsolvated forms. Suitable pharmaceutically acceptable solvates are hydrates, e.g., hemihydrate, monohydrate, dihydrate, or trihydrate.
[0096] Compounds of any one of the formulas disclosed herein can exist in several different tautomeric forms, and a reference to a compound of formula (I) includes all such forms. For the avoidance of doubt, where a compound can exist in one of several tautomeric forms and only one is specifically described or shown, all other compounds are nevertheless encompassed by formula (I). Examples of tautomeric forms include keto-, enol-, and enolate-forms of the following tautomeric pairs: keto / enol (shown below), imine / enamine, amide / iminoalcohol, amidine / amidine, nitroso / oxime, thioketone / enithiol, and nitro / acintro. [ka]
[0097] Any compound of any one of the formulas disclosed herein that contains an amine functional group can also form an N-oxide. Reference herein to a compound of formula (I) that contains an amine functional group also includes an N-oxide. When a compound contains several amine functional groups, one or more nitrogen atoms can be oxidized to form an N-oxide. A specific example of an N-oxide is the N-oxide of a nitrogen atom of a tertiary amine or a nitrogen-containing heterocycle. N-oxides can be formed by treating the corresponding amine with an oxidizing agent such as hydrogen peroxide or a peracid (e.g., peroxycarboxylic acid), see, for example, Advanced Organic Chemistry, by Jerry March, 4th Edition, Wiley Interscience, pages 1977. More specifically, N-oxides can be prepared by the procedure of L.W. Deady (see, for example, Syn.Comm. 1977, 7, 509-514), which involves reacting an amine compound with meta-chloroperoxybenzoic acid (mCPBA) in an inert solvent such as dichloromethane.
[0098] The compounds of any one of the formulas disclosed herein can be administered in the form of prodrugs, which are decomposed in the human or animal body to release the compounds of the present disclosure. Prodrugs can be used to modify the physical properties and / or pharmacokinetic properties of the compounds of the present disclosure. Prodrugs can be formed when the compounds of the present disclosure contain a suitable group or substituent to which a property-modifying group can be attached. Examples of prodrugs include derivatives containing in vivo cleavable alkyl or acyl substituents in the ester or amide group of any one of the formulas disclosed herein.
[0099] As used herein, the term "isomerism" means compounds that have the same molecular formula but differ in the sequence of bonding of their atoms or the arrangement of their atoms in space. Isomers that differ in the arrangement of their atoms in space are termed "stereoisomers." Stereoisomers that are not mirror images of one another are termed "diastereomers," and stereoisomers that are non-superimposable mirror images of each other are termed "enantiomers" or sometimes optical isomers. A mixture containing equal amounts of individual optical isomeric forms of opposite chirality is termed a "racemic mixture."
[0100] As used herein, the term "chiral center" refers to a carbon atom bonded to four non-identical substituents.
[0101] As used herein, the term "chiral isomer" means a compound having at least one chiral center. Compounds having more than one chiral center can exist as individual diastereomers or as a mixture of diastereomers, termed a "diastereomeric mixture." When one chiral center is present, a stereoisomer can be characterized by the absolute configuration (R or S) of that chiral center. Absolute configuration refers to the arrangement in space of the substituents attached to the chiral center. The substituents attached to the chiral center under consideration are ranked according to the Sequence Rule of Cahn, Ingold and Prelog (Cahn et al., Angew. Chem. Inter. Edit. 1966, 5, 385; Errata 511; Cahn et al., Angew. Chem. 1966, 78, 413; Cahn and Ingold, J. Chem. Soc. 1951 (London), 612; Cahn et al., Experientia 1956, 12, 81; Cahn, J. Chem. Educ. 1964, 41, 116).
[0102] As used herein, the term "geometric isomer" refers to diastereomers that owe their existence to hindered rotation about a double bond or a cycloalkyl linker (e.g., 1,3-cyclobutyl). These configurations are distinguished in their names by the prefixes cis and trans or Z and E, which indicate whether the groups are on the same or opposite sides of a double bond in the molecule, according to the Cahn-Ingold-Prelog rules.
[0103] It is understood that the compounds of the present disclosure may be represented as different chiral or geometric isomers, and when a compound has chiral or geometric isomeric forms, all isomeric forms are intended to be included within the scope of the present disclosure, and it is understood that the naming of the compound does not mean that all isomers may have the same level of activity.
[0104] It is understood that the structures and other compounds discussed in this disclosure include all atropisomers thereof, and it is also understood that not all atropisomers may have the same level of activity.
[0105] As used herein, the term "atropisomer" refers to a type of stereoisomer in which the atoms of two isomers are arranged differently in space. Atropisomers exist because of restricted rotation of large groups around a central bond. Such atropisomers typically exist as mixtures, although recent advances in chromatography have made it possible to isolate mixtures of two atropisomers in selected cases.
[0106] As used herein, the term "tautomer" refers to one of two or more structural isomers that exist in equilibrium and are readily converted from one isomeric form to another. This conversion results in the formal migration of a hydrogen atom accompanied by the switching of adjacent conjugated double bonds. Tautomers exist as a mixture of tautomeric sets in solution. In solutions where tautomerization is possible, a chemical equilibrium of tautomers is reached. The exact ratio of tautomers depends on several factors, including temperature, solvent, and pH. The concept of tautomers that are interconvertible by tautomerism is called tautomerism. Of the various types of tautomerism possible, two are commonly observed: keto-enol tautomerism, in which a simultaneous shift of electrons and a hydrogen atom occurs. Ring-chain tautomerism occurs when an aldehyde group (-CHO) in a sugar molecule reacts with one of the hydroxyl groups (-OH) in the same molecule to give a cyclic (annular) form, such as that exhibited by glucose.
[0107] It is understood that the compounds of the present disclosure may be represented as different tautomeric forms. It is also understood that, where a compound has tautomeric forms, all tautomeric forms are intended to be included within the scope of the present disclosure, and the naming of a compound does not exclude any tautomeric form. It is understood that certain tautomers may have a higher level of activity than other tautomers.
[0108] Compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are called "isomers." Isomers that differ in the arrangement of their atoms in space are called "stereoisomers." Stereoisomers that are not mirror images of each other are called "diastereomers," and stereoisomers that are non-superimposable mirror images of each other are called "enantiomers." When a compound has an asymmetric center, for example, it is bonded to four different groups, a pair of optical isomers is possible. An optical isomer can be characterized by the absolute configuration of its asymmetric center and described by the R- and S-sequencing rules of Cahn and Prelog, or by the way the molecule rotates the plane of polarized light and is designated as dextrorotatory or levorotatory (i.e., as (+)- or (-)-isomers, respectively). Chiral compounds can exist as either individual optical isomers or as mixtures thereof. A mixture containing equal proportions of optical isomers is called a "racemic mixture."
[0109] The compounds of the present disclosure may have one or more asymmetric centers, and therefore, such compounds can be produced as individual (R)- or (S)-stereoisomers or as mixtures thereof. Unless otherwise specified, the description or naming of a particular compound in the present specification and claims is intended to include both individual optical isomers and their racemic or other mixtures. Methods for determining stereochemistry and separating stereoisomers are well known in the art, for example, by synthesis from optically active starting materials or by resolution of racemic forms (see the discussion in Chapter 4 of "Advanced Organic Chemistry," 4th edition, J. March, John Wiley and Sons, New York, 2001). Some of the compounds of the present disclosure may have geometric isomeric centers (E isomers and Z isomers).
[0110] Thus, the present disclosure includes compounds of any one of the formulas disclosed herein as defined herein when made available by organic synthesis and made available in the human or animal body by cleavage of the prodrug. Thus, the present disclosure also includes compounds of any one of the formulas disclosed herein produced by organic synthetic means, as well as such compounds produced in the human or animal body by metabolism of precursor compounds, and compounds of any one of the formulas disclosed herein can be synthetically produced compounds or metabolically produced compounds.
[0111] Suitable pharmaceutically acceptable prodrugs of a compound of any one of the formulae disclosed herein are those that, based on sound medical judgment, are suitable for administration to a subject without undesirable pharmacological activity and without undue toxicity. Various forms of prodrugs are described, for example, in the following documents: a) Methods in Enzymology, Vol. 42, pp. 309-396, edited by K. Widder et al. (Academic Press, 1985); b) Design of Prodrugs, edited by H. Bundgaard (Elsevier, 1985); c) A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen and H. Bundgaard, Chapter 5 "Design and Application of Prodrugs", by H. Bundgaard, pp. 113-191 (1991); d) H. Bundgaard, Advanced Drug Delivery Reviews, 8, 1-38 (1992); e) H. Bundgaard et al., Journal of Pharmaceutical Sciences, 77, 285 (1988); f) N. Kakeya, et al. al., Chem. Pharm. Bull., 32, 692 (1984), g) T. Higuchi and V. Stella, “Pro-Drugs as Novel Delivery Systems”, ACS Symposium Series, Volume 14, and h) E. Roche (editor), “Bioreversible Carriers in Drug Design”, Pergamon Press, 1987.
[0112] Suitable pharmaceutically acceptable prodrugs of the compounds of any one of the formulas disclosed herein having a hydroxy group are, for example, in vivo cleavable esters or ethers thereof. The in vivo cleavable esters or ethers of the compounds of any one of the formulas disclosed herein containing a hydroxy group are, for example, pharmaceutically acceptable esters or ethers that are cleaved in a subject to generate the parent hydroxy compound. Suitable pharmaceutically acceptable ester-forming groups for the hydroxy group include inorganic esters such as phosphate esters (including phosphoramido cyclic esters). Further suitable pharmaceutically acceptable ester-forming groups for the hydroxy group include C1-C esters such as acetyl, benzoyl, phenylacetyl, and substituted benzoyl and phenylacetyl groups. 10 C1-C groups such as alkanoyl groups and ethoxycarbonyl groups 10 Examples of suitable phenylacetyl and benzoyl ring substituents include aminomethyl, N-alkylaminomethyl, N,N-dialkylaminomethyl, morpholinomethyl, piperazin-1-ylmethyl, and 4-(C-C alkyl)piperazin-1-ylmethyl. Suitable pharmaceutically acceptable ether-forming groups for hydroxy groups include α-acyloxyalkyl groups such as acetoxymethyl and pivaloyloxymethyl.
[0113] Suitable pharmaceutically acceptable prodrugs of a compound of any one of the formulae disclosed herein having a carboxy group include, for example, an in vivo cleavable amide thereof, an amine such as ammonia, a C group such as methylamine, etc. 1-4Alkylamines, (C1-C4 alkyl)2 amines, for example, dimethylamine, N-ethyl-N-methylamine or diethylamine, C1-C4 alkoxy-C2-C4 alkylamines such as 2-methoxyethylamine, phenyl-C1-C4 alkylamines such as benzylamine, and amides formed with amino acids or esters thereof, such as glycine.
[0114] Suitable pharmaceutically acceptable prodrugs of a compound of any one of the formulae disclosed herein having an amino group are, for example, in vivo cleavable amide derivatives thereof. Suitable pharmaceutically acceptable amides from an amino group include, for example, C1-C2 acetyl, benzoyl, phenylacetyl, and substituted benzoyl and phenylacetyl groups. 10 Included are amides formed with alkanoyl groups. Examples of ring substituents on the phenylacetyl and benzoyl groups include aminomethyl, N-alkylaminomethyl, N,N-dialkylaminomethyl, morpholinomethyl, piperazin-1-ylmethyl, and 4-(C1-C4 alkyl)piperazin-1-ylmethyl.
[0115] The dosage regimen utilizing the compound is selected according to various factors, including the type, species, age, weight, sex, and medical condition of the subject, the severity of the condition being treated, the route of administration, the subject's renal and hepatic function, and the particular compound or salt thereof used. An ordinarily skilled physician or veterinarian can readily determine and prescribe the effective amount of the drug required to prevent, counter, or arrest the progression of the condition. An ordinarily skilled physician or veterinarian can readily determine and prescribe the effective amount of the drug required to counter or stop the progression of the condition.
[0116] Techniques for formulation and administration of the disclosed compounds of this disclosure are described in Remington: The Science and Practice of Pharmacy, 1999. thEdition, Mack Publishing Co., Easton, PA (1995). In one embodiment, the compounds described herein and their pharmaceutically acceptable salts are used in pharmaceutical preparations in combination with a pharmaceutically acceptable carrier or diluent. Suitable pharmaceutically acceptable carriers include inert solid fillers or diluents, and sterile aqueous or organic solutions. The compound is present in such pharmaceutical compositions in an amount sufficient to provide the desired dosage within the range described herein.
[0117] Unless otherwise indicated, all percentages and ratios used herein are by weight. Other features and advantages of the present disclosure are apparent from the different examples. The examples provided illustrate different components and methodologies useful for implementing the present disclosure. These examples do not limit the claimed disclosure. Based on the present disclosure, one skilled in the art can identify and employ other components and methodologies useful for implementing the present disclosure.
[0118] In the synthetic schemes described herein, compounds may be depicted in one specific configuration for simplicity. Such specific configurations should not be interpreted as limiting the present disclosure to one or more isomers, tautomers, positional isomers, or stereoisomers, nor do they exclude mixtures of isomers, tautomers, positional isomers, or stereoisomers. However, it should be understood that a given isomer, tautomer, positional isomer, or stereoisomer may have a higher level of activity than another isomer, tautomer, positional isomer, or stereoisomer.
[0119] All publications and patent documents cited herein are incorporated by reference as if each such publication or document was specifically and individually indicated to be incorporated herein by reference. Citation of publications and patent documents is not intended as an admission that any is pertinent prior art, nor does it constitute any admission as to the contents or date thereof. While the invention has now been described by way of written description, those skilled in the art will recognize that the invention can be practiced in various embodiments, and that the foregoing description and examples which follow are for purposes of illustration and not limiting the scope of the claims which follow.
[0120] As used herein, the phrase "compounds of the present disclosure" refers generically and specifically to those compounds disclosed herein.
[0121] Compounds of the Disclosure In some aspects, the present disclosure provides, inter alia, a compound of formula (I): [ka] or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein: A is a saturated or partially unsaturated monocyclic, bicyclic, or tricyclic 4-14 membered heterocycloalkyl or NRR, where the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R; R1 is a -(CH2) group of 4 to 14 ring atoms, including at least one nitrogen ring atom and 0 to 2 additional ring heteroatoms independently selected from N, O, and S; 0-2 -heterocycloalkyl, and R 1 is optionally substituted with 1, 2, 3, or 4 R6; R2 is hydrogen, C 1-7 Alkyl, or C 3-8 is cycloalkyl, R3, Halo, C 1-7 Alkyl, OR5, N(R5)2, C 3-8cycloalkyl, or heterocycloalkyl; R4 is an aryl or bicyclic 9-membered heteroaryl containing 2, 3, or 4 heteroatoms independently selected from N, O, and S, and R4 is optionally substituted with 1, 2, or 3 R7; Each R5 is independently C 1-7 Alkyl, C 1-7 Haloalkyl, C 3-8 cycloalkyl, or heterocycloalkyl; Each R6 is independently selected from hydroxy, halogen, C 1-7 Alkyl, -(CH2) 0-3 -NR a R b , C 1-7 Heteroalkyl, -(CH2) 0-3 -C 3-8 Cycloalkyl, -NR'-(CH2) 0-3 -C 3-8 Cycloalkyl, -(CH2) 0-3 -heterocycloalkyl, -C(O)-heterocycloalkyl, or -O-heterocycloalkyl, wherein alkyl is selected from 1 to 4 independently selected halogen, OH, or C 1-7 cycloalkyl and heterocycloalkyl are optionally substituted with 1 to 4 independently selected C 1-7 optionally substituted with alkyl, halogen, or OH; Or two R6 together form an oxo (=O), Or two R6s together, C 1-7 alkylene to form a ring, and each R' is hydrogen or C 1-7 is alkyl, Each R7 is independently halo, cyano, C 1-7 Alkyl, C 1-7 Haloalkyl, C 1-7 Alkoxy, C 1-7 Haloalkoxy, or C 3-8 is cycloalkyl, C 1-7 alkyl is optionally substituted with OH; each R a However, independently, H, C1-7 Alkyl, C 1-7 Haloalkyl, or C 3-8 is cycloalkyl, Each R b However, independently, H, C 1-7 Alkyl, C 1-7 Haloalkyl, or C 3-8 The compound, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, is provided, wherein:
[0122] In some aspects, the present disclosure provides a compound of formula (I): [ka] or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein: A is a saturated or partially unsaturated monocyclic or bicyclic 4-11 membered nitrogen-containing heterocycloalkyl or NRR, where the nitrogen-containing heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R; R1 is heterocycloalkyl containing one nitrogen ring atom optionally substituted with 1, 2, 3, or 4 R6; R2 is hydrogen, C 1-7 Alkyl, or C 3-8 is cycloalkyl, R3 is C 1-7 Alkyl, OR5, N(R5)2, C 3-8 cycloalkyl, or heterocycloalkyl; R4 is a bicyclic 9-membered heteroaryl containing 2, 3, or 4 heteroatoms independently selected from N and O, and R4 is optionally substituted with 1, 2, or 3 R7; Each R5 is independently C 1-7 Alkyl, C 1-7 Haloalkyl, C 3-8 cycloalkyl, or heterocycloalkyl; Each R6 is independently selected from hydroxy, halogen, C 1-7 Alkyl, -(CH2) 0-3 -NRa R b , C 1-7 Heteroalkyl, -(CH2) 0-3 -C 3-8 Cycloalkyl, -NR'-(CH2) 0-3 -C 3-8 Cycloalkyl, -(CH2) 0-3 -heterocycloalkyl, -C(O)-heterocycloalkyl, or -O-heterocycloalkyl, wherein alkyl is selected from 1 to 4 independently selected halogen, OH, or C 1-7 cycloalkyl and heterocycloalkyl are optionally substituted with 1 to 4 independently selected C 1-7 optionally substituted with alkyl, halogen, or OH; Or two R6 together form an oxo (=O), Or two R6s together, C 1-7 alkylene to form a ring, and each R' is hydrogen or C alkyl; each R7 independently represents a halo, C 1-7 Alkyl, C 1-7 Haloalkyl, C 1-7 Alkoxy, or C 1-7 haloalkoxy, Each R a However, independently, H, C 1-7 Alkyl, C 1-7 Haloalkyl, or C 3-8 is cycloalkyl, Each R b However, independently, H, C 1-7 Alkyl, C 1-7 Haloalkyl, or C 3-8 The compound, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, is provided, wherein:
[0123] In some aspects, the present disclosure provides a compound of formula (I): [ka] or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein: A is a saturated or partially unsaturated monocyclic, bicyclic, or tricyclic 4-14 membered heterocycloalkyl or NRR, where the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R; R1 is a -(CH2) group of 4 to 14 ring atoms, including at least one nitrogen ring atom and 0 to 2 additional ring heteroatoms independently selected from N, O, and S; 0-2 -heterocycloalkyl, and R 1 is optionally substituted with 1, 2, 3, or 4 R6; R2 is hydrogen, C 1-7 Alkyl, or C 3-8 is cycloalkyl, R3 is H, halo, C 1-7 Alkyl, OR5, N(R5)2, C 3-8 cycloalkyl, or heterocycloalkyl; R4 is an aryl or bicyclic 9-membered heteroaryl containing 2, 3, or 4 heteroatoms independently selected from N, O, and S, and R4 is optionally substituted with 1, 2, or 3 R7; Each R5 is independently C 1-7 Alkyl, C 3-8 cycloalkyl, or heterocycloalkyl; Each R6 is independently hydroxy, C 1-7 Alkyl, Amino, C 1-7 Heteroalkyl, -(CH2) 0-3 -C 3-8 Cycloalkyl, -NR'-(CH2) 0-3 -C 3-8 Cycloalkyl, -(CH2) 0-3 -heterocycloalkyl, -C(O)-heterocycloalkyl, or -O-heterocycloalkyl, wherein alkyl is optionally substituted with 1 to 4 independently selected halogen or OH, and cycloalkyl and heterocycloalkyl are each independently substituted with 1 to 4 independently selected C 1-7 optionally substituted with alkyl, halogen, or OH; Or two R6 together form an oxo (=O), Or two R6s together, C 1-7 alkylene to form a ring, Each R' is hydrogen or C 1-7 is alkyl, Each R7 is independently halo, cyano, C 1-7 Alkyl, C 1-7 Haloalkyl, C 1-7 Alkoxy, C 1-7 Haloalkoxy, or C 3-8 is cycloalkyl, C 1-7 Provided is the compound, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein alkyl is optionally substituted with OH.
[0124] In some aspects, the present disclosure provides a compound of formula (I): [ka] or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein: A is a saturated or partially unsaturated monocyclic, bicyclic, or tricyclic 4-14 membered heterocycloalkyl or NRR, where the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R; R1 is a -(CH2) group of 4 to 14 ring atoms, including at least one nitrogen ring atom and 0 to 2 additional ring heteroatoms independently selected from N, O, and S; 0-2 -heterocycloalkyl, and R 1 is optionally substituted with 1, 2, 3, or 4 R6; R2 is hydrogen, C 1-7 Alkyl, or C 3-8 is cycloalkyl, R3 is H, halo, C 1-7 Alkyl, OR5, N(R5)2, C 3-8 cycloalkyl, or heterocycloalkyl; R4 is a bicyclic 9-membered heteroaryl containing 2, 3, or 4 heteroatoms independently selected from N, O, and S, and R4 is optionally substituted with 1, 2, or 3 R7; Each R5 is independently C 1-7 Alkyl, C 3-8 cycloalkyl, or heterocycloalkyl; Each R6 is independently hydroxy, C 1-7 Alkyl, Amino, C 1-7 Heteroalkyl, -(CH2) 0-3 -C 3-8 Cycloalkyl, -NR'-(CH2) 0-3 -C 3-8 Cycloalkyl, -(CH2) 0-3 -heterocycloalkyl, -C(O)-heterocycloalkyl, or -O-heterocycloalkyl, wherein alkyl is optionally substituted with 1 to 4 independently selected halogen or OH, and cycloalkyl and heterocycloalkyl are each independently substituted with 1 to 4 independently selected C 1-7 optionally substituted with alkyl, halogen, or OH; Or two R6 together form an oxo (=O), Or two R6s together, C 1-7 alkylene to form a ring, Each R' is hydrogen or C 1-7 is alkyl, Each R7 is independently halo, cyano, C 1-7 Alkyl, C 1-7 Haloalkyl, C 1-7 Alkoxy, C 1-7 Haloalkoxy, or C 3-8 is cycloalkyl, C 1-7 Provided is the compound, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein alkyl is optionally substituted with OH.
[0125] In some aspects, the present disclosure provides a compound of formula (I): [ka] or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein: A is nitrogen-containing heterocycloalkyl or NRR, where the nitrogen-containing heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R; R1 is heterocycloalkyl containing one nitrogen ring atom optionally substituted with 1, 2, 3, or 4 R6; R2 is hydrogen, C 1-7 Alkyl, or C 3-8 is cycloalkyl, R3 is H, C 1-7 Alkyl, OR5, N(R5)2, C 3-8 cycloalkyl, or heterocycloalkyl; R4 is a bicyclic 9-membered heteroaryl containing 2, 3, or 4 heteroatoms independently selected from N and O, and R4 is optionally substituted with 1, 2, or 3 R7; Each R5 is independently C 1-7 Alkyl, C 3-8 cycloalkyl, or heterocycloalkyl; Each R6 is independently C 1-7 Alkyl, Amino, Amino-C 1-7 Alkyl, C 3-8 Cycloalkyl, heterocycloalkyl, and C 1-7 alkoxy-heterocycloalkyl, or two R6 together form C 1-7 Forming an alkylene each R7 independently represents a halo, C 1-7 Alkyl, C 1-7 Haloalkyl, C 1-7 Alkoxy, or C 1-7 The compound, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, is provided, wherein the compound is haloalkoxy.
[0126] For compounds of formula (I), A, R1, R2, R3, R4, R5, R6, and R7 can each be selected from the groups described herein, where applicable, and it is understood that any group described herein for any of A, R1, R2, R3, R4, R5, R6, and R7 can be combined with any group described herein for one or more of the remainder of A, R1, R2, R3, R4, R5, R6, and R7, where applicable.
[0127] In some embodiments, the compound of Formula (I) is a compound of Formula (Ia): [ka] , where the variable definitions are as indicated herein.
[0128] In some embodiments, the compound of Formula (I) is a compound of Formula (Ia): [ka] or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
[0129] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-11 membered nitrogen-containing heterocycloalkyl, and A is attached through the nitrogen of the heterocycloalkyl.
[0130] In some embodiments, the compound of Formula (I) is a compound of Formula (Ib): [ka] where the variable definitions are as indicated herein.
[0131] In some embodiments, the compound of Formula (I) is a compound of Formula (Ib): [ka] or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
[0132] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-11 membered nitrogen-containing heterocycloalkyl, and A is attached through the nitrogen of the heterocycloalkyl.
[0133] In some embodiments, the compound of Formula (I) is a compound of Formula (Ic): [ka] where the variable definitions are as indicated herein.
[0134] In some embodiments, the compound of Formula (I) is a compound of Formula (Ic): [ka] or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
[0135] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-11 membered nitrogen-containing heterocycloalkyl, and A is attached through the nitrogen of the heterocycloalkyl.
[0136] In some embodiments, the compound of Formula (I) is a compound of Formula (Id): [ka] where the variable definitions are as indicated herein.
[0137] In some embodiments, the compound of formula (I) is a compound of formula (Id): [ka] or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
[0138] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-11 membered nitrogen-containing heterocycloalkyl, and A is attached through the nitrogen of the heterocycloalkyl.
[0139] In some embodiments, A is a 4-11 membered nitrogen-containing heterocycloalkyl, the nitrogen-containing heterocycloalkyl containing 1 or 2 nitrogen ring atoms and 0-2 additional ring heteroatoms selected from O and S, and is optionally substituted with 1, 2, 3, or 4 R; Each R6 is independently C 1-7 Alkyl, -(CH2) 0-3 -NR a R b , C 3-8 cycloalkyl, or heterocycloalkyl, or two R6 taken together form C 1-7 alkylene to form a ring, Each R a are independently H or C 1-7 is alkyl, Each R b are independently H or C 1-7 It is alkyl.
[0140] In some embodiments, A is a nitrogen-containing heterocycloalkyl, the nitrogen-containing heterocycloalkyl containing 1 or 2 nitrogen ring atoms and 0-2 additional ring heteroatoms selected from O and S, and is optionally substituted with 1, 2, 3, or 4 R, each R independently being selected from C. 1-7 Alkyl, Amino, C 1-7 Alkylamino, C 3-8 cycloalkyl, or heterocycloalkyl, or two R6 taken together form C 1-7 Forms an alkylene.
[0141] In some embodiments, each R6 is independently C 1-7 alkyl, or heterocycloalkyl, or two R6 taken together form C1-7 In some embodiments, each R is independently methyl, ethyl, isopropyl, methoxy-azetidinyl, or pyrrolidinyl, or two R together form ethylene or propylene.
[0142] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-9 membered heterocycloalkyl or NR1R2, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.
[0143] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.
[0144] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms.
[0145] In some embodiments, A is a saturated monocyclic or bicyclic 4-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.
[0146] In some embodiments, A is a saturated monocyclic or bicyclic 4-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms.
[0147] In some embodiments, A is a partially unsaturated monocyclic or bicyclic 4-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.
[0148] In some embodiments, A is a partially unsaturated monocyclic or bicyclic 4-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms.
[0149] In some embodiments, A is a saturated monocyclic 4-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.
[0150] In some embodiments, A is a saturated monocyclic 4-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms.
[0151] In some embodiments, A is a partially unsaturated monocyclic 4-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.
[0152] In some embodiments, A is a partially unsaturated monocyclic 4-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms.
[0153] In some embodiments, A is a saturated bicyclic 4-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.
[0154] In some embodiments, A is a saturated bicyclic 4-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms.
[0155] In some embodiments, A is a partially unsaturated bicyclic 4-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.
[0156] In some embodiments, A is a partially unsaturated bicyclic 4-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms.
[0157] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-8 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.
[0158] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-8 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms.
[0159] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-7 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.
[0160] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-7 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms.
[0161] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-6 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.
[0162] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-6 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms.
[0163] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-5 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.
[0164] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-5 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms.
[0165] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 5-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.
[0166] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 5-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms.
[0167] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 5-8 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.
[0168] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 5-8 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms.
[0169] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 5-7 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.
[0170] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 5-7 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms.
[0171] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 6-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.
[0172] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 6-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms.
[0173] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 6-8 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.
[0174] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 6-8 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms.
[0175] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 6-7 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.
[0176] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 6-7 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms.
[0177] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 7-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.
[0178] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 7-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms.
[0179] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 7-8 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.
[0180] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 7-8 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms.
[0181] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 9-membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.
[0182] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 9-membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms.
[0183] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 8-membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.
[0184] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 8-membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms.
[0185] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 7-membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.
[0186] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 7-membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms.
[0187] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 6-membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.
[0188] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 6-membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms.
[0189] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 5-membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.
[0190] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 5-membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms.
[0191] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R6.
[0192] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms.
[0193] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is substituted with 1, 2, 3, or 4 R6.
[0194] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is substituted with 1, 2, or 3 R6.
[0195] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is substituted with 1 R6.
[0196] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is substituted with 2 R6.
[0197] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is substituted with 3 R6.
[0198] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains one nitrogen ring atom.
[0199] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains two nitrogen ring atoms.
[0200] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains one nitrogen ring atom and is optionally substituted with 1, 2, 3, or 4 R6.
[0201] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains two nitrogen ring atoms and is optionally substituted with 1, 2, or 3 R6.
[0202] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains one nitrogen ring atom and is substituted with 1, 2, 3, or 4 R6.
[0203] In some embodiments, A is a saturated or partially unsaturated monocyclic or bicyclic 4-9 membered heterocycloalkyl, wherein the heterocycloalkyl contains two nitrogen ring atoms and is substituted with 1, 2, or 3 R6.
[0204] In some embodiments, A is piperazinyl, diazepanyl, octahydropyrrolopyrazinyl, diazaspirooctanyl, pyrrolidinyl, octahydropyrrolopyrroyl, diazaspirononanyl, diazaspiroheptanyl, or diazabicyclooctanyl, each optionally substituted with 1, 2, 3, or 4 R6.
[0205] In some embodiments, A is [ka] where: Y is absent, N or CH; R9 is hydrogen, C 1-7 Alkyl, or (CH2) m -NR 14 R 15 and R 10 is hydrogen or C 1-7 is alkyl, R 11 is hydrogen or C 1-7 is alkyl, R 12 is hydrogen or C 1-7 is alkyl, R 13 is hydrogen or C 1-7 is alkyl, Each R 14 and R 15 are independently hydrogen, C 1-7 Alkyl, and C 3-8 is cycloalkyl, n is 0, 1, or 2; m is 0, 1, or 2, Or R9 and R 10 Together, C 1-7 Forming an alkylene, or Or R9 and R 12 Together, C 1-7 Forming an alkylene, or Or R 10 and R 11 Together, C 2-7 Alkylene, or C 1-7 forming a 4- to 6-membered heterocycloalkyl optionally substituted with alkyl; Or R 10 and R 12 Together, C 1-7 Alkylene, or C 1-7 forming a 4- to 6-membered heterocycloalkyl optionally substituted with alkyl; Or R 10 and R 14 Together, C 1-7 Forming an alkylene, or Or R 12 and R 13 Together, C 2-7 Forming an alkylene, or Or R 12 and R 14 Together, C 1-7 Forming an alkylene, or Or R 14 and R 15 Together, C 2-7 Forms an alkylene, which is C 1-7 Optionally substituted with alkoxy.
[0206] In some embodiments, A is [ka] and Y is absent, N or CH; R9 is hydrogen, C 1-7 Alkyl, or (CH2) m -NR 14 R 15 and R 10 C optionally substituted with hydrogen or one or more halo 1-7 is alkyl, R 11 C optionally substituted with hydrogen or one or more halo 1-7 is alkyl, R 12 C optionally substituted with hydrogen or one or more halo 1-7 is alkyl, R 13 C optionally substituted with hydrogen or one or more halo 1-7 is alkyl, Each R 14 and R 15 are independently hydrogen, C 1-7 Alkyl, and C 3-8 is cycloalkyl, n is 0, 1, or 2; m is 0, 1, or 2, Or R9 and R 10 Together, C 1-7 alkylene to form a ring, or Or R9 and R 12 Together, C 1-7 alkylene to form a ring, or Or R 10 and R 11 Together, C 2-7 Alkylene to form a ring, or C 1-7 forming a 4- to 6-membered heterocycloalkyl optionally substituted with alkyl; Or R 10 and R 12 Together, C 1-7 Alkylene to form a ring, or C 1-7 forming a 4- to 6-membered heterocycloalkyl optionally substituted with alkyl; Or R 10 and R 14 Together, C 1-7 alkylene to form a ring, or Or R 12 and R 13 Together, C 2-7 alkylene to form a ring, or Or R 12 and R 14 Together, C 1-7 alkylene to form a ring, or Or R 14 and R 15 Together, C 2-7 Alkylene forms a ring.
[0207] In some embodiments, Y is N or CH. In some embodiments, Y is absent. In some embodiments, Y is N. In some embodiments, Y is CH.
[0208] In some embodiments, R9 is hydrogen, C 1-7 Alkyl, or (CH2) m -NR 14 R 15 In some embodiments, R9 is hydrogen, pyrrolidinyl, or methoxy-azetidinyl. In some embodiments, R9 is hydrogen. In some embodiments, R9 is C 1-7 In some embodiments, R is (CH) m -NR 14 R 15 is.
[0209] In some embodiments, Y is CH and R is (CH) m -NR 14 R 15 is.
[0210] In some embodiments, R9 is -NH(CH3), -N(CH3)2, -NH(CH2CH3), -CH2NH(CH3), or -CH2N(CH3)2.
[0211] In some embodiments, R 10 is hydrogen or C 1-7 In some embodiments, R 10 is hydrogen, methyl, ethyl, or isopropyl.
[0212] In some embodiments, R 10 is hydrogen. In some embodiments, R 10 is C 1-7 It is alkyl.
[0213] In some embodiments, R 11 is hydrogen or C 1-7 In some embodiments, R 11 is hydrogen or methyl. In some embodiments, R 11 is hydrogen. In some embodiments, R 11 is C 1-7 It is alkyl.
[0214] In some embodiments, R 12 is hydrogen or C 1-7 In some embodiments, R 12 is hydrogen or methyl. In some embodiments, R 12 is hydrogen. In some embodiments, R 12 is C 1-7 It is alkyl.
[0215] In some embodiments, R 13 is hydrogen or C 1-7 In some embodiments, R 13 is hydrogen. In some embodiments, C 1-7 Alkyl.
[0216] In some embodiments, R 14 is hydrogen, C 1-7 Alkyl, or C 3-8 In some embodiments, R 14 is hydrogen. In some embodiments, R 14 is C 1-7 In some embodiments, R 14 is C 3-8 It is cycloalkyl.
[0217] In some embodiments, R 15 is hydrogen, C 1-7 Alkyl, or C 3-8 In some embodiments, R 15 is hydrogen. In some embodiments, R 15 is C 1-7 In some embodiments, R 15 is C 3-8 It is cycloalkyl.
[0218] In some embodiments, n is 0, 1, or 2. In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n is 2.
[0219] In some embodiments, m is 0, 1, or 2. In some embodiments, m is 0. In some embodiments, m is 1. In some embodiments, m is 2.
[0220] In some embodiments, R and R 10 Together, C 1-7 In some embodiments, R and R form an alkylene. 10 together to form a ring, forming propylene.
[0221] In some embodiments, R and R 12 Together, C 1-7 Forms an alkylene.
[0222] In some embodiments, R 10 and R 11 Together, C 2-7 Alkylene, or C 1-7 In some embodiments, R 10 and R 11 Together, C 2-7 In some embodiments, R 10 and R 11 together to form a ring, forming ethylene.
[0223] In some embodiments, R 10 and R 11 Together, C 1-7 In some embodiments, R 10 and R 11 Together, C 1-7 In some embodiments, R 10 and R 11 Together, C 1-7In some embodiments, R 10 and R 11 Together, C 1-7 Forms a 6-membered heterocycloalkyl optionally substituted with alkyl.
[0224] In some embodiments, R 10 and R 11 Together, C 1-7 In some embodiments, R 10 and R 11 Together, C 1-7 In some embodiments, R 10 and R 11 Together, C 1-7 In some embodiments, R 10 and R 11 Together, C 1-7 Forms a 6-membered heterocycloalkyl substituted with alkyl.
[0225] In some embodiments, R 10 and R 12 Together, C 1-7 Alkylene, or C 1-7 In some embodiments, R 10 and R 12 Together, C 1-7 Forms an alkylene.
[0226] In some embodiments, R 10 and R 12 Together, C 1-7 In some embodiments, R 10 and R 12 Together, C 1-7In some embodiments, R 10 and R 12 Together, C 1-7 In some embodiments, R 10 and R 12 Together, C 1-7 Forms a 6-membered heterocycloalkyl optionally substituted with alkyl.
[0227] In some embodiments, R 10 and R 12 Together, C 1-7 In some embodiments, R 10 and R 12 Together, C 1-7 In some embodiments, R 10 and R 12 Together, C 1-7 In some embodiments, R 10 and R 12 Together, C 1-7 Forms a 6-membered heterocycloalkyl substituted with alkyl.
[0228] In some embodiments, R 10 and R 14 Together, C 1-7 Forms an alkylene.
[0229] In some embodiments, R 12 and R 13 Together, C 2-7 Forms an alkylene.
[0230] In some embodiments, R 12 and R 14 Together, C 1-7 Forms an alkylene.
[0231] In some embodiments, R 14 and R 15 Together, C 2-7 In some embodiments, R 14 and R 15 together to form a ring, forming propylene or butylene.
[0232] In some embodiments, R 14 and R 15 Together, C 2-7 Forms an alkylene, which is C 1-7 Optionally substituted with alkoxy.
[0233] In some embodiments, R 14 and R 15 Together, C 2-7 Forms an alkylene, which is C 1-7 It is substituted with alkoxy.
[0234] In some embodiments, Y is CH and R is (CH) m -NR 14 R 15 is.
[0235] In some embodiments, R9 is hydrogen, pyrrolidinyl, or methoxy-azetidinyl.
[0236] In some embodiments, R 10 is hydrogen, methyl, ethyl, or isopropyl.
[0237] In some embodiments, R 11 is hydrogen or methyl.
[0238] In some embodiments, R 12 is hydrogen or methyl.
[0239] In some embodiments, R and R 10 together to form propylene.
[0240] In some embodiments, R 10 and R 11 together to form ethylene.
[0241] In some embodiments, R 14 and R 15 together to form propylene or butylene.
[0242] In some embodiments, A is [ka] wherein R9, R 10 , R 11 , R 12 , and R 13 is as defined above, and each R 16 are independently hydrogen or C 1-7 alkyl, each p is 0, 1, or 2, each o is 0, 1, or 2, and each A is optionally substituted with 1 or 2 R6.
[0243] In some embodiments, A is [ka] and
[0244] In the formula, R9, R 10 , R 11 , R 12 , and R 13 is as defined in any one of the preceding claims, and each R 16 are independently hydrogen or C 1-7 alkyl, each p is 0, 1, or 2, each o is 0, 1, or 2, and each A is optionally substituted with 1 or 2 R6.
[0245] In some embodiments, A is piperazinyl, diazepanyl, octahydropyrrolopyrazinyl, diazaspirooctanyl, pyrrolidinyl, octahydropyrrolopyrroyl, diazaspirononanyl, diazaspiroheptanyl, or diazabicyclooctanyl, wherein the piperazinyl, diazepanyl, octahydropyrrolopyrazinyl, diazaspirooctanyl, pyrrolidinyl, octahydropyrrolopyrroyl, diazaspirononanyl, diazaspiroheptanyl, or diazabicyclooctanyl are each optionally substituted with 1, 2, 3, or 4 R6.
[0246] In some embodiments, A is [ka] is.
[0247] In some embodiments, A is [ka] is.
[0248] In some embodiments, R 16 is hydrogen or C 1-7 In some embodiments, R 16 is hydrogen. In some embodiments, R 16 is C 1-7 It is alkyl.
[0249] In some embodiments, A is [ka] is.
[0250] In some embodiments, A is NR1R2.
[0251] In some embodiments, R1 is a heterocycloalkyl containing 1 nitrogen ring atom.
[0252] In some embodiments, R1 is a heterocycloalkyl containing 1 nitrogen ring atom, and the heterocycloalkyl is optionally substituted with 1, 2, 3, or 4 R6.
[0253] In some embodiments, R1 is a heterocycloalkyl containing 1 nitrogen ring atom, and the heterocycloalkyl is substituted with 1, 2, 3, or 4 R6.
[0254] In some embodiments, R1 is a heterocycloalkyl containing 1 nitrogen ring atom, and the heterocycloalkyl is substituted with 1, 2, or 3 R6.
[0255] In some embodiments, R1 is a heterocycloalkyl containing 1 nitrogen ring atom, and the heterocycloalkyl is substituted with 1 R6.
[0256] In some embodiments, R1 is a heterocycloalkyl containing one nitrogen ring atom, and the heterocycloalkyl is substituted with two R6.
[0257] In some embodiments, R1 is a heterocycloalkyl containing 1 nitrogen ring atom, and the heterocycloalkyl is substituted with 3 R6.
[0258] In some embodiments, R1 is a heterocycloalkyl containing 1 nitrogen ring atom, and the heterocycloalkyl is substituted with 4 R6.
[0259] In some embodiments, R2 is hydrogen, C 1-7 Alkyl, or C 3-8 It is cycloalkyl.
[0260] In some embodiments, R2 is hydrogen or C 1-7 It is alkyl.
[0261] In some embodiments, R2 is hydrogen.
[0262] In some embodiments, R2 is C 1-7 In some embodiments, R2 is alkyl. In some embodiments, R2 is methyl. In some embodiments, R2 is ethyl. In some embodiments, R2 is propyl. In some embodiments, R2 is butyl. In some embodiments, R2 is pentyl. In some embodiments, R2 is hexyl. In some embodiments, R2 is heptyl. In some embodiments, R2 is isopropyl. In some embodiments, R2 is isobutyl. In some embodiments, R2 is isopentyl. In some embodiments, R2 is isohexyl. In some embodiments, R2 is secbutyl. In some embodiments, R2 is secpentyl. In some embodiments, R2 is sechexyl. In some embodiments, R2 is tertbutyl.
[0263] In some embodiments, R2 is C 3-8 In some embodiments, R2 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl.
[0264] In some embodiments, R3 is H, halo, C 1-7 Alkyl, -OR5, -N(R5)2, C 3-8 It is cycloalkyl, or heterocycloalkyl.
[0265] In some embodiments, R3 is H, C 1-7 Alkyl, -OR5, -N(R5)2, C 3-8 It is cycloalkyl, or heterocycloalkyl.
[0266] In some embodiments, R3 is H or C 1-7 It is alkyl.
[0267] In some embodiments, R3 is H.
[0268] In some embodiments, R3 is halo. In some embodiments, R3 is F, Cl, Br, or I. In some embodiments, R3 is F, Cl, or Br. In some embodiments, R3 is F or Cl. In some embodiments, R3 is F. In some embodiments, R3 is Cl. In some embodiments, R3 is Br. In some embodiments, R3 is I.
[0269] In some embodiments, R3 is C 1-7 In some embodiments, R3 is alkyl. In some embodiments, R3 is methyl. In some embodiments, R3 is ethyl. In some embodiments, R3 is propyl. In some embodiments, R3 is butyl. In some embodiments, R3 is pentyl. In some embodiments, R3 is hexyl. In some embodiments, R3 is heptyl. In some embodiments, R3 is isopropyl. In some embodiments, R3 is isobutyl. In some embodiments, R3 is isopentyl. In some embodiments, R3 is isohexyl. In some embodiments, R3 is secbutyl. In some embodiments, R3 is secpentyl. In some embodiments, R3 is sechexyl. In some embodiments, R3 is tertbutyl.
[0270] In some embodiments, R3 is -OR5 or -N(R5)2. In some embodiments, R3 is -OR5. In some embodiments, R3 is -N(R5)2.
[0271] In some embodiments, R3 is methoxy, ethoxy, or n-propoxy. In some embodiments, R3 is methoxy. In some embodiments, R3 is ethoxy.
[0272] In some embodiments, R3 is C 3-8It is cycloalkyl or heterocycloalkyl.
[0273] In some embodiments, R3 is C 3-8 In some embodiments, R3 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl.
[0274] In some embodiments, R3 is heterocycloalkyl.
[0275] In some embodiments, R 4 is an aryl or bicyclic 9-membered heteroaryl containing 2, 3, or 4 heteroatoms independently selected from N, O, or S.
[0276] In some embodiments, R4 is an aryl or bicyclic 9-membered heteroaryl containing 2, 3, or 4 heteroatoms independently selected from N or O.
[0277] In some embodiments, R4 is aryl.
[0278] In some embodiments, R4 is aryl optionally substituted with 1, 2, or 3 R7.
[0279] In some embodiments, R4 is aryl substituted with 1, 2, or 3 R7. In some embodiments, R4 is aryl substituted with 1 R7. In some embodiments, R4 is aryl substituted with 2 R7. In some embodiments, R4 is aryl substituted with 3 R7.
[0280] In some embodiments, R4 is phenyl.
[0281] In some embodiments, R4 is phenyl optionally substituted with 1, 2, or 3 R7.
[0282] In some embodiments, R4 is phenyl substituted with 1, 2, or 3 R7. In some embodiments, R4 is phenyl substituted with 1 R7. In some embodiments, R4 is phenyl substituted with 2 R7. In some embodiments, R4 is phenyl substituted with 3 R7.
[0283] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 2, 3, or 4 heteroatoms independently selected from N, O, and S.
[0284] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 2, 3, or 4 heteroatoms independently selected from N and O.
[0285] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 2 or 3 heteroatoms independently selected from N, O, and S.
[0286] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 2 or 3 heteroatoms independently selected from N and O.
[0287] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 2, 3, or 4 heteroatoms independently selected from N, O, and S, wherein R4 is optionally substituted with 1, 2, or 3 R7.
[0288] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 2, 3, or 4 heteroatoms independently selected from N and O, wherein R4 is 1, 2, or 3 optionally substituted R7.
[0289] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 2 or 3 heteroatoms independently selected from N, O, and S, wherein R4 is optionally substituted with 1, 2, or 3 R7.
[0290] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 2 or 3 heteroatoms independently selected from N and O, wherein R4 is optionally substituted with 1, 2, or 3 R7.
[0291] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 2, 3, or 4 heteroatoms independently selected from N and O, wherein R4 is substituted with 1, 2, or 3 R7.
[0292] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 2 or 3 heteroatoms independently selected from N and O, wherein R4 is substituted with 1, 2, or 3 R7.
[0293] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 2, 3, or 4 heteroatoms independently selected from N and O, wherein R4 is substituted with 1 R7.
[0294] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 2 or 3 heteroatoms independently selected from N and O, wherein R4 is substituted with 1 R7.
[0295] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 2, 3, or 4 heteroatoms independently selected from N and O, wherein R4 is substituted with 2 R7.
[0296] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 2 or 3 heteroatoms independently selected from N and O, wherein R4 is substituted with 2 R7.
[0297] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 2, 3, or 4 heteroatoms independently selected from N and O, wherein R4 is substituted with 3 R7.
[0298] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 2 or 3 heteroatoms independently selected from N and O, wherein R4 is substituted with 3 R7.
[0299] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing two heteroatoms independently selected from N and O, wherein R4 is optionally substituted with 1, 2, or 3 R7.
[0300] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing two heteroatoms independently selected from N and O, wherein R4 is substituted with 1, 2, or 3 R7.
[0301] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing two heteroatoms independently selected from N and O, wherein R4 is substituted with one R7.
[0302] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing two heteroatoms independently selected from N and O, wherein R4 is substituted with two R7.
[0303] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing two heteroatoms independently selected from N and O, wherein R4 is substituted with three R7.
[0304] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 3 heteroatoms independently selected from N and O, wherein R4 is optionally substituted with 1, 2, or 3 R7.
[0305] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 3 heteroatoms independently selected from N and O, wherein R4 is substituted with 1, 2, or 3 R7.
[0306] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 3 heteroatoms independently selected from N and O, wherein R4 is substituted with 1 R7.
[0307] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 3 heteroatoms independently selected from N and O, wherein R4 is substituted with 2 R7.
[0308] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 3 heteroatoms independently selected from N and O, wherein R4 is substituted with 3 R7.
[0309] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 4 heteroatoms independently selected from N and O, wherein R4 is optionally substituted with 1, 2, or 3 R7.
[0310] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 4 heteroatoms independently selected from N and O, wherein R4 is substituted with 1, 2, or 3 R7.
[0311] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 4 heteroatoms independently selected from N and O, wherein R4 is substituted with 1 R7.
[0312] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 4 heteroatoms independently selected from N and O, wherein R4 is substituted with 2 R7.
[0313] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing 4 heteroatoms independently selected from N and O, wherein R4 is substituted with 3 R7.
[0314] In some embodiments, R4 is selected from imidazo[1,2-a]pyrazine, benzo[d]oxazole, or imidazo[1,2-a]pyrazine, each optionally substituted with 1, 2, 3, or 4 R7.
[0315] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing two heteroatoms independently selected from N and O, wherein R4 can be optionally substituted with 1, 2, or 3 R7.
[0316] In some embodiments, R4 is a bicyclic 9-membered heteroaryl containing two heteroatoms independently selected from N and O, wherein R4 is substituted with 1 or 2 R7.
[0317] In some embodiments, R4 is [ka] is.
[0318] In some embodiments, R4 is [ka] is.
[0319] In some embodiments, R4 is [ka] is.
[0320] In some embodiments, R4 is selected from imidazo[1,2-a]pyrazine, benzo[d]oxazole, or imidazo[1,2-a]pyrazine, wherein the imidazo[1,2-a]pyrazine, benzo[d]oxazole, or imidazo[1,2-a]pyrazine is each optionally substituted with 1, 2, 3, or 4 R7.
[0321] In some embodiments, R4 is [ka] is.
[0322] In some embodiments, R4 is [ka] is.
[0323] In some embodiments, R4 is [ka] is.
[0324] In some embodiments, each R5 is independently C 1-7 Alkyl, C 3-8 It is cycloalkyl, or heterocycloalkyl.
[0325] In some embodiments, each R5 is independently C 1-7 In some embodiments, each R is independently alkyl. In some embodiments, each R is independently methyl. In some embodiments, each R is independently ethyl. In some embodiments, each R is independently propyl. In some embodiments, each R is independently butyl. In some embodiments, each R is independently pentyl. In some embodiments, each R is independently hexyl. In some embodiments, each R is independently heptyl. In some embodiments, each R is independently isopropyl. In some embodiments, each R is independently isobutyl. In some embodiments, each R is independently isopentyl. In some embodiments, each R is independently isohexyl. In some embodiments, each R is independently secbutyl. In some embodiments, each R is independently secpentyl. In some embodiments, each R is independently sechexyl. In some embodiments, each R is independently tertbutyl.
[0326] In some embodiments, each R5 is independently C 3-8 It is cycloalkyl or heterocycloalkyl.
[0327] In some embodiments, each R5 is independently C 3-8 In some embodiments, R5 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl.
[0328] In some embodiments, each R5 is independently heterocycloalkyl.
[0329] In some embodiments, each R6 is independently C 1-7 Alkyl, Amino, C 1-7 Alkylamino, C 3-8 cycloalkyl, or heterocycloalkyl, or two R6 taken together form C 1-7 Forms an alkylene.
[0330] In some embodiments, each R6 is independently C 1-7 alkyl, or heterocycloalkyl, or two R6 taken together form C 1-7 In some embodiments, each R is independently methyl, ethyl, isopropyl, methoxy-azetidinyl, or pyrrolidinyl, or two R are taken together to form an ethylene or propylene ring.
[0331] In some embodiments, each R6 is independently -(CH2) 0-3 -NR a R b is.
[0332] In some embodiments, R a is H and R b is C 1-7 In some embodiments, R a and R bare each independently C 1-7 In some embodiments, R a and R b are each independently H.
[0333] In some embodiments, each R is independently -NH(CH), -N(CH), -NH(CHCH), -CHNH(CH), or -CHN(CH). In some embodiments, each R is independently -NH(CH). In some embodiments, each R is independently -N(CH). In some embodiments, each R is independently -NH(CHCH). In some embodiments, each R is independently -CHNH(CH). In some embodiments, each R is independently -CHN(CH).
[0334] In some embodiments, each R6 is independently C 1-7 Alkyl, Amino, C 1-7 Alkylamino, C 3-8 It is cycloalkyl, or heterocycloalkyl.
[0335] In some embodiments, each R6 is independently C 1-7In some embodiments, each R is independently alkyl. In some embodiments, each R is independently methyl. In some embodiments, each R is independently ethyl. In some embodiments, each R is independently propyl. In some embodiments, each R is independently butyl. In some embodiments, each R is independently pentyl. In some embodiments, each R is independently hexyl. In some embodiments, each R is independently heptyl. In some embodiments, each R is independently isopropyl. In some embodiments, each R is independently isobutyl. In some embodiments, each R is independently isopentyl. In some embodiments, each R is independently isohexyl. In some embodiments, each R is independently secbutyl. In some embodiments, each R is independently secpentyl. In some embodiments, each R is independently sechexyl. In some embodiments, each R is independently tertbutyl.
[0336] In some embodiments, each R6 is independently amino or amino-C 1-7 It is alkyl.
[0337] In some embodiments, each R6 is independently amino. In some embodiments, R6 is independently amino-C 1-7 It is alkyl.
[0338] In some embodiments, each R6 is independently C 3-8 Cycloalkyl, heterocycloalkyl, and C 1-7 It is an alkoxy-heterocycloalkyl.
[0339] In some embodiments, each R6 is independently C 3-8 It is cycloalkyl.
[0340] In some embodiments, each R is independently selected from heterocycloalkyl and C 1-7It is an alkoxy-heterocycloalkyl.
[0341] In some embodiments, each R is independently heterocycloalkyl. In some embodiments, each R is independently C 1-7 It is an alkoxy-heterocycloalkyl.
[0342] In some embodiments, two R6 together represent C 1-7 Forms an alkylene.
[0343] In some embodiments, each R7 is independently halo, cyano, C 1-7 Alkyl, C 1-7 Haloalkyl, C 1-7 Alkoxy C 1-7 Haloalkoxy, or C 3-8 It is cycloalkyl.
[0344] In some embodiments, each R7 is independently halo or cyano.
[0345] In some embodiments, each R7 is independently halo. In some embodiments, each R7 is independently selected from F, Cl, Br, and I. In some embodiments, each R7 is independently selected from F, Cl, or Br. In some embodiments, each R7 is independently F. In some embodiments, each R7 is independently Cl. In some embodiments, each R7 is independently Br. In some embodiments, each R7 is independently I.
[0346] In some embodiments, each R7 is independently cyano.
[0347] In some embodiments, each R7 is independently C 1-7 Alkyl, C 1-7 Haloalkyl, C 1-7 Alkoxy C 1-7 Haloalkoxy, or C 3-8 It is cycloalkyl.
[0348] In some embodiments, each R7 is independently C 1-7 Alkyl, C 1-7 Haloalkyl, C 1-7 Alkoxy, or C 1-7 It is derived from haloalkoxy.
[0349] In some embodiments, each R7 is independently C 1-7 In some embodiments, each R7 is independently alkyl. In some embodiments, each R7 is independently methyl. In some embodiments, each R7 is independently ethyl. In some embodiments, each R7 is independently propyl. In some embodiments, each R7 is independently butyl. In some embodiments, each R7 is independently pentyl. In some embodiments, each R7 is independently hexyl. In some embodiments, each R7 is independently heptyl. In some embodiments, each R7 is independently isopropyl. In some embodiments, each R7 is independently isobutyl. In some embodiments, each R7 is independently isopentyl. In some embodiments, each R7 is independently isohexyl. In some embodiments, each R7 is independently secbutyl. In some embodiments, each R7 is independently secpentyl. In some embodiments, each R7 is independently sechexyl. In some embodiments, each R7 is independently tertbutyl.
[0350] In some embodiments, each R7 is independently C optionally substituted with OH. 1-7 It is alkyl.
[0351] In some embodiments, each R7 is independently a C substituted with OH. 1-7In some embodiments, each R7 is independently methyl substituted with OH. In some embodiments, each R7 is independently ethyl substituted with OH. In some embodiments, each R7 is independently propyl substituted with OH. In some embodiments, each R7 is independently butyl substituted with OH. In some embodiments, each R7 is independently pentyl substituted with OH. In some embodiments, each R7 is independently hexyl substituted with OH. In some embodiments, each R7 is independently heptyl substituted with OH. In some embodiments, each R7 is independently isopropyl substituted with OH. In some embodiments, each R7 is independently isobutyl substituted with OH. In some embodiments, each R7 is independently isopentyl substituted with OH. In some embodiments, each R7 is independently isohexyl substituted with OH. In some embodiments, each R7 is independently secbutyl substituted with OH. In some embodiments, each R7 is independently sec-pentyl substituted with OH. In some embodiments, each R7 is independently sec-hexyl substituted with OH. In some embodiments, each R7 is independently tert-butyl substituted with OH.
[0352] In some embodiments, each R7 is independently C 1-7 Haloalkyl, C 1-7 Alkoxy, or C 1-7 It is haloalkoxy.
[0353] In some embodiments, each R7 is independently C 1-7 It is haloalkyl.
[0354] In some embodiments, each R7 is independently C 1-7 It is an alkoxy.
[0355] In some embodiments, each R7 is independently C 1-7 It is haloalkoxy.
[0356] In some embodiments, each R7 is independently C 3-8 It is cycloalkyl.
[0357] In some embodiments, the compound is selected from the compounds set forth in Table 1 and their pharmaceutically acceptable salts, solvates, or prodrugs.
[0358] In some embodiments, the compound is selected from the compounds set forth in Table 1 and their pharmaceutically acceptable salts.
[0359] In some embodiments, the compound is selected from prodrugs of the compounds set forth in Table 1 and pharmaceutically acceptable salts thereof.
[0360] In some embodiments, the compound is selected from the compounds set forth in Table 1. [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5] [Table 1-6] [Table 1-7] [Table 1-8] [Table 1-9] [Table 1-10]
Table 1-11
Table 1-12
Table 1-13
Table 1-14
Table 1-15
Table 1-16
Table 1-17
Table 1-18
Table 1-19
Table 1-20
Table 1-21
Table 1-22
Table 1-23
Table 1-24
Table 1-25
Table 1-26
Table 1-27
Table 1-28
Table 1-29
Table 1-30
Table 1-31
Table 1-32
Table 1-33
Table 1-34
Table 1-35
Table 1-36
Table 1-37
Table 1-38
Table 1-39
Table 1-40
Table 1-41
Table 1-42
Table 1-43
Table 1-44
Table 1-45
Table 1-46
Table 1-47
Table 1-48
Table 1-49
Table 1-50
Table 1-51
Table 1-52
Table 1-53
Table 1-54
Table 1-55
Table 1-56
Table 1-57
Table 1-58
Table 1-59
Table 1-60
Table 1-61
Table 1-62
Table 1-63
Table 1-64
Table 1-65
Table 1-66
Table 1-67
Table 1-68
Table 1-69
Table 1-70
Table 1-71
Table 1-72
Table 1-73
Table 1-74
Table 1-75
Table 1-76
Table 1-77
Table 1-78
Table 1-79
Table 1-80
Table 1-81
Table 1-82
Table 1-83
Table 1-84
Table 1-85
Table 1-86
Table 1-87
Table 1-88
Table 1-89
Table 1-90
Table 1-91
Table 1-92
Table 1-93
Table 1-94
Table 1-95
[0361] For the avoidance of doubt, it is to be understood that, as used herein, when a group is modified by "as described herein," that group encompasses the broadest definition on the first occurrence, as well as each and every specific definition for that group.
[0362] The various functional groups and substituents comprising the compound of formula (I) are typically selected so that the molecular weight of the compound does not exceed 1000 daltons. More typically, the molecular weight of the compound is less than 900, e.g., less than 800, or less than 750, or less than 700, or less than 650 daltons. More conveniently, the molecular weight is less than 600, e.g., 550 daltons or less.
[0363] It will be understood that the compounds of any one of the formulae disclosed herein, and any pharmaceutically acceptable salts thereof, include all isomeric forms of stereoisomers and mixtures of stereoisomers of the compounds.
[0364] It should be understood that compounds of any formula described herein include the compound itself, as well as salts thereof, and solvates thereof, if applicable.
[0365] The in vivo effects of any one of the compounds of the formulas disclosed herein may be exerted in part by one or more metabolic products formed in the human or animal body after administration of any one of the compounds of the formulas disclosed herein.As described herein, the in vivo effects of any one of the compounds of the formulas disclosed herein may also be exerted by the metabolism of a precursor compound (prodrug).
[0366] Preferably, the present disclosure excludes any individual compound that does not have biological activity as defined herein.
[0367] Synthesis method By way of example only, schemes for preparing the small molecule splicing modulators (SMSMs) described herein are provided.
[0368] In some embodiments, a scheme for preparing SMSM is set forth herein in Scheme 1 below. [ka]
[0369] In some aspects, the disclosure provides methods of preparing the compounds of the disclosure.
[0370] In some aspects, the disclosure provides methods of preparing compounds comprising one or more of the steps described herein.
[0371] In some aspects, the disclosure provides compounds that are obtainable by, obtained by, or obtained directly by the methods for preparing the compounds described herein.
[0372] In some aspects, the present disclosure provides intermediates described herein that are suitable for use in the methods for preparing the compounds described herein.
[0373] The compounds of the present disclosure may be prepared by any suitable technique known in the art. Specific processes for preparing these compounds are further described in the accompanying Examples.
[0374] In the descriptions of synthetic methods described herein and in any reference synthetic methods used to prepare starting materials, it is understood that all proposed reaction conditions, including choice of solvent, reaction atmosphere, reaction temperature, duration of experiment, and work-up procedures, can be selected by one of ordinary skill in the art.
[0375] One skilled in the art of organic synthesis understands that the functionality present on various portions of the molecule must be compatible with the reagents and reaction conditions employed.
[0376] It will be understood that during the synthesis of the compounds of the present disclosure in the processes defined herein, or during the synthesis of certain starting materials, it may be desirable to protect certain substituents to prevent their undesired reactions. Those skilled in the art will understand when such protection is necessary and how such protecting groups can be introduced and subsequently removed. For examples of protecting groups, see one of the many general textbooks on this subject, for example, "Protective Groups in Organic Synthesis" by Theodora Green (Publisher: John Wiley & Sons). Protecting groups may be removed by any convenient method described in the literature or known to chemists of ordinary skill as suitable for removing the protecting group in question, and such methods will be selected to remove the protecting group while minimizing interference with groups elsewhere in the molecule. Thus, when reactants contain groups such as amino, carboxy, or hydroxy, it may be desirable to protect the group in some of the reactions described herein.
[0377] For example, suitable protecting groups for amino or alkylamino groups include, for example, acyl groups, such as alkanoyl groups (e.g., acetyl), alkoxycarbonyl groups (e.g., methoxycarbonyl, ethoxycarbonyl, or t-butoxycarbonyl), arylmethoxycarbonyl groups (e.g., benzyloxycarbonyl), or aroyl groups (e.g., benzoyl). The deprotection conditions for the above-mentioned protecting groups necessarily vary depending on the choice of protecting group. Thus, for example, acyl groups or aroyl groups, such as alkanoyl or alkoxycarbonyl groups, can be removed by hydrolysis using a suitable base, such as an alkali metal hydroxide, for example, lithium hydroxide or sodium hydroxide. Alternatively, acyl groups such as tert-butoxycarbonyl groups may be removed by treatment with a suitable acid, for example hydrochloric, sulfuric or phosphoric acid, or trifluoroacetic acid, and arylmethoxycarbonyl groups (such as benzyloxycarbonyl groups) may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid, for example boron tris(trifluoroacetate). A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or hydrazine.
[0378] Suitable protecting groups for hydroxyl groups include, for example, acyl groups, such as alkanoyl groups (e.g., acetyl), aroyl groups (e.g., benzoyl), or arylmethyl groups (e.g., benzyl). The deprotection conditions for the above-mentioned protecting groups necessarily vary depending on the choice of protecting group. Thus, for example, acyl groups, such as alkanoyl or aroyl groups, can be removed by hydrolysis using a suitable base, such as an alkali metal hydroxide, for example, lithium, sodium hydroxide, or ammonia. Alternatively, arylmethyl groups, such as benzyl groups, can be removed by hydrogenation over a catalyst, such as palladium on carbon.
[0379] A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or ethyl group, which may be removed by hydrolysis with a base such as sodium hydroxide, or for example a tert-butyl group, which may be removed by treatment with an acid, for example an organic acid, such as trifluoroacetic acid, or for example a benzyl group, which may be removed by hydrogenation over a catalyst such as palladium on carbon.
[0380] Once a compound of formula (I) has been synthesized by any one of the processes defined herein, the process may then further comprise the additional steps of (i) removing any protecting groups present, (ii) converting the compound of formula (I) to another compound of formula (I), (iii) forming a pharmaceutically acceptable salt, hydrate, or solvate thereof, and / or (iv) forming a prodrug thereof.
[0381] The resulting compound of formula (I) can be isolated and purified using techniques well known in the art.
[0382] The reaction of the compounds is advantageously carried out in the presence of a suitable solvent, preferably inert under the respective reaction conditions. Examples of suitable solvents include hydrocarbons such as hexane, petroleum ether, benzene, toluene, or xylene; chlorinated hydrocarbons such as trichloroethylene, 1,2-dichloroethane, tetrachloromethane, chloroform, or dichloromethane; alcohols such as methanol, ethanol, isopropanol, n-propanol, n-butanol, or tert-butanol; ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF), 2-methyltetrahydrofuran, cyclopentyl methyl ether (CPME), methyl tert-butyl ether (MTBE), or dioxane; ethylene glycol ethers, propylene ... Examples of suitable solvents include, but are not limited to, glycol ethers such as ethanol monomethyl or monoethyl ether, or ethylene glycol dimethyl ether (diglyme); ketones such as acetone, methyl isobutyl ketone (MIBK) or butanone; amides such as acetylamide, dimethylacetylamide, dimethylformamide (DMF) or N-methylpyrrolidinone (NMP); nitriles such as acetonitrile; sulfoxides such as dimethyl sulfoxide (DMSO); nitro compounds such as nitromethane or nitrobenzene; esters such as ethyl acetate or methyl acetate; or mixtures of such solvents, or mixtures with water.
[0383] The reaction temperature is preferably between about -100°C and 300°C, depending on the reaction step and conditions used.
[0384] The reaction time generally ranges from 1 minute to several days, depending on the reactivity of each compound and the reaction conditions. Suitable reaction times can be easily determined by methods known in the art, such as reaction monitoring. Based on the reaction temperature described above, suitable reaction times are generally within the range of 10 minutes to 48 hours.
[0385] Moreover, by utilizing the procedures described herein, in conjunction with ordinary skill in the art, additional compounds of the present disclosure can be readily prepared. Those skilled in the art will readily understand that known variations of the conditions and processes of the following preparative procedures can be used to prepare these compounds. As will be appreciated by those skilled in the art of organic synthesis, the compounds of the present disclosure are readily accessible by a variety of synthetic routes, some of which are illustrated in the accompanying examples. Those skilled in the art will readily recognize what types of reagents and reaction conditions to use and how to apply and adapt them, whenever necessary or useful, to obtain compounds of the present disclosure. Furthermore, some of the compounds of the present disclosure can be readily synthesized by reacting other compounds of the present disclosure under suitable conditions, for example, by applying standard synthetic methods such as reduction, oxidation, addition, or substitution reactions, to convert one specific functional group present in a compound of the present disclosure or a suitable precursor molecule to another functional group, which methods are well known to those skilled in the art. Similarly, those skilled in the art will apply synthetic protecting (or protecting) groups whenever necessary or useful. Suitable protecting groups, as well as methods for introducing and removing them, are well known to those skilled in the art of chemical synthesis and are described in more detail, for example, in P.G.M.Wuts, T.W. Greene, "Greene's Protective Groups in Organic Synthesis," 4th edition (2006) (John Wiley & Sons).
[0386] General routes for preparing the compounds of the present application are described herein.
[0387] Biological assays Once produced, compounds designed, selected, and / or optimized by the above methods can be characterized using a variety of assays known to those of skill in the art to determine whether the compounds have biological activity. For example, molecules can be characterized by conventional assays, including but not limited to, the assays described below, to determine whether they have the predicted activity, binding activity, and / or binding specificity.
[0388] Pharmaceutical Compositions
[0389] In some aspects, the present disclosure provides pharmaceutical compositions comprising a compound of the present disclosure as an active ingredient. In some embodiments, the present disclosure provides pharmaceutical compositions comprising at least one compound of each of the formulas described herein, or a pharmaceutically acceptable salt or solvate thereof, and one or more pharmaceutically acceptable carriers or excipients. In some embodiments, the present disclosure provides pharmaceutical compositions comprising at least one compound selected from Table 1.
[0390] As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product resulting directly or indirectly from combining the specified ingredients in the specified amounts. The compounds of the present disclosure can be formulated for oral administration in the form of tablets, capsules (each of which includes sustained- or time-release formulations), pills, powders, granules, elixirs, tinctures, suspensions, syrups, emulsions, etc. The compounds of the present disclosure can also be formulated for intravenous (bolus or intrafusion), intraperitoneal, topical, subcutaneous, intramuscular, or transdermal (e.g., patch) administration, all using forms well known to those of ordinary skill in the pharmaceutical arts.
[0391] The formulation of the present disclosure may be in the form of an aqueous solution containing an aqueous vehicle. The aqueous vehicle component may include water and at least one pharmaceutically acceptable excipient. Suitable acceptable excipients include those selected from the group consisting of solubility enhancers, chelating agents, preservatives, isotonicity agents, viscosity / suspending agents, buffers, and pH adjusters, and mixtures thereof.
[0392] Any suitable solubility enhancer can be used. Examples of solubility enhancers include cyclodextrins such as those selected from the group consisting of hydroxypropyl-β-cyclodextrin, methyl-β-cyclodextrin, randomly methylated-β-cyclodextrin, ethylated-β-cyclodextrin, triacetyl-β-cyclodextrin, peracetylated-β-cyclodextrin, carboxymethyl-β-cyclodextrin, hydroxyethyl-β-cyclodextrin, 2-hydroxy-3-(trimethylammonio)propyl-β-cyclodextrin, glucosyl-β-cyclodextrin, sulfated-β-cyclodextrin (S-β-CD), maltosyl-β-cyclodextrin, β-cyclodextrin, sulfobutyl ether, branched-β-cyclodextrin, hydroxypropyl-γ-cyclodextrin, randomly methylated-γ-cyclodextrin, and trimethyl-γ-cyclodextrin, and mixtures thereof.
[0393] Any suitable chelating agent can be used, examples of suitable chelating agents include those selected from the group consisting of ethylenediaminetetraacetic acid and its metal salts, edetate disodium, edetate trisodium, and edetate tetrasodium, and mixtures thereof. Any suitable preservative can be used. Examples of preservatives include those selected from the group consisting of quaternary ammonium salts such as benzalkonium halides (preferably benzalkonium chloride), chlorhexidine gluconate, benzethonium chloride, cetylpyridinium chloride, benzyl bromide, phenylmercuric nitrate, phenylmercuric acetate, phenylmercuric neodecanoate, merthiolate, methylparaben, propylparaben, sorbic acid, potassium sorbate, sodium benzoate, sodium propionate, ethyl p-hydroxybenzoate, propylaminopropyl biguanide, and butyl-p-hydroxybenzoate, and sorbic acid, and mixtures thereof.
[0394] The aqueous vehicle may also contain a tonicity agent to adjust tonicity (osmotic pressure), which may be selected from the group consisting of glycols (such as propylene glycol, diethylene glycol, triethylene glycol), glycerol, dextrose, glycerin, mannitol, potassium chloride, and sodium chloride, and mixtures thereof.
[0395] The aqueous vehicle may also contain a viscosity / suspending agent. Suitable viscosity / suspending agents include those selected from the group consisting of cellulose derivatives such as methylcellulose, ethylcellulose, hydroxyethylcellulose, polyethylene glycol (such as polyethylene glycol 300, polyethylene glycol 400), carboxymethylcellulose, hydroxypropylmethylcellulose, and crosslinked acrylic acid polymers (carbomers), such as acrylic acid polymers crosslinked with polyalkenyl ethers or divinyl glycol (Carbopols—e.g., Carbopol 934, Carbopol 934P, Carbopol 971, Carbopol 974, and Carbopol 974P), and mixtures thereof.
[0396] To adjust the formulation to an acceptable pH (typically in the pH range of about 5.0 to about 9.0, more preferably about 5.5 to about 8.5, particularly about 6.0 to about 8.5, about 7.0 to about 8.5, about 7.2 to about 7.7, about 7.1 to about 7.9, or about 7.5 to about 8.0), the formulation may contain a pH modifier. The pH modifier is typically a mineral acid or metal hydroxide base selected from potassium hydroxide, sodium hydroxide, and hydrochloric acid, and mixtures thereof, preferably sodium hydroxide and / or hydrochloric acid. These acidic and / or basic pH modifiers are added to adjust the formulation to a target acceptable pH range. Therefore, depending on the formulation, it may not be necessary to use both an acid and a base; adding one of the acids or bases may be sufficient to bring the mixture to the desired pH range.
[0397] The aqueous vehicle may also contain a buffering agent to stabilize the pH. If used, the buffer is selected from the group consisting of phosphate buffers (such as sodium dihydrogen phosphate and disodium hydrogen phosphate), borate buffers (such as boric acid or salts thereof including disodium tetraborate), citrate buffers (such as citric acid or salts thereof including sodium citrate), and ε-aminocaproic acid, and mixtures thereof.
[0398] The formulation may further comprise a wetting agent. Suitable types of wetting agents include those selected from the group consisting of polyoxypropylene-polyoxyethylene block copolymers (poloxamers), polyethoxylated ethers of castor oil, polyoxyethylated sorbitan esters (polysorbates), polymers of oxyethylated octylphenol (Tyloxapol), polyoxyl 40 stearate, fatty acid glycol esters, fatty acid glyceryl esters, sucrose fatty acid esters, and polyoxyethylene fatty acid esters, and mixtures thereof.
[0399] According to a further aspect of the present disclosure, there is provided a pharmaceutical composition comprising a compound of the present disclosure as defined above, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, in association with a pharmaceutically acceptable diluent or carrier. In some embodiments, provided herein is a pharmaceutical composition comprising a compound of the present disclosure as defined above, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, and one or more pharmaceutically acceptable excipients.
[0400] Compositions of the present disclosure may be in a form suitable for oral use (e.g., as tablets, troches, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), topical use (e.g., as creams, ointments, gels, or aqueous or oily solutions or suspensions), administration by inhalation (e.g., as a finely divided powder or liquid aerosol), administration by insufflation (e.g., as a finely divided powder), or parenteral administration (e.g., as a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular, intraperitoneal, or intramuscular administration, or as a suppository for rectal administration).
[0401] The compositions of the present disclosure can be obtained by conventional procedures using conventional pharmaceutical excipients well known in the art. Thus, compositions intended for oral use may contain, for example, one or more coloring agents, sweeteners, flavoring agents, and / or preservatives.
[0402] An effective amount of a compound of the present disclosure for use in therapy is an amount sufficient to treat or prevent, slow the progression of, and / or alleviate the symptoms associated with the disease or disorder referred to herein.
[0403] An effective amount of a compound of the present disclosure for use in therapy is an amount sufficient to treat, slow the progression of, and / or alleviate the symptoms associated with the disease or disorder referred to herein.
[0404] The size of a dose of a compound of formula (I) for therapeutic or prophylactic purposes will naturally vary depending on the nature and severity of the condition, the age and sex of the animal or subject, and the route of administration, in accordance with well-known medical principles.
[0405] How to use Provided herein are methods for treating a disorder associated with a nucleotide repeat expansion, comprising administering to a subject a therapeutically effective amount of a compound or pharmaceutical composition described herein.
[0406] In some embodiments, the nucleotide repeat expansion comprises a nucleotide sequence that is repeated two or more times, and the nucleotide sequence is selected from the group consisting of CAG, CAG / CTG, GCG, GCN, CGG, CCG, CCCCGCCCCGCG, GCA, GGGGCC, CTG, GAA, ATTCT, TGGAA, GGCCTG, AAGGG, CCCTCT, ATTTT / ATTTC, and CCCTCT.
[0407] In some embodiments, the nucleotide repeat expansion comprises a trinucleotide sequence that is repeated two or more times, and the trinucleotide sequence is selected from the group consisting of CAG, CTG, CGG, and GCN.
[0408] A method of treating a disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound or pharmaceutical composition described herein, wherein the disease is selected from the group consisting of dentatorubral-pallidoluysian atrophy, Huntington's disease, spinal-bulbar muscular atrophy, SCA1 (Spinocerebellar ataxia type 1), SCA2 (Spinocerebellar ataxia type 2), SCA3 (Spinocerebellar ataxia type 3 or Machado-Joseph disease), SCA6 (Spinocerebellar ataxia type 6), SCA7 (Spinocerebellar ataxia type 7), SCA12 (Spinocerebellar ataxia type 12), SCA17 (Spinocerebellar ataxia type 18), SCA19 (Spinocerebellar ataxia type 21), SCA20 (Spinocerebellar ataxia type 22), SCA21 (Spinocerebellar ataxia type 23), SCA22 (Spinocerebellar ataxia type 24), SCA23 (Spinocerebellar ataxia type 25), SCA24 (Spinocerebellar ataxia type 26), SCA25 (Spinocerebellar ataxia type 27), SCA26 (Spinocerebellar ataxia type 28), SCA27 (Spinocerebellar ataxia type 29), SCA28 (Spinocerebellar ataxia type 29), SCA29 (Spinocerebellar ataxia type 30), SCA29 (Spinocerebellar ataxia type 31), SCA29 (Spinocerebellar ataxia type 32), SCA29 (Spinocerebellar ataxia type 33), SCA30 (Spinocerebellar ataxia type 34), SCA31 (Spinocerebellar ataxia type Provided herein are methods for treating a neurodegenerative disorder selected from the group consisting of: cerebellar ataxia type 17), FRAXA (Fragile X syndrome), FXTAS (Fragile X-associated tremor / ataxia syndrome), FRAXE (Fragile XE mental retardation), Baratela-Scott syndrome, FRDA (Friedreich ataxia), DM1 (myotonic dystrophy type 1), DM2 (myotonic dystrophy type 2), SCA8 (Spinocerebellar ataxia type 8), Fuchs endothelial corneal dystrophy, Desbuquois dysplasia, amyotrophic lateral sclerosis, and frontotemporal dementia.
[0409] In some embodiments, the disease is Huntington's disease.
[0410] Provided herein is a method of treating a disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound or pharmaceutical composition disclosed herein, wherein the disease is Huntington's disease.
[0411] Provided herein is a method of treating a disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound or pharmaceutical composition disclosed herein, wherein the disease is myotonic atrophy.
[0412] In some embodiments, the disease is FRAXA (Fragile X Syndrome), FXTAS (Fragile X Associated Tremor / Ataxia Syndrome), or FRAXE (Fragile XE Mental Retardation).
[0413] Provided herein is a method of treating a disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound or pharmaceutical composition disclosed herein, wherein the disease is FRAXA (Fragile X Syndrome), FXTAS (Fragile X-associated Tremor / Ataxia Syndrome), or FRAXE (Fragile XE Mental Retardation).
[0414] Route of administration The compounds of the present disclosure or pharmaceutical compositions containing these compounds may be administered to a subject by any convenient route of administration, whether systemic / peripheral or local (ie, to the desired site of action).
[0415] Routes of administration include, but are not limited to, oral (e.g., by ingestion), buccal, sublingual, transdermal (e.g., by patch, plaster, etc.), transmucosal (e.g., by patch, plaster, etc.), intranasal (e.g., by nasal spray), intraocular (e.g., by eye drops), pulmonary (e.g., using an aerosol, e.g., via an aerosol, e.g., through the mouth or nose, by inhalation or insufflation therapy), rectal (e.g., by suppository or enema), vaginal (e.g., by pessary), parenteral, e.g., by injection including subcutaneous, intradermal, intramuscular, intravenous, intraarterial, intracardiac, intrathecal, intraspinal, intracapsular, subcapsular, intraorbital, intraperitoneal, intratracheal, subcutaneous, intraarticular, intraarterial, subarachnoid, and intrapleural, by implantation of a depot or reservoir, e.g., subcutaneous or intramuscular injection.
[0416] The present disclosure includes the following embodiments 1 to 35. 1. A compound of formula (I), [ka] or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein: A is a saturated or partially unsaturated monocyclic, bicyclic, or tricyclic 4-14 membered heterocycloalkyl or NRR, wherein said heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R; R1 is a -(CH2) group of 4 to 14 ring atoms, including at least one nitrogen ring atom and 0 to 2 additional ring heteroatoms independently selected from N, O, and S; 0-2 -heterocycloalkyl, and R 1 is optionally substituted with 1, 2, 3, or 4 R6; R2 is hydrogen, C 1-7 Alkyl, or C 3-8 is cycloalkyl, R3 is H, halo, C 1-7 Alkyl, OR5, N(R5)2, C 3-8 cycloalkyl, or heterocycloalkyl; R4 is an aryl or bicyclic 9-membered heteroaryl containing 2, 3, or 4 heteroatoms independently selected from N, O, and S, and R4 is optionally substituted with 1, 2, or 3 R7; Each R5 is independently C 1-7 Alkyl, C 3-8 cycloalkyl, or heterocycloalkyl; Each R6 is independently hydroxy, C 1-7 Alkyl, Amino, C 1-7 Heteroalkyl, -(CH2) 0-3 -C 3-8 Cycloalkyl, -NR'-(CH2) 0-3 -C 3-8 Cycloalkyl, -(CH2) 0-3 -heterocycloalkyl, -C(O)-heterocycloalkyl, or -O-heterocycloalkyl, wherein alkyl is optionally substituted with 1 to 4 independently selected halogen or OH, and cycloalkyl and heterocycloalkyl are each independently substituted with 1 to 4 independently selected C 1-7 optionally substituted with alkyl, halogen, or OH; Or two R6 together form an oxo (=O), Or two R6s together, C 1-7 alkylene to form a ring, Each R' is hydrogen or C 1-7 is alkyl, Each R7 is independently halo, cyano, C 1-7 Alkyl, C 1-7 Haloalkyl, C 1-7 Alkoxy, C 1-7 Haloalkoxy, or C 3-8 is cycloalkyl, C 1-7 The compound, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein alkyl is optionally substituted with OH. 2. A compound of formula (I), [ka] or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein: A is a saturated or partially unsaturated monocyclic or bicyclic 4-11 membered nitrogen-containing heterocycloalkyl or NRR, wherein said nitrogen-containing heterocycloalkyl contains 1 or 2 nitrogen ring atoms and is optionally substituted with 1, 2, 3, or 4 R; R1 is heterocycloalkyl containing one nitrogen ring atom optionally substituted with 1, 2, 3, or 4 R6; R2 is hydrogen, C 1-7 Alkyl, or C 3-8 is cycloalkyl, R3 is H, C 1-7 Alkyl, OR5, N(R5)2, C 3-8 cycloalkyl, or heterocycloalkyl; R4 is a bicyclic 9-membered heteroaryl containing 2, 3, or 4 heteroatoms independently selected from N and O, and R4 is optionally substituted with 1, 2, or 3 R7; Each R5 is independently C 1-7 Alkyl, C 3-8 cycloalkyl, or heterocycloalkyl; Each R6 is independently hydroxy, C 1-7 Alkyl, Amino, C 1-7 Heteroalkyl, -(CH2) 0-3 -C 3-8 Cycloalkyl, -NR'-(CH2) 0-3 -C3-8 Cycloalkyl, -(CH2) 0-3 -heterocycloalkyl, -C(O)-heterocycloalkyl, or -O-heterocycloalkyl, wherein alkyl is optionally substituted with 1 to 4 independently selected halogen or OH, and cycloalkyl and heterocycloalkyl are each independently substituted with 1 to 4 independently selected C 1-7 optionally substituted with alkyl, halogen, or OH; Or two R6 together form an oxo (=O), Or two R6s together, C 1-7 alkylene to form a ring, each R7 independently represents a halo, C 1-7 Alkyl, C 1-7 Haloalkyl, C 1-7 Alkoxy, or C 1-7 The compound, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, which is haloalkoxy. 3. A is a 4-11 membered nitrogen-containing heterocycloalkyl, said nitrogen-containing heterocycloalkyl containing 1 or 2 nitrogen ring atoms and 0-2 additional ring heteroatoms selected from O and S, and is optionally substituted with 1, 2, 3, or 4 R; Each R6 is independently C 1-7 Alkyl, Amino, C 1-7 Alkylamino, C 3-8 Cycloalkyl, heterocycloalkyl, and C 1-7 alkoxy-heterocycloalkyl, or two R6 together form C 1-7 The compound according to any of the previous embodiments, which forms an alkylene. 4. Each R6 is independently C 1-7 Alkyl, heterocycloalkyl, or C 1-7 alkoxy-heterocycloalkyl, or two R6 together form C 1-7 The compound according to any one of the preceding embodiments, which forms an alkylene. 5. A compound according to any one of the preceding embodiments, wherein each R6 is independently methyl, ethyl, isopropyl, methoxy-azetidinyl, or pyrrolidinyl, or two R6 together form ethylene or propylene. 6.A is [ka] and Y is absent, N or CH; R9 is hydrogen, C 1-7 Alkyl, or (CH2) m -NR 14 R 15 and R 10 is hydrogen or C 1-7 is alkyl, R 11 is hydrogen or C 1-7 is alkyl, R 12 is hydrogen or C 1-7 is alkyl, R 13 is hydrogen or C 1-7 is alkyl, Each R 14 and R 15 are independently hydrogen, C 1-7 Alkyl, and C 3-8 is cycloalkyl, n is 0, 1, or 2; m is 0, 1, or 2, Or R9 and R 10 Together, C 1-7 Forming an alkylene, or Or R9 and R 12 Together, C 1-7 Forming an alkylene, or Or R 10 and R 11 Together, C 2-7 Alkylene, or C 1-7 forming a 4- to 6-membered heterocycloalkyl optionally substituted with alkyl; Or R10 and R 12 Together, C 1-7 Alkylene, or C 1-7 forming a 4- to 6-membered heterocycloalkyl optionally substituted with alkyl; Or R 10 and R 14 Together, C 1-7 Forming an alkylene, or Or R 12 and R 13 Together, C 2-7 Forming an alkylene, or Or R 12 and R 14 Together, C 1-7 Forming an alkylene, or Or R 14 and R 15 Together, C 2-7 Forms an alkylene, which is C 1-7 The compound according to any one of the preceding embodiments, optionally substituted with alkoxy. 7. The compound according to any one of the preceding embodiments, wherein Y is N. 8. Y is CH and R9 is (CH2) m -NR 14 R 15 The compound of any one of the preceding embodiments, wherein 9. The compound according to any one of the preceding embodiments, wherein n is 1. 10. A compound according to any one of the preceding embodiments, wherein R9 is hydrogen, pyrrolidinyl, or methoxy-azetidinyl. 11.R 10 The compound of any one of the preceding embodiments, wherein is hydrogen, methyl, ethyl, or isopropyl. 12.R 11 The compound according to any one of the preceding embodiments, wherein is hydrogen or methyl. 13.R 12 The compound according to any one of the preceding embodiments, wherein is hydrogen or methyl. 14.R 13The compound of any one of the preceding embodiments, wherein is hydrogen. 15.R9 and R 10 together form propylene. 16.R 10 and R 11 together to form ethylene. 17.R 14 and R 15 together form propylene or butylene. 18.A is, [ka] wherein R9, R 10 , R 11 , R 12 , and R 13 is as defined in any one of the preceding embodiments, and each R 16 are independently hydrogen or C 1-7 A compound according to any one of the preceding embodiments, wherein R is alkyl, each p is 0, 1, or 2, each o is 0, 1, or 2, and each A is optionally substituted with 1 or 2 R6. 19. A compound according to any one of the preceding embodiments, wherein A is piperazinyl, diazepanyl, octahydropyrrolopyrazinyl, diazaspirooctanyl, pyrrolidinyl, octahydropyrrolopyrroyl, diazaspirononanyl, diazaspiroheptanyl, or diazabicyclooctanyl, and wherein piperazinyl, diazepanyl, octahydropyrrolopyrazinyl, diazaspirooctanyl, pyrrolidinyl, octahydropyrrolopyrroyl, diazaspirononanyl, diazaspiroheptanyl, or diazabicyclooctanyl is each optionally substituted with 1, 2, 3, or 4 R6. 20. A compound according to any one of the preceding embodiments, wherein A is NR1R2. 21.A is, [ka] The compound of any one of the preceding embodiments, wherein 22. A compound according to any one of the previous embodiments, wherein R4 is a bicyclic 9-membered heteroaryl containing two heteroatoms independently selected from N and O, and R4 can be optionally substituted with 1, 2, or 3 R7. 23. A compound according to any one of the previous embodiments, wherein R4 is a bicyclic 9-membered heteroaryl containing two heteroatoms independently selected from N and O, and R4 is substituted with one or two R7. 24.R4 is, [ka] The compound of any one of the preceding embodiments, wherein 25.R4 is, [ka] The compound of any one of the preceding embodiments, wherein 26. A compound according to any one of the preceding embodiments, wherein R4 is selected from imidazo[1,2-a]pyrazine, benzo[d]oxazole, or imidazo[1,2-a]pyrazine, wherein the imidazo[1,2-a]pyrazine, benzo[d]oxazole, or imidazo[1,2-a]pyrazine is each optionally substituted with 1, 2, 3, or 4 R7. 27.R4 is, [ka] The compound of any one of the preceding embodiments, wherein 28.R4 is, [ka] The compound of any one of the preceding embodiments, wherein 29. A compound according to any one of the preceding embodiments, selected from the compounds in Table 1. 30. A compound according to any one of the preceding embodiments, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, for use as a small molecule splicing modulator. 31. A pharmaceutical composition comprising a compound according to any one of the preceding embodiments, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, and one or more pharmaceutically acceptable excipients. 32. A method of treating a disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of any one of embodiments 1-30 or a pharmaceutical composition of embodiment 31, wherein the disease is selected from the group consisting of dentatorubral-pallidoluysian atrophy, Huntington's disease, spinal-bulbar muscular atrophy, SCA1 (Spinocerebellar ataxia type 1), SCA2 (Spinocerebellar ataxia type 2), SCA3 (Spinocerebellar ataxia type 3 or Machado-Joseph disease), SCA6 (Spinocerebellar ataxia type 6), SCA7 (Spinocerebellar ataxia type 7), SCA12 (Spinocerebellar ataxia type 8), SCA9 (Spinocerebellar ataxia type 9), SCA10 (Spinocerebellar ataxia type 10), SCA11 (Spinocerebellar ataxia type 11), SCA12 (Spinocerebellar ataxia type 12), SCA13 (Spinocerebellar ataxia type 13 or Machado-Joseph disease), SCA14 (Spinocerebellar ataxia type 14), SCA15 (Spinocerebellar ataxia type 15), SCA16 (Spinocerebellar ataxia type 16), SCA17 (Spinocerebellar ataxia type 17), SCA18 (Spinocerebellar ataxia type 18), SCA19 (Spinocerebellar ataxia type 19), SCA20 (Spinocerebellar ataxia type 20), SCA21 (Spinocerebellar ataxia type 21 or Machado-Joseph disease), SCA22 (Spinocerebellar ataxia type 22 or Machado-Joseph disease), SCA23 (Spinocerebellar a the method, wherein the cause is selected from the group consisting of spinocerebellar ataxia type 12, SCA17 (spinocerebellar ataxia type 17), FRAXA (fragile X syndrome), FXTAS (fragile X-associated tremor / ataxia syndrome), FRAXE (fragile XE mental retardation), Baratela-Scott syndrome, FRDA (Friedreich ataxia), DM1 (myotonic dystrophy type 1), DM2 (myotonic dystrophy type 2), SCA8 (spinocerebellar ataxia type 8), Fuchs endothelial corneal dystrophy, Desbuquois dysplasia, amyotrophic lateral sclerosis, and frontotemporal dementia. 33. A method of treating a disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of any one of embodiments 1-30 or a pharmaceutical composition of embodiment 31, wherein the disease is Huntington's disease. 34. A method of treating a disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of any one of embodiments 1-30 or a pharmaceutical composition of embodiment 31, wherein the disease is myotonic dystrophy type 1. 35. A method of treating a disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of any one of embodiments 1-30 or a pharmaceutical composition of embodiment 31, wherein the disease is FRAXA (Fragile X Syndrome), FXTAS (Fragile X-associated Tremor / Ataxia Syndrome), or FRAXE (Fragile XE Mental Retardation). [Example]
[0417] For illustrative purposes, neutral compounds of formula (I) are synthesized and tested in the Examples. It is understood that neutral compounds of formula (I) can be converted to the corresponding pharmaceutically acceptable salts of the compounds using routine techniques in the art (e.g., by saponifying an ester to a carboxylate, or by hydrolyzing an amide to form the corresponding carboxylic acid, and then converting the carboxylic acid to a carboxylate salt).
[0418] Nuclear magnetic resonance (NMR) spectra were recorded at 400 MHz or 300 MHz as indicated; chemical shifts (δ) are reported in parts per million (ppm). Spectra were recorded using Bruker or Varian instruments with 8, 16, or 32 scans.
[0419] Unless otherwise noted, LC-MS chromatograms and spectra were recorded using an Agilent 1200 or Shimadzu LC-20 AD&MS 2020 instrument with a C-18 column, such as a C18 2.1 x 30 mm column. The injection volume was 0.7-8.0 μl, and the flow rate was typically 0.8 or 1.2 ml / min. Detection methods were diode array (DAD) or evaporative light scattering (ELSD) with positive ion electrospray ionization. The MS range was 100-1000 Da. The solvent was a gradient of water and acetonitrile containing a polymerization modifier, such as trifluoroacetic acid or ammonium carbonate (typically 0.01-0.04%).
[0420] Shorthand: [Table 2]
[0421] Example A. 2,8-Dimethylimidazo[1,2-a]pyrazin-6-amine [ka] Step 1: Preparation of 5-bromo-3-methylpyrazin-2-amine 3-Methylpyrazin-2-amine (25.37 g, 174.26 mmol) and pyridine (15.16 g, 191.68 mmol, 15.5 mL) were mixed in CHCl (300 mL), bromine (29.24 g, 182.96 mmol, 9.38 mL) was added dropwise, and the mixture was stirred at room temperature overnight. The resulting mixture was then washed with water and brine and evaporated under reduced pressure to give pure 5-bromo-3-ethylpyrazin-2-amine (30.08 g, Y: 92%). ESI-MS (M+H) + :189.0. 1 H NMR (500 MHz, DMSO-d6) δ 7.87 (s, 1H), 6.4 (br s, 2H), 2.25 (s, 3H).
[0422] Step 2: Preparation of 6-bromo-2,8-dimethylimidazo[1,2-a]pyrazine To a mixture of 4-methylbenzene-1-sulfonic acid hydrate (1.49 g, 7.82 mmol) and pyridine (618.53 mg, 7.82 mmol, 630.0 μL) in i-PrOH (100 mL) was added 5-bromo-3-methylpyrazin-2-amine (14.71 g, 78.2 mmol) and 1-bromo-2,2-dimethoxypropane (16.46 g, 89.93 mmol, 12.16 mL), and the reaction mixture was heated to 90° C. for 4 h. The resulting mixture was diluted with DCM, washed with saturated sodium bicarbonate solution, dried (NaSO), and concentrated under reduced pressure to give pure 6-bromo-2,8-dimethylimidazo[1,2-a]pyrazine (15.3 g, Y: 68%). 1H NMR (400 MHz, DMSO-d6) δ 9.03 (s, 1H), 8.08 (s, 1H, 2.76 (s, 3H), 2.51 (s, 3H).
[0423] Step 3: Preparation of 2,8-dimethylimidazo[1,2-a]pyrazin-6-amine 6-Bromo-2,8-dimethylimidazo[1,2-a]pyrazine (10.0 g, 44.23 mmol), tert-butyl carbamate (4.35 g, 37.16 mmol), Pd(dba) (1.42 g, 1.55 mmol), [5-(diphenylphosphanyl)-9,9-dimethyl-9H-xanthen-4-yl]diphenylphosphane (2.69 g, 4.64 mmol), and cesium carbonate (20.18 g, 61.93 mmol) were suspended in degassed anhydrous 1,4-dioxane. The mixture was heated at 100 °C overnight under N. After cooling to room temperature, the mixture was diluted with ethyl acetate, and the organic layer was washed with water and saturated brine, dried over magnesium sulfate, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography to give tert-butyl N-2,8-dimethylimidazo[1,2-a]pyrazin-6-ylcarbamate, which was treated with a 10% solution of HCl in dioxane to give 2,8-dimethylimidazo[1,2-a]pyrazin-6-amine (5.56 g, Y: 63%) as the HCl salt. ESI-MS (M+H) + :163.0. 1 H NMR (400 MHz, DMSO-d6) δ 8.02 (s, 1H), 7.71 (s, 1H), 5.20 (br s, 2H), 2.68 (s, 3H), 2.43 (s, 3H).
[0424] Example B N-(2,8-dimethylimidazo[1,2-a]pyrazin-6-yl)-4-ethoxy-2-(methylsulfinyl)pyrimidine-5-carboxamide [ka] Step 1: Preparation of ethyl 4-ethoxy-2-(methylsulfanyl)pyrimidine-5-carboxylate An ice-cold suspension of ethyl 4-chloro-2-(methylsulfanyl)pyrimidine-5-carboxylate 1 (30.0 g, 128.93 mmol) in 300 ml of ethanol was treated dropwise with a solution of sodium ethoxide prepared from sodium (3.26 g, 141.82 mmol) and 300 ml of ethanol. After 1 h at room temperature, the mixture was evaporated and the residue was partitioned between 400 ml of dichloromethane and 400 ml of water. The organic phase was separated, dried over magnesium sulfate, filtered, and evaporated to give ethyl 4-ethoxy-2-(methylsulfanyl)pyrimidine-5-carboxylate (31.0 g, Y: 94%) as a colorless oil. 1 H NMR (400 MHz, chloroform-d6) δ: 8.81 (s, 1H), 4.56 (q, J = 6.8 Hz, 2H), 4.35 (q, J = 6.8 Hz, 2H), 2.58 (s, 3H), 1.46 (t, J = 7.1 Hz, 3H), 1.38 (t, J = 7.1 Hz, 3H).
[0425] Step 2: Preparation of 4-ethoxy-2-(methylsulfanyl)pyrimidine-5-carboxylic acid A mixture of ethyl 4-ethoxy-2-(methylsulfanyl)pyrimidine-5-carboxylate 2 (31.0 g, 127.94 mmol) and lithium hydroxide monohydrate (8.05 g, 191.92 mmol) was stirred overnight at room temperature in a mixture of ethanol (100 mL) and HO (40 mL). The reaction mixture was then concentrated under reduced pressure to remove ethanol, and the resulting aqueous solution was neutralized to pH 5 with 10% NaHSO and extracted with EtOAc (2 x 100 mL). The organic layers were combined, dried over NaSO, and evaporated to give pure 4-ethoxy-2-(methylsulfanyl)pyrimidine-5-carboxylic acid (22.0 g, Y: 76.2%). ESI-MS (M+H) + :215.2. 1H NMR (400 MHz, DMSO-d6) δ:8.43 (s, 1H), 4.39 (q, J = 6.8 Hz, 2H), 2.47 (s, 3H), 1.29 (t, J = 7.1 Hz, 3H).
[0426] Step 3: Preparation of N-(2,8-dimethylimidazo[1,2-a]pyrazin-6-yl)-4-ethoxy-2-(methylthio)pyrimidine-5-carboxamide 4-Ethoxy-2-(methylsulfanyl)pyrimidine-5-carboxylic acid (9.86 g, 46.01 mmol) was suspended in DMF (150 mL) and ethylbis(propan-2-yl)amine (11.89 g, 92.03 mmol) was added, followed by [(dimethylamino)(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yloxy)methylidene]dimethylazanium, hexafluoro-lambda 5-phosphanide (HATU) (20.99 g, 55.22 mmol). The resulting mixture was stirred at room temperature for 30 minutes. 2,8-Dimethylimidazo[1,2-a]pyrazin-6-amine (9.13 g, 46.01 mmol) was then added in one portion, and the reaction mixture was stirred at room temperature overnight. The formed precipitate was filtered, washed with MeCN (60 mL), MTBE (60 mL) and dried under vacuum to give N-(2,8-dimethylimidazo[1,2-a]pyrazin-6-yl)-4-ethoxy-2-(methylthio)pyrimidine-5-carboxamide (11.82 g, Y: 72%). 1 H NMR (400 MHz, chloroform-d) δ: 9.8 (s, 1H), 9.13 (s, 1H), 9.10 (s, 1H), 7.44 (s, 1H), 4.75 (q, J = 6.8 Hz), 2.82 (s, 3H), 2.61 (s, 3H), 2.50 (s, 3H), 1.63 (t, J = 7.1 Hz).
[0427] Step 4: Preparation of N-(2,8-dimethylimidazo[1,2-a]pyrazin-6-yl)-4-ethoxy-2-(methylsulfinyl)pyrimidine-5-carboxamide To a solution of N-(2,8-dimethylimidazo[1,2-a]pyrazin-6-yl)-4-ethoxy-2-(methylthio)pyrimidine-5-carboxamide (11.82 g, 33.0 mmol) in dichloromethane (200 mL) was added 3-chlorobenzene-1-carboperoxoic acid (7.12 g, 41.2 mmol) (75% purity) dropwise over 1 h at 0° C. and the reaction mixture was stirred at room temperature for 1 h. The crude reaction mixture was poured into NaOH (1 M, 100 ml) and the organic material was extracted twice with dichloromethane. The combined organic layers were washed with brine, dried over MgSO, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by crystallization from a minimal amount of MTBE to give N-(2,8-dimethylimidazo[1,2-a]pyrazin-6-yl)-4-ethoxy-2-(methylsulfinyl)pyrimidine-5-carboxamide (9.27 g, Y: 75%). ESI-MS (M+H)+: 375.0. 1 H NMR (400 MHz, chloroform-d) δ: 9.85 (s, 1H), 9.44 (s, 1H), 9.13 (s, 1H), 7.49 (s, 1H), 4.90 (q, J = 6.8 Hz, 2H), 3.0 (s, 3H), 2.54 (s, 3H), 2.53 (s, 3H), 1.68 (t, J = J = 7.1 Hz, 3H).
[0428] Example C. 2-4-[(tert-butoxy)carbonyl]piperazin-1-yl-4-ethoxypyrimidine-5-carboxylic acid [ka] Step 1: Preparation of ethyl 4-ethoxy-2-methanesulfinylpyrimidine-5-carboxylate To a solution of ethyl 4-ethoxy-2-(methylsulfanyl)pyrimidine-5-carboxylate (15.0 g, 61.91 mmol) in chloroform (150 mL), 3-chlorobenzene-1-carboperoxoic acid (MCPBA) (12.82 g, 74.29 mmol) was added in portions under ice cooling, and the reaction mixture was stirred for 2 hours. The resulting mixture was filtered, and the filtrate was washed with saturated aqueous sodium bicarbonate (100 mL) and brine (50 mL). The organic layer was dried over anhydrous sodium sulfate, and the solvent was evaporated in vacuo to give crude ethyl 4-ethoxy-2-methanesulfinylpyrimidine-5-carboxylate (15.75 g, Y: 78.8%). 1 H NMR (500 MHz, DMSO-d6) δ 9.01 (s, 1H), 4.54 (q, J = 7.2 Hz 2H), 4.30 (q, J = 7.2 Hz, 2H), 2.88 (s, 3H), 1.35 (t, J = 7.1 Hz, 3H), 1.29 (t, J = 7.1 Hz, 3H).
[0429] Step 2: Preparation of ethyl 2-4-[(tert-butoxy)carbonyl]piperazin-1-yl-4-ethoxypyrimidine-5-carboxylate tert-Butyl piperazine-1-carboxylate (11.36 g, 60.98 mmol) was added dropwise to a suspension of ethyl 4-ethoxy-2-methanesulfinylpyrimidine-5-carboxylate (15.75 g, 60.98 mmol) and potassium carbonate (25.28 g, 182.93 mmol) in MeCN (200 mL) cooled to 0 °C, and the reaction was stirred at room temperature overnight. The resulting mixture was then filtered, and the MeCN was evaporated under reduced pressure. The residue was partitioned between EtOAc and HO. The organic layer was dried over anhydrous MgSO, filtered, and concentrated in vacuo. The residue was purified by flash chromatography (4 / 1; Hex / EtOAc) to give ethyl 2-4-[(tert-butoxy)carbonyl]piperazin-1-yl-4-ethoxypyrimidine-5-carboxylate (7.0 g, Y: 28.7%). 1H NMR (400 MHz, DMSO-d6) δ 8.61 (s, 1H), 4.39 (q, J = 7.2 Hz, 2H), 4.17 (q, J = 7.2 Hz, 2H), 3.85-3.75 (m, 4H), 3.45-3.35 (m, 4H), 1.41 (s, 9H), 1.31 (t, J = 7.1 Hz, 3H), 1.24 (t, J = 7.1 Hz, 3H).
[0430] Step 3: Preparation of 2-4-[(tert-butoxy)carbonyl]piperazin-1-yl-4-ethoxypyrimidine-5-carboxylic acid A mixture of ethyl 2-4-[(tert-butoxy)carbonyl]piperazin-1-yl-4-ethoxypyrimidine-5-carboxylate (7.0 g, 18.4 mmol) and lithium hydroxide monohydrate (926.57 mg, 22.08 mmol) in a mixture of ethanol (100 mL) and HO (40 mL) was stirred overnight. The reaction mixture was then concentrated under reduced pressure to remove ethanol, and the resulting aqueous solution was neutralized to pH = 5 with 10% NaHSO and extracted with EtOAc (2 x 100 mL). The organic layers were combined, dried over NaSO, and evaporated under reduced pressure to give pure 2-4-[(tert-butoxy)carbonyl]piperazin-1-yl-4-ethoxypyrimidine-5-carboxylic acid (6.15 g, Y: 90.1%). ESI-MS (M+H) + :353.0. 1 H NMR (400 MHz, DMSO-d6) δ 12.28 (br s, 1H), 8.61 (s, 1H), 4.40 (q, J = 7.2 Hz, 2H), 3.83 - 3.75 (m, 4H), 3.45-3.35 (m, 4H), 1.42 (s, 9H), 1.32(t, J = 7.1 Hz, 3H).
[0431] Example D. tert-Butyl 4-(5-carbamoyl-4-ethoxypyrimidin-2-yl)piperazine-1-carboxylate [ka] Step 1: Preparation of tert-butyl 4-(5-carbamoyl-4-ethoxypyrimidin-2-yl)piperazine-1-carboxylate Ethyl 2-4-[(tert-butoxy)carbonyl]piperazin-1-yl-4-ethoxypyrimidine-5-carboxylate (1.0 g, 2.62 mmol) was dissolved in NH3 / MeOH (20 mL) and the reaction mixture was sealed and heated to 70 °C overnight. The reaction mixture was cooled and evaporated in vacuo to give the title product (883 mg, Y: 95%). ESI-MS (M+H) + :352.4.
[0432] Example E. 4-Ethoxy-N-8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl-2-methanesulfinylpyrimidine-5-carboxamide [ka] Step 1: Preparation of 4-ethoxy-N-8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl-2-(methylsulfanyl)-pyrimidine-5-carboxamide 4-Ethoxy-2-(methylsulfanyl)pyrimidine-5-carboxylic acid (9.86 g, 46.01 mmol) was suspended in MeCN (200 mL), and ethylbis(propan-2-yl)amine (11.89 g, 92.03 mmol) was added, followed by [(dimethylamino)(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yloxy)methylidene]dimethylazanium, hexafluoro-lambda 5-phosphanide (HATU) (20.99 g, 55.22 mmol). The mixture was stirred at room temperature for 30 minutes. 8-Fluoro-2-methylimidazo[1,2-a]pyridin-6-amine (7.6 g, 46.01 mmol) was then added in one portion, and the reaction mixture was stirred at room temperature overnight. The precipitate that formed was filtered, washed with MeCN (60 mL), MTBE (60 mL), and dried in vacuo to give pure 4-ethoxy-N-8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl-2-(methylsulfanyl)pyrimidine-5-carboxamide (6.6 g, Y: 37.7%). ESI-MS (M+H) + :362.0. 1 H NMR (400 MHz, DMSO-d6) δ 10.10 (s, 1H), 9.07 (s, 1H), 8.68 (s, 1H), 7.90 (d, J = 3.1 Hz, 1H), 7.15 (d, J = 12.3 Hz, 1H), 4.53 (q, J = 7.2, 2H), 2.56 (s, 3H), 2.32 (s, 3H), 1.39 (t, J = 7.1, 3H).
[0433] Step 2: Preparation of 4-ethoxy-N-8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl-2-methanesulfinyl-pyrimidine-5-carboxamide To a solution of 4-ethoxy-N-8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl-2-(methylsulfanyl)pyrimidine-5-carboxamide (6.63 g, 18.35 mmol) in dichloromethane was added 3-chlorobenzene-1-carboperoxoic acid (3.8 g, 22.02 mmol) (75% purity) dropwise over 1 h at 0° C., and the reaction mixture was stirred at room temperature for 1 h. The crude reaction mixture was poured into NaOH (1 M, 100 mL) and the organic material was extracted twice with dichloromethane. The combined organic layers were washed with brine, dried over MgSO, filtered, and the filtrate was concentrated under reduced pressure to give the crude product, which was purified by crystallization from a minimal amount of MTBE to give 4-ethoxy-N-8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl-2-methanesulfinylpyrimidine-5-carboxamide (5.2 g, Y: 71.3%). ESI-MS (M+H): 378.0. 1 H NMR (400 MHz, DMSO-d6) δ 10.50 (s, 1H), 9.10 (s, 1H), 8.95 (s, 1H), 7.94 (d, J = 3.2 Hz, 1H), 7.12 (d, J = 12.3 Hz, 1H), 4.58 (q, J = 7.2 Hz, 2H), 2.91 (s, 3H), 2.33 (s, 3H), 1.38 (t, J = 7.1, 3H).
[0434] Example 1. N-(8-Fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4-methoxy-2-(piperazin-1-yl)pyrimidine-5-carboxamide, HCl (Compound 1). [ka] Step 1: Synthesis of methyl 4-methoxy-2-(methylthio)pyrimidine-5-carboxylate [ka] To a stirred solution of methyl 4-chloro-2-(methylthio)pyrimidine-5-carboxylate (5.0 g, 21.5 mmol) in MeOH (50 mL) under an argon atmosphere, NaOMe (3.61 g, 64.5 mmol) was added, and the mixture was stirred at room temperature for 5 hours. The reaction mixture was quenched with acetic acid (10 mL). After concentration under reduced pressure, the residue was purified by silica gel column chromatography (PE / EA=4:1) to give methyl 4-methoxy-2-(methylthio)pyrimidine-5-carboxylate (3.85 g, Y: 83.7%) as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ 8.75 (s, 1H), 4.01 (s, 3H), 3.81 (s, 3H), 2.57 (s, 3H).ESI-MS (M+H) + :215.1.
[0435] Step 2: Synthesis of methyl 4-methoxy-2-(methylsulfinyl)pyrimidine-5-carboxylate [ka] To a stirred solution of methyl 4-methoxy-2-(methylthio)pyrimidine-5-carboxylate (200 mg, 0.93 mmol) in DCM (10 mL) was added m-CPBA (161 mg, 0.93 mmol) at 0 °C. The mixture was warmed to room temperature and stirred for 1 h. The reaction mixture was diluted with DCM (50 mL) and quenched with saturated aqueous NaSO (10 mL). The organic phase was washed with saturated aqueous sodium carbonate (10 mL) and dried over sodium sulfate. After concentration under reduced pressure, the crude methyl 4-methoxy-2-(methylsulfinyl)pyrimidine-5-carboxylate (200 mg, Y: 93%) was used in the next step without further purification as a white solid. ESI-MS (M+H) + :230.9.
[0436] Step 3: Synthesis of methyl 2-(4-(tert-butoxycarbonyl)piperazin-1-yl)-4-methoxypyrimidine-5-carboxylate [ka] To a stirred solution of methyl 4-methoxy-2-(methylsulfinyl)pyrimidine-5-carboxylate (200 mg, 0.87 mmol) in MeCN (8 mL) was added tert-butyl piperazine-1-carboxylate (323 mg, 1.74 mmol) and potassium carbonate (236 mg, 1.74 mmol). The mixture was stirred for 10 min. After concentration, the residue was treated with EA / water (20 mL, 1:1). The organic phase was separated, and the aqueous phase was extracted with EA (10 mL × 3). The combined organics were dried over sodium sulfate. After concentration under reduced pressure, the crude methyl 2-(4-(tert-butoxycarbonyl)piperazin-1-yl)-4-methoxypyrimidine-5-carboxylate (300 mg, Y: 96%) was used in the next step without further purification as a white solid. ESI-MS (M+H) + :353.0.
[0437] Step 4: Synthesis of 2-(4-(tert-butoxycarbonyl)piperazin-1-yl)-4-methoxypyrimidine-5-carboxylic acid [ka] To a solution of methyl 2-(4-(tert-butoxycarbonyl)piperazin-1-yl)-4-methoxypyrimidine-5-carboxylate (150 mg, 0.426 mmol) in THF (8 mL), MeOH (8 mL), and HO (4 mL) was added LiOH.HO (100 mg, 2.13 mmol) at room temperature. The reaction mixture was stirred at room temperature for 3 hours. After concentration, the residue was diluted with water (20 mL), and the pH was adjusted to 5-6 with 1N aqueous HCl. A solid formed, which was collected by filtration and washed three times with water (3 mL × 3). The solid was dried under vacuum at 55 °C to give the title product (140 mg, Y: 97%) as a yellow solid. 1H NMR (400 MHz, CDCl3) δ 8.86 (s, 1H), 4.09 (s, 3H), 3.91 (s, 4H), 3.54 - 3.50 (m, 4H), 1.49 (s, 9H).ESI-MS (M+H) + :339.0.
[0438] Step 5: Synthesis of 6-bromo-8-fluoro-2-methylimidazo[1,2-a]pyridine [ka] A mixture of 4-1 (10 g, 52.6 mmol) and 1-bromopropan-2-one (17.9 g, 131.6 mmol) in EtOH (80 mL) was heated to 80 °C for 16 h. LCMS showed that 15% of SM remained and 50% of DP had formed. The reaction was stopped and cooled to room temperature. The solvent was removed under vacuum, and the residue was purified by silica gel column chromatography (PE / EA = 4:1) to give 6-bromo-8-fluoro-2-methylimidazo[1,2-a]pyridine (5.0 g, Y: 41.7%) as a pale pink solid. 1 H NMR (400 MHz, CDCl3) δ 8.03 (d, J = 1.4 Hz, 1H), 7.38 (d, J = 1.4 Hz, 1H), 6.97 (dd, J = 9.6, 1.5 Hz, 1H), 2.47 (s, 3H).ESI-MS (M+H) + :229.1, 231.1.
[0439] Step 6: Synthesis of N-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-1,1-diphenylmethanimine [ka] A mixture of 6-bromo-8-fluoro-2-methylimidazo[1,2-a]pyridine (1.5 g, 6.58 mmol), diphenylmethanimine (1.25 g, 6.91 mmol), Pd(OAc) (148 mg, 0.658 mmol), BINAP (818 mg, 1.316 mmol), and CsCO (4.28 g, 13.16 mmol) in dioxane (70 mL) was purged with N three times at room temperature. The mixture was then heated at 115 °C for 16 h. The solvent was removed, and the residue was purified by silica gel column chromatography (0-50% EA in PE) to give the title product (336 mg (pure) + 400 mg (impurity), yield: 35%) as a light brown solid. ESI-MS (M+H) + :330.1.
[0440] Step 7: Synthesis of 8-fluoro-2-methylimidazo[1,2-a]pyridin-6-amine hydrochloride [ka] To a solution of N-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-1,1-diphenylmethanimine (336 mg, 1.02 mmol) in DCM (10 mL) was added HCl-dioxane (4 M, 2.6 mL, 10.2 mmol) at 0° C. The mixture was stirred at room temperature for 2 hours. After concentration, the residue was treated with EA. The solid was collected by filtration, washed with EA, and dried under vacuum to give the title product (180 mg, yield: 90%) as a yellow solid. 1 H NMR (400 MHz, DMSO-d6) δ 8.05 (dd, J = 2.2, 1.0 Hz, 1H), 7.87 (d, J = 1.6 Hz, 1H), 7.40 (dd, J = 12.3, 1.6 Hz, 1H), 5.35 (s, 3H), 2.43 (d, J = 0.9 Hz, 3H).
[0441] Step 8: Synthesis of tert-butyl 4-(5-((8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)carbamoyl)-4-methoxypyrimidin-2-yl)piperazine-1-carboxylate [ka] To a stirred solution of 2-(4-(tert-butoxycarbonyl)piperazin-1-yl)-4-methoxypyrimidine-5-carboxylic acid (120 mg, 0.36 mmol) in DMF (5 mL) was added 8-fluoro-2-methylimidazo[1,2-a]pyridin-6-amine (107 mg, 0.53 mmol), TEA (107 mg, 1.07 mmol), and HATU (202 mg, 0.53 mmol). The mixture was stirred at room temperature for 2 hours. Water was added, and the precipitate was collected by filtration. The filter cake was washed with water and dried under vacuum to give tert-butyl 4-(5-((8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)carbamoyl)-4-methoxypyrimidin-2-yl)piperazine-1-carboxylate (100 mg, Y: 58%) as a gray solid, which was used in the next step without further purification. ESI-MS (M+H) + :486.1.
[0442] Step 9: Synthesis of N-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4-methoxy-2-(piperazin-1-yl)pyrimidine-5-carboxamide, HCl [ka] To a solution of tert-butyl 4-(5-((8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)carbamoyl)-4-methoxypyrimidin-2-yl)piperazine-1-carboxylate (90 mg, 0.19 mmol) in DCM (10 mL) was added a solution of HCl in 1,4-dioxane (1 mL, 4 mmol, 4 M) at 0° C. The mixture was stirred at room temperature for 1 hour. After concentration, the residue was purified by preparative HPLC (0.05% HCl in MeCN / water) to give N-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4-methoxy-2-(piperazin-1-yl)pyrimidine-5-carboxamide (48 mg, Y: 62%) as the HCl salt as a gray solid. 1H NMR (400 MHz, CD3OD) δ 9.44 (d, J = 1.1 Hz, 1H), 8.86 (s, 1H), 8.10 (dd, J = 2.2, 1.1 Hz, 1H), 8.01 (dd, J = 11.5, 1.5 Hz, 1H), 4.24 - 4.17 (m, 7H), 3.36 - 3.32 (m, 4H), 2.57 (d, J = 1.0 Hz, 3H).ESI-MS (M+H) + :386.1.
[0443] Example 2. 4-Ethoxy-N-{8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl}-2-(piperazin-1-yl)pyrimidine-5-carboxamide (Compound 2) [ka] Step 1: Preparation of 4-ethoxy-N-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(piperazin-1-yl)pyrimidine-5-carboxamide hydrochloride To a solution of 4-ethoxy-N-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(methylsulfinyl)pyrimidine-5-carboxamide (50 mg, 0.13 mmol) in ACN (5 mL) was added piperazine (56 mg, 0.65 mmol) and K2CO3 (53 mg, 0.39 mmol). The reaction mixture was stirred at room temperature for 1 hour. The solid was filtered and the filtrate was concentrated. The residue was purified by preparative HPLC (0.05% HCl in MeCN / water) to give the title product (22 mg, Y: 39%) as a yellow solid. ESI-MS (M+H) + :400.1. 1H NMR (400 MHz, MeOD) δ 9.01 (d, J = 1.4 Hz, 1H), 8.82 (s, 1H), 7.73 (d, J = 2.3 Hz, 1H), 7.17 (dd, J = 11.8, 1.5 Hz, 1H), 4.67 - 4.61 (m, 2H), 4.22 - 4.10 (m, 4H), 3.37 - 3.31 (m, 4H), 2.42 (s, 3H), 1.54 (t, J = 7.1 Hz, 3H).
[0444] Example 3. 4-Ethoxy-N-{8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl}-2-[(3R)-3-methylpiperazin-1-yl]pyrimidine-5-carboxamide (Compound 3) [ka] Step 1: Synthesis of 4-ethoxy-2-(methylthio)pyrimidine-5-carboxylic acid To a solution of ethyl 4-ethoxy-2-(methylthio)pyrimidine-5-carboxylate (8.4 g, 34.71 mmol) in THF (100 mL) and HO (20 mL) was added LiOH . HO (6.9 g, 173.55 mmol) was added at room temperature. The reaction mixture was stirred at room temperature overnight. The solvent was removed under vacuum. The residue was diluted with water (20 mL) and adjusted to pH = 5-6 with 2N HCl. A solid formed, which was collected by filtration and washed three times with water (5 mL x 3). The solid was dried under vacuum at 55 °C to give 4-ethoxy-2-(methylthio)pyrimidine-5-carboxylic acid (7.1 g, Y: 95%) as a white solid. ESI-MS (M+H) + :214.9. 1 H NMR (400 MHz, DMSO-d6) δ 13.00 (s, 1H), 8.74 (s, 1H), 4.49 (m, 2H), 2.54 (s, 3H), 1.34 (t, J = 7.2, 3H).
[0445] Step 2: Synthesis of 4-ethoxy-N-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(methylthio)pyrimidine-5-carboxamide To a mixture of 4-ethoxy-2-(methylthio)pyrimidine-5-carboxylic acid (500 mg, 2.33 mmol) in DMF (10 mL), 8-fluoro-2-methylimidazo[1,2-a]pyridin-6-amine (422 mg, 2.56 mmol), DIEA (902 mg, 6.99 mmol), and HATU (1.3 g, 3.49 mmol) were added at 0 °C. The mixture was stirred at room temperature for 1 hour and quenched with water (10 mL). The mixture was filtered, and the cake was washed with EtOAc (5 mL) and dried under vacuum. The product, 4-ethoxy-N-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(methylthio)pyrimidine-5-carboxamide (360 mg, Y: 59%), was obtained as a yellow solid. ESI-MS (M+H) + :362.1. 1 H NMR (400 MHz, DMSO-d6) δ 10.16 (s, 1H), 9.11 (s, 1H), 8.69 (s, 1H), 7.95 (s, 1H), 7.21 (d, J = 12.2 Hz, 1H), 4.55 (q, J = 7.0 Hz, 2H), 2.57 (s, 3H), 2.35 (s, 3H), 1.40 (t, J = 7.0 Hz, 3H).
[0446] Step 3: Synthesis of 4-ethoxy-N-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(methylsulfinyl)pyrimidine-5-carboxamide To a mixture of 4-ethoxy-N-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(methylthio)pyrimidine-5-carboxamide (360 mg, 1.00 mmol) in DCM (10 mL) was added m-CPBA (156 mg, 0.90 mmol) at 0 °C. The reaction mixture was stirred at 0 °C for 1 h and quenched with saturated aqueous NaSO. The mixture was extracted with DCM (10 mL × 3). The combined organics were dried over sodium sulfate and concentrated. Crude 4-ethoxy-N-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(methylsulfinyl)pyrimidine-5-carboxamide (360 mg, Y: 95%) was obtained as a yellow solid, which was used in the next step without further purification. ESI-MS (M+H) + :378.0.
[0447] Step 4: Synthesis of tert-butyl (R)-4-(4-ethoxy-5-((8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)carbamoyl)pyrimidin-2-yl)-2-methylpiperazine-1-carboxylate To a solution of 4-ethoxy-N-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(methylsulfinyl)pyrimidine-5-carboxamide (90 mg, 0.24 mmol) in ACN (5 mL) was added tert-butyl (R)-2-methylpiperazine-1-carboxylate (48 mg, 0.24 mmol) and KCO (99 mg, 0.72 mmol). The reaction mixture was stirred at room temperature for 3 hours. After concentration, the residue was purified by silica gel column chromatography (DCM:MeOH=20:1) to give tert-butyl (R)-4-(4-ethoxy-5-((8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)carbamoyl)pyrimidin-2-yl)-2-methylpiperazine-1-carboxylate (50 mg, Y: 41%) as a yellow solid. ESI-MS (M+H) + :514.2. 1H NMR (400 MHz, CDCl3) δ 9.21 (s, 1H), 9.10 (d, J = 1.6 Hz, 1H), 8.99 (s, 1H), 7.40 (d, J = 2.3 Hz, 1H), 6.57 (dd, J = 10.9, 1.6 Hz, 1H), 4.62 - 4.60 (m, 4H), 4.38 (br s, 1H), 3.96 (d, J = 9.4 Hz, 1H), 3.29 (d, J = 12.1 Hz, 1H), 3.15 (m, 2H), 2.47 (s, 3H), 1.58 (t, J = 7.2Hz, 3H), 1.49 (s, 9H), 1.14 (d, J = 6.7 Hz, 3H).
[0448] Step 5: Synthesis of (R)-4-ethoxy-N-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(3-methylpiperazin-1-yl)pyrimidine-5-carboxamide hydrochloride To a solution of tert-butyl (R)-4-(4-ethoxy-5-((8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)carbamoyl)pyrimidin-2-yl)-2-methylpiperazine-1-carboxylate (45 mg, 0.088 mmol) in DCM (5 mL) was added a solution of HCl in 1,4-dioxane (1 mL, 4 mmol, 4 M) at 0° C. The reaction mixture was stirred at room temperature for 2 hours. After concentration, the residue was purified by preparative HPLC (0.05% HCl in MeCN / water) to give the title product (15.25 mg, Y: 39%) as a yellow solid. ESI-MS (M+H) + :414.4. 1H NMR (400 MHz, DMSO-d6) δ 10.37 (s, 1H), 9.80 (d, J = 13.5 Hz, 2H), 9.50 (t, J = 4.0 Hz, 1H), 8.65 (d, J = 10.8 Hz, 1H), 8.31 (s, 1H), 8.08 (d, J = 11.9 Hz, 1H), 4.65 (d, J = 13.6 Hz, 2H), 4.53 (q, J =7.2, 2H), 3.51 (t, J = 11.4 Hz, 1H), 3.32 (m, 3H), 3.02 (d, J = 9.6 Hz, 1H), 2.50 (s, 3H), 1.41 (t, J = 7.2 Hz, 3H), 1.34 (d, J = 5.7 Hz, 3H).
[0449] Example 4. 2-[(3R,5S)-3,5-Dimethylpiperazin-1-yl]-4-ethoxy-N-{8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl}pyrimidine-5-carboxamide hydrochloride (Compound 4) [ka] Step 1: Preparation of 2-(3,5-dimethylpiperazin-1-yl)-4-ethoxy-N-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)pyrimidine-5-carboxamide hydrochloride To a solution of 4-ethoxy-N-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(methylsulfinyl)pyrimidine-5-carboxamide (50 mg, 0.13 mmol) in ACN (5 mL) was added 2,6-dimethylpiperazine (16 mg, 0.13 mmol) and K2CO3 (53 mg, 0.39 mmol). The reaction mixture was stirred at room temperature for 3 hours. The solid was filtered and the filtrate was concentrated. The residue was purified by preparative HPLC (0.05% HCl in MeCN / water) to give the title product (46 mg, Y: 76%) as a yellow solid. ESI-MS (M+H) + :428.4. 1H NMR (400 MHz, DMSO) δ 10.37 (s, 1H), 9.80 (br s, 2H), 9.50 (t, J = 4.0 Hz, 1H), 8.65 (d, J = 10.8 Hz, 1H), 8.31 (s, 1H), 8.08 (d, J = 11.9 Hz, 1H), 4.65 (d, J = 13.6 Hz, 2H), 4.57 - 4.52 (m, 2H), 3.51 (t, J = 11.4 Hz, 1H), 3.34- 3.30 (m, 3H), 3.02 (d, J = 9.6 Hz, 1H), 2.50 (s, 3H), 1.41 (t, J = 8.2 Hz, 3H), 1.34 (d, J = 5.7 Hz, 6H).
[0450] Example 5. 4-Ethoxy-N-{8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl}-2-{octahydropyrrolo[1,2-a]pyrazin-2-yl}pyrimidine-5-carboxamide (Compound 5) [ka] Step 1: Preparation of 4-ethoxy-N-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)pyrimidine-5-carboxamide TFA salt To a solution of 4-ethoxy-N-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(methylsulfinyl)pyrimidine-5-carboxamide (54 mg, 0.143 mmol) in MeCN (4 mL) was added octahydropyrrolo[1,2-a]pyrazine dihydrochloride (33 mg, 0.172 mmol) and K2CO3 (60 mg, 0.429 mmol) at room temperature. The reaction mixture was stirred at room temperature for 1 hour. After concentration, the residue was purified by preparative TLC (DCM:MeOH = 20:1) and further purified by preparative HPLC (MeCN / water 0.05% TFA) to give the title product (25 mg, Y: 36%) as a yellow solid. ESI-MS (M+H) + :440.1. 1H NMR (400 MHz, DMSO-d6) δ 10.57, 9.89 (br s, 1H), 9.89 (s, 1H), 9.26 (s, 1H), 8.68 (s, 1H), 8.08 (s, 1H), 7.55 (d, J = 11.9 Hz, 1H), 5.06 - 5.02 (m, 1H), 4.56 (q, J = 7.0 Hz, 2H), 4.16 (br s, 2H), 3.52 (br s, 2H), 3.35 (br s, 1H), 3.25 - 2.96 (m, 3H), 2.41 (s, 3H), 2.19 - 2.15 (m, 2H), 1.90 - 1.86 (m, 2H), 1.43 (t, J = 7.0 Hz, 3H).
[0451] Example 6. 4-Ethoxy-N-{8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl}-2-(4-methylpiperazin-1-yl)pyrimidine-5-carboxamide (Compound 6) [ka] Step 1: Preparation of 4-ethoxy-N-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(4-methylpiperazin-1-yl)pyrimidine-5-carboxamide hydrochloride To a solution of 4-ethoxy-N-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(methylsulfinyl)pyrimidine-5-carboxamide (50 mg, 0.13 mmol) in ACN (5 mL) was added 1-methylpiperazine (13 mg, 0.13 mmol) and K2CO3 (53 mg, 0.39 mmol). The reaction mixture was stirred at room temperature for 1 hour. The solid was filtered and the filtrate was concentrated. The residue was purified by preparative HPLC (0.05% HCl in MeCN / water) to give the title product (35 mg, Y: 60%) as a yellow solid. ESI-MS (M+H) + :414.1. 1H NMR (400 MHz, DMSO) δ 11.11 (br s, 1H), 10.20 (s, 1H), 9.46 (s, 1H), 8.69 (s, 1H), 8.26 (s, 1H), 7.94 (d, J = 10.7 Hz, 1H), 4.77 (d, J = 14.0 Hz, 2H), 4.55 (q, J = 7.0 Hz, 2H), 3.50 - 3.44 (m, 4H), 3.12 - 3.04 (m, 2H), 2.80 (d, J = 4.2 Hz, 3H), 2.48 (s, 3H), 1.42 (t, J = 7.0Hz, 3H)
[0452] Example 7. 4-Ethoxy-N-{8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl}-2-[(3S)-3-methylpiperazin-1-yl]pyrimidine-5-carboxamide (Compound 7) [ka] Step 1: Preparation of tert-butyl (S)-4-(4-ethoxy-5-((8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)carbamoyl)pyrimidin-2-yl)-2-methylpiperazine-1-carboxylate To a solution of 4-ethoxy-N-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(methylsulfinyl)pyrimidine-5-carboxamide (80 mg, 0.21 mmol) in ACN (5 mL) was added tert-butyl (S)-2-methylpiperazine-1-carboxylate (84 mg, 0.42 mmol) and K2CO3 (87 mg, 0.63 mmol). The reaction mixture was stirred at room temperature for 1 hour. After concentration, the residue was purified by silica gel column chromatography (DCM:MeOH = 20:1, v / v) to give the title product (60 mg, Y: 56%) as a yellow solid. ESI-MS (M+H) + :514.2. 1H NMR (400 MHz, CDCl3) δ 9.14 (s, 1H), 9.02 (d, J = 1.5 Hz, 1H), 8.91 (s, 1H), 7.33 (d, J = 2.5 Hz, 1H), 6.50 (dd, J = 10.9, 1.5 Hz, 1H), 4.70 - 4.46 (m, 4H), 4.31 - 4.29 (m, 1H), 3.89 - 3.87 (m, 1H), 3.24 - 3.22 (m, 1H), 3.15 - 2.98 (m, 2H), 2.40 (s, 3H), 1.52 (t, J = 7.1 Hz, 3H), 1.42 (s, 9H), 1.07 (d, J = 6.7 Hz, 3H).
[0453] Step 2: Preparation of (S)-4-ethoxy-N-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(3-methylpiperazin-1-yl)pyrimidine-5-carboxamide TFA salt To a solution of tert-butyl (S)-4-(4-ethoxy-5-((8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)carbamoyl)pyrimidin-2-yl)-2-methylpiperazine-1-carboxylate (55 mg, 0.11 mmol) in DCM (5 mL) was added TFA (1 mL) at 0° C. The reaction mixture was stirred at 0° C. for 1 h. The resulting mixture was diluted with DCM and concentrated to dryness, which was repeated three times. The residue was triturated with PE:EA=10:1 (5 ml) and filtered. The solid was dried under vacuum to give the title product (22.48 mg, Y: 40%) as a yellow solid. ESI-MS (M+H) + :414.4. 1H NMR (400 MHz, DMSO-d6) δ 9.85 (s, 1H), 9.23 (s, 2H), 8.90 (s, 1H), 8.67 (s, 1H), 8.05 (s, 1H), 7.50 (d, J = 12.1 Hz, 1H), 4.68 - 4.65 (m, 2H), 4.55 (q, J = 6.9 Hz, 2H), 3.45 - 3.33 (m, 3H), 3.17 - 3.14 (m, 2H), 2.40 (s, 3H), 1.43 (t, J = 7.0 Hz, 3H), 1.28 (d, J = 6.4Hz, 3H).
[0454] Example 8. 4-Ethoxy-N-{8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl}-2-{octahydropyrrolo[3,4-c]pyrrol-2-yl}pyrimidine-5-carboxamide (Compound 8) [ka] Step 1: Preparation of tert-butyl 5-(4-ethoxy-5-((8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)carbamoyl)pyrimidin-2-yl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate To a solution of 4-ethoxy-N-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(methylsulfinyl)pyrimidine-5-carboxamide (60 mg, 0.16 mmol) in MeCN (3 mL) was added tert-butyl hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate (67 mg, 0.32 mmol) and K2CO3 (66 mg, 0.48 mmol). The reaction mixture was stirred at room temperature for 1 hour. After concentration, the residue was purified by silica gel column chromatography (DCM:MeOH = 20:1, v / v) to give the title product (50 mg, Y: 60%) as a yellow solid. ESI-MS (M+H) + :526.2. 1H NMR (400 MHz, CDCl3) δ 9.24 (s, 1H), 9.11 (s, 1H), 9.00 (s, 1H), 7.40 (d, J = 2.5 Hz, 1H), 6.57 (d, J = 10.8 Hz, 1H), 4.63 (q, J = 7.1 Hz, 2H), 3.89 (br s, 2H), 3.64 (br s, 2H), 3.34 - 3.30 (m, 2H), 3.01 (br s, 2H), 2.47 (s, 3H), 1.60 - 1.57 (m, 5H), 1.46 (s, 9H)
[0455] Step 2: Preparation of 4-ethoxy-N-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)pyrimidine-5-carboxamide TFA salt To a solution of tert-butyl 5-(4-ethoxy-5-((8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)carbamoyl)pyrimidin-2-yl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate (40 mg, 0.076 mmol) in DCM (5 mL) was added TFA (1 mL) at 0° C. The reaction mixture was stirred at 0° C. for 1 h. The resulting mixture was diluted with DCM and concentrated to dryness, which was repeated three times. The residue was triturated with PE:EA=10:1 (5 mL). The solid was collected by filtration and dried under vacuum to give the title product (7.82 mg, Y: 20%) as a yellow solid. ESI-MS (M+H) + :426.4. 1H NMR (400 MHz, DMSO-d6) δ 9.91 (s, 1H), 9.63 - 9.60 (m, 2H), 9.29 (s, 1H), 8.64 (s, 1H), 8.10 (s, 1H), 7.66 (d, J = 12.1 Hz, 1H), 4.55 (q, J = 7.0 Hz, 2H), 3.86 - 3.78 (m, 4H), 3.44 - 3.42 (m, 2H), 3.13 (br s, 4H), 2.42 (s, 3H), 1.43 (t, J = 7.0 Hz, 3H).
[0456] Example 9. 4-Ethoxy-N-{2-methylimidazo[1,2-a]pyrazin-6-yl}-2-(piperazin-1-yl)pyrimidine-5-carboxamide (Compound 9) [ka] Step 1: Preparation of 4-ethoxy-N-(2-methylimidazo[1,2-a]pyrazin-6-yl)-2-(methylthio)pyrimidine-5-carboxamide To a mixture of 2-methylimidazo[1,2-a]pyrazin-6-amine hydrochloride (359 mg, 1.95 mmol) in DMF (10 mL) was added 4-ethoxy-2-(methylthio)pyrimidine-5-carboxylic acid (627 mg, 2.93 mmol), DIPEA (755 mg, 5.85 mmol), and HATU (1.1 g, 2.93 mmol) at 0 °C. The mixture was stirred at room temperature for 1 h. After dilution with water (10 mL), the mixture was filtered, and the cake was washed with EtOAc (5 mL) and dried under vacuum to give the title product (160 mg, Y: 24%) as a yellow solid. ESI-MS (M+H) + :345.1. 1H NMR (400 MHz, CDCl3) δ 9.88 (s, 1H), 9.27 (d, J = 1.4 Hz, 1H), 9.14 (s, 1H), 8.75 (d, J = 0.7 Hz, 1H), 7.50 (s, 1H), 4.75 (q, J = 7.1 Hz, 2H), 2.61 (s, 3H), 2.52 (s, 3H), 1.62 (t, J = 7.1 Hz, 3H).
[0457] Step 2: Preparation of 4-ethoxy-N-(2-methylimidazo[1,2-a]pyrazin-6-yl)-2-(methylsulfinyl)pyrimidine-5-carboxamide To a mixture of 4-ethoxy-N-(2-methylimidazo[1,2-a]pyrazin-6-yl)-2-(methylthio)pyrimidine-5-carboxamide (155 mg, 0.45 mmol) in DCM (5 mL) was added m-CPBA (86 mg, 0.50 mmol) at 0 °C. The reaction mixture was stirred at 0 °C for 1 h and quenched with saturated aqueous NaSO. The mixture was extracted with DCM (10 mL × 3). The combined organic layers were dried over sodium sulfate and concentrated. The crude title product (150 mg, Y: 93%) was obtained as a yellow solid, which was used in the next step without further purification. ESI-MS (M+H) + :361.0.
[0458] Step 3: Preparation of tert-butyl 4-(4-ethoxy-5-((2-methylimidazo[1,2-a]pyrazin-6-yl)carbamoyl)pyrimidin-2-yl)piperazine-1-carboxylate To a solution of 4-ethoxy-N-(2-methylimidazo[1,2-a]pyrazin-6-yl)-2-(methylsulfinyl)pyrimidine-5-carboxamide (50 mg, 0.14 mmol) in MeCN (3 mL) was added tert-butyl piperazine-1-carboxylate (52 mg, 0.28 mmol) and KCO (58 mg, 0.42 mmol) at room temperature. The reaction mixture was stirred at room temperature for 2 hours. After concentration, the residue was purified by silica gel column chromatography (DCM:MeOH=20:1) to give the title product (35 mg, Y: 52%) as a yellow solid. ESI-MS (M+H) + :483.2. 1 H NMR (400 MHz, CDCl3) δ 9.81 (s, 1H), 9.27 (d, J = 1.4 Hz, 1H), 9.00 (s, 1H), 8.74 (s, 1H), 7.47 (s, 1H), 4.64 (q, J = 7.1 Hz, 2H), 3.90 (br s, 4H), 3.57 - 3.48 (m, 4H), 2.51 (s, 3H), 1.59 (t, J = 7.1 Hz, 3H), 1.50 (s, 9H).
[0459] Step 4: Preparation of 4-ethoxy-N-(2-methylimidazo[1,2-a]pyrazin-6-yl)-2-(piperazin-1-yl)pyrimidine-5-carboxamide TFA salt To a solution of tert-butyl 4-(4-ethoxy-5-((2-methylimidazo[1,2-a]pyrazin-6-yl)carbamoyl)pyrimidin-2-yl)piperazine-1-carboxylate (35 mg, 0.073 mmol) in DCM (10 mL) was added TFA (2 mL) at 0° C. The reaction mixture was stirred at room temperature for 2 hours. The resulting mixture was diluted with DCM and concentrated to dryness. The residue was treated with PE:EA (10:1) and the precipitate was filtered. The solid was washed with PE and dried under vacuum to give the title product (19.59 mg, Y: 56%) as a yellow solid. ESI-MS (M+H) + :383.2. 1H NMR (400 MHz, DMSO-d6) δ 9.91 (s, 1H), 9.36 (d, J = 1.4 Hz, 1H), 8.98 (br s, 2H), 8.87 (s, 1H), 8.80 (s, 1H), 8.08 (s, 1H), 4.59 (t, J = 7.1 Hz, 2H), 4.08 - 4.00 (m, 4H), 3.23 (br s, 4H), 2.42 (s, 3H), 1.48 (t, J = 7.1 Hz, 3H).
[0460] Example 10. 2-(3,3-Dimethylpiperazin-1-yl)-4-ethoxy-N-{2-methylimidazo[1,2-a]pyrazin-6-yl}pyrimidine-5-carboxamide (Compound 10) [ka] Step 1: Preparation of 2-(3,3-dimethylpiperazin-1-yl)-4-ethoxy-N-(2-methylimidazo[1,2-a]pyrazin-6-yl)pyrimidine-5-carboxamide To a solution of 4-ethoxy-N-(2-methylimidazo[1,2-a]pyrazin-6-yl)-2-(methylsulfinyl)pyrimidine-5-carboxamide (50 mg, 0.14 mmol) in MeCN (3 mL) was added 2,2-dimethylpiperazine (32 mg, 0.28 mmol) and K2CO3 (58 mg, 0.42 mmol). The reaction mixture was stirred at room temperature for 2 hours. After concentration, the residue was purified by silica gel column chromatography (DCM:MeOH = 10:1, v / v) to give the title product as a free base. The TFA salt was obtained after treatment with a DCM / TFA system to give the title product (37 mg, Y: 49%) as a yellow solid. ESI-MS (M+H) + :411.1. 1H NMR (400 MHz, DMSO-d6) δ 9.91 (s, 1H), 9.36 (d, J = 1.2 Hz, 1H), 9.04 (s, 2H), 8.86 (s, 1H), 8.79 (s, 1H), 8.08 (s, 1H), 4.60 (q, J = 6.9 Hz, 2H), 4.05 (br s, 2H), 3.90 (s, 2H), 3.28 (br s, 2H), 2.42 (s, 3H), 1.48 (t, J = 7.0 Hz, 3H), 1.32 (s, 6H).
[0461] Example 11. 4-Ethoxy-2-(3-ethylpiperazin-1-yl)-N-{8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl}pyrimidine-5-carboxamide (Compound 11) [ka] Step 1: Preparation of tert-butyl 4-(4-ethoxy-5-((8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)carbamoyl)pyrimidin-2-yl)-2-ethylpiperazine-1-carboxylate To a solution of 4-ethoxy-N-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(methylsulfinyl)pyrimidine-5-carboxamide (80 mg, 0.212 mmol) in MeCN (8 mL) was added tert-butyl 2-ethylpiperazine-1-carboxylate (55 mg, 0.255 mmol) and K2CO3 (59 mg, 0.424 mmol). The reaction mixture was stirred at room temperature for 1 hour. After concentration, the residue was purified by silica gel column chromatography (EA:PE=1:5) to give the title product (50 mg, Y: 44%) as a yellow solid. ESI-MS (M+H) + :528.3.
[0462] Step 2: Preparation of 4-ethoxy-2-(3-ethylpiperazin-1-yl)-N-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)pyrimidine-5-carboxamide TFA salt To a solution of tert-butyl 4-(4-ethoxy-5-((8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)carbamoyl)pyrimidin-2-yl)-2-ethylpiperazine-1-carboxylate (50 mg, 0.088 mmol) in DCM (5 mL) was added TFA (1 mL) at 0° C. The reaction mixture was stirred at room temperature for 1 h. After concentration, the residue was purified by preparative HPLC (0.05% TFA in MeCN / water) to give the title product (13.6 mg, Y: 33%) as a yellow solid. ESI-MS (M+H) + :428.2. 1 H NMR (400 MHz, DMSO-d6) δ 9.82 (s, 1H), 9.21 (s, 1H), 9.06 (s, 1H), 8.86 (s, 1H), 8.68 (s, 1H), 8.03 (s, 1H), 7.47 (d, J = 12.0 Hz, 1H), 4.75 - 4.61 (m, 2H), 4.58 - 4.49 (m, 2H), 3.48 - 3.36 (m, 2H), 3.19 - 3.10 (m, 3H), 2.39 (s, 3H), 1.70 - 1.60 (m, 2H), 1.43 (t, J = 7.0 Hz, 3H), 1.00 (t, J = 7.5 Hz, 3H).
[0463] Example 12. 4-Ethoxy-N-(4-fluoro-2-methyl-1,3-benzoxazol-6-yl)-2-(piperazin-1-yl)pyrimidine-5-carboxamide (Compound 12) [ka] Step 1: Synthesis of N-(4-bromo-2,6-difluorophenyl)acetamide To a mixture of 4-bromo-2,6-difluoroaniline (5 g, 24.1 mmol) in AcOH (20 mL) was added acetic anhydride (15 mL) at 0 °C, and the reaction mixture was stirred at 0 °C for 2 h. The mixture was diluted with water (250 mL). The precipitate was collected, washed with water (50 mL), and dried to give the desired product (4.5 g, crude yield: 85%) as a white solid, which was used in the next step without further purification. ESI-MS: [M+H] + 250.0
[0464] Step 2: Synthesis of 6-bromo-4-fluoro-2-methylbenzo[d]oxazole A suspension of N-(4-bromo-2,6-difluorophenyl)acetamide (3 g, 12.0 mmol) and Cs2CO3 (7.8 g, 24.0 mmol) in NMP (50 mL) was stirred at 150 °C for 3 h. After cooling to room temperature, the mixture was diluted with water (250 mL) and extracted with EA (150 mL × 2). The organic layer was washed with brine, dried over Na2SO4, and concentrated to dryness. The crude was purified by silica gel column (10-50% EA in PE). The product (1.2 g, Y: 44%) was obtained as a colorless oil. ESI-MS: [M+H] + 230.1
[0465] Step 3: Synthesis of N-(4-fluoro-2-methylbenzo[d]oxazol-6-yl)-1,1-diphenylmethanimine. A mixture of 6-bromo-4-fluoro-2-methylbenzo[d]oxazole (1.2 g, 5.02 mmol), diphenylmethanimine (1.3 g, 7.50 mmol), Pd(dba) (240 mg, 0.25 mmol), BINAP (150 mg, 0.25 mmol), and CsCO (5.0 g, 15.1 mmol) in tolune (25 mL) was purged with N three times at room temperature. The reaction mixture was then stirred at 100 °C for 16 h. After cooling to room temperature, the mixture was diluted with water and extracted with EA. The EA layer was washed with brine, dried over anhydrous NaSO, and concentrated to dryness. The crude material was purified by silica gel column chromatography (10-100% EA in PE). The product (500 mg, yield: 35%) was obtained as a yellow oil. ESI-MS: [M+H] + 331.1
[0466] Step 4: Synthesis of 4-fluoro-2-methylbenzo[d]oxazol-6-amine A mixture of N-(4-fluoro-2-methylbenzo[d]oxazol-6-yl)-1,1-diphenylmethanimine (500 mg, 1.6 mmol), NHOH.HCl (260 mg, 3.2 mmol), and NaOAc (600 mg, 8.1 mmol) in MeOH (50 ml) was stirred at room temperature for 1 h. The mixture was concentrated under reduced pressure. The residue was diluted with water (50 mL) and extracted with EA (50 ml × 2). The combined organics were washed with brine, dried over anhydrous NaSO, filtered, and concentrated. The crude product (250 mg, crude yield: 93%) as a yellow oil was used in the next step without further purification. ESI-MS: [M+H] + 166.9.
[0467] Step 5: Synthesis of 4-ethoxy-N-(4-fluoro-2-methylbenzo[d]oxazol-6-yl)-2-(methylthio)pyrimidine-5-carboxamide To a solution of 4-fluoro-2-methylbenzo[d]oxazol-6-amine (250 mg, 1.5 mmol) in DMF (10 mL) was added 4-ethoxy-2-(methylthio)pyrimidine-5-carboxylic acid (400 mg, 1.8 mmol), HATU (680 mg, 1.8 mmol), and DIEA (590 mg, 4.5 mmol). The reaction mixture was stirred at room temperature for 1 h. Water (50 mL) was added, and the mixture was filtered to obtain a filter cake. The crude material was purified by silica gel column chromatography (10-100% EA in PE). The product (160 mg, 30% yield) was obtained as a yellow solid. ESI-MS: [M+H] + 363.1
[0468] Step 6: Synthesis of 4-ethoxy-N-(4-fluoro-2-methylbenzo[d]oxazol-6-yl)-2-(methylsulfinyl)pyrimidine-5-carboxamide To a mixture of 4-ethoxy-N-(4-fluoro-2-methylbenzo[d]oxazol-6-yl)-2-(methylthio)pyrimidine-5-carboxamide (30 mg, 0.08 mmol) in DCM (5 mL) was added m-CPBA (16 mg, 0.09 mmol) at 0° C., and the mixture was stirred at room temperature for 30 minutes. The reaction mixture was diluted with water (15 mL) and extracted with DCM (20 mL×2). The combined organics were washed with brine and dried over sodium sulfate. After concentration under reduced pressure, the crude title product (30 mg, crude yield: 94%) was obtained as a yellow solid, which was used directly in the next step. ESI-MS: [M+H] + 379.1
[0469] Step 7: Synthesis of tert-butyl 4-(4-ethoxy-5-((4-fluoro-2-methylbenzo[d]oxazol-6-yl)carbamoyl)pyrimidin-2-yl)piperazine-1-carboxylate A stirred solution of 4-ethoxy-N-(4-fluoro-2-methylbenzo[d]oxazol-6-yl)-2-(methylsulfinyl)pyrimidine-5-carboxamide (30 mg, 0.08 mmol), tert-butyl piperazine-1-carboxylate (19 mg, 0.1 mmol), and K2CO3 (33 mg, 0.24 mmol) in ACN (5 mL) was stirred at room temperature for 3 hours. After filtration, the filtrate was concentrated to dryness, and the residue was diluted with water and extracted with EA. The organic phase was washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated to give the title product (30 mg, crude, yield: 75%) as a yellow solid, which was used directly in the next step. ESI-MS: [M+H] + 501.2
[0470] Step 8: Synthesis of 4-ethoxy-N-(4-fluoro-2-methylbenzo[d]oxazol-6-yl)-2-(piperazin-1-yl)pyrimidine-5-carboxamide To a solution of tert-butyl 4-(4-ethoxy-5-((4-fluoro-2-methylbenzo[d]oxazol-6-yl)carbamoyl)pyrimidin-2-yl)piperazine-1-carboxylate (30 mg, 0.06 mmol) in DCM (5 ml) was added TFA (0.5 mL) at 0° C. The reaction mixture was warmed to room temperature and stirred for 1 h. After concentration, the residue was purified by preparative HPLC to give the title product (5 mg, yield: 20%) as a white solid. ESI-MS: [M+H] + 401.0. 1 H NMR (400 MHz, MeOD-d4) δ 8.83 (d, J = 1.5 Hz, 1H), 7.93 (s, 1H), 7.39 - 7.35 (m, 1H), 4.65 (d, J = 7.1 Hz, 2H), 4.19 - 4.15 (m, 4H), 3.33 - 3.30 (m, 4H), 2.64 (s, 3H), 1.55 (t, J = 7.1 Hz, 3H).
[0471] Example 14. 4-Ethoxy-N-(4-fluoro-2-methyl-1,3-benzoxazol-6-yl)-2-{octahydropyrrolo[3,4-c]pyrrol-2-yl}pyrimidine-5-carboxamide (Compound 14) [ka] Step 1: Synthesis of tert-butyl 5-(4-ethoxy-5-((4-fluoro-2-methylbenzo[d]oxazol-6-yl)carbamoyl)pyrimidin-2-yl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate To a suspension of 4-ethoxy-N-(4-fluoro-2-methylbenzo[d]oxazol-6-yl)-2-(methylsulfinyl)pyrimidine-5-carboxamide (60 mg, 0.158 mmol) and tert-butyl hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate (35 mg, 0.190 mmol) in MeCN (2 mL), K2CO3 (65 mg, 0.594 mmol) was added, and the reaction mixture was stirred at room temperature for 2 h. The mixture was diluted with water and extracted with EA. The EA layer was washed with brine, dried over Na2SO4, and concentrated to dryness. The crude material was purified by silica gel column chromatography (10-50% EA in PE). The product was obtained as an off-white solid (50 mg, yield: 40%). MS m / z (ESI): [M+H] + 527.3. 1 H NMR (400 MHz, DMSO-d6) δ 9.85 (s, 1H), 8.63 (s, 1H), 8.00 (d, J = 1.5 Hz, 1H), 7.51 (dd, J = 12.2, 1.6 Hz, 1H), 4.54 (q, J = 7.0 Hz, 2H), 3.80 (s, 2H), 3.59 - 3.42 (m, 4H), 3.19 - 3.13 (m, 2H), 2.99 (s, 2H), 2.61 (S, 3H), 1.44 (t, J = 7.0 Hz, 3H), 1.39 (s, 9H).
[0472] Step 2: Synthesis of 4-ethoxy-N-(4-fluoro-2-methylbenzo[d]oxazol-6-yl)-2-(hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)pyrimidine-5-carboxamide To a solution of tert-butyl 5-(4-ethoxy-5-((4-fluoro-2-methylbenzo[d]oxazol-6-yl)carbamoyl)pyrimidin-2-yl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate (50 mg, 0.095 mmol) in DCM (5 mL) was added TFA (0.5 mL) at 0° C. After the addition, the reaction was stirred at room temperature for 1 h. After concentration, the crude was purified by preparative HPLC to give the title product (10 mg, yield: 25%) as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ 9.22 (d, J = 1.4 Hz, 1H), 8.31 (s, 2H), 7.93 (d, J = 2.4 Hz, 1H), 7.87 - 7.79 (m, 3H), 7.09 (s, 1H), 3.61 (s, 4H), 2.89 (s, 4H), 2.38 (s, 3H).MS m / z (ESI): [M+H] + 427.2. 1 H NMR (400 MHz, DMSO) δ 9.86 (s, 1H), 8.64 (s, 1H), 8.00 (s, 1H), 7.52 (d, J = 12.4 Hz, 1H), 4.56 - 4.54 (m, 2H), 3.87 - 3.77 (m, 2H), 3.54 (d, J = 9.2 Hz, 2H), 3.26 - 3.20 (m, 2H), 3.03 (s, 2H), 2.96 (d, J = 10.9 Hz, 2H), 2.61 (s, 3H), 1.44 (t, J = 7.0 Hz, 3H).
[0473] Example 15. 2-(1,4-diazepan-1-yl)-4-ethoxy-N-{8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl}pyrimidine-5-carboxamide (Compound 15) [ka] Step 1: tert-butyl 4-(4-ethoxy-5-((8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)carbamoyl)pyrimidin-2-yl)-1,4-diazepane-1-carboxylate To a solution of 4-ethoxy-N-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(methylsulfinyl)pyrimidine-5-carboxamide (90 mg, 0.24 mmol) in ACN (5 mL) was added tert-butyl 1,4-diazepane-1-carboxylate (48 mg, 0.24 mmol) and K2CO3 (99 mg, 0.72 mmol). The reaction mixture was stirred at room temperature for 3 hours. After concentration, the residue was purified by silica gel column chromatography (DCM:MeOH=20:1) to give the title product (60 mg, Y: 48%) as a yellow solid. ESI-MS (M+H) + :514.1.
[0474] Step 2: 2-(1,4-diazepan-1-yl)-4-ethoxy-N-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)pyrimidine-5-carboxamide 2,2,2-trifluoroacetate To a solution of tert-butyl 4-(4-ethoxy-5-((8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)carbamoyl)pyrimidin-2-yl)-1,4-diazepane-1-carboxylate (51 mg, 0.1 mmol) in DCM (3 mL) was added TFA (1 mL) at 0° C. The reaction mixture was stirred for 30 min. After concentration, the residue was purified by preparative HPLC (0.05% TFA in MeCN / water) to give the title product (11 mg, Y: 21%) as a yellow solid. ESI-MS (M+H) + :414.0. 1H NMR (400 MHz, DMSO) δ 9.77 (s, 1H), 9.22 (s, 1H), 8.80 - 8.58 (m, 3H), 8.03 (s, 1H), 7.49 (s, 1H), 4.55 (q, J = 7.0 Hz, 2H), 4.03 (br s, 2H), 3.89 (d, J = 6.2 Hz, 2H), 3.31 (s, 3H), 3.21 (br s, 2H), 2.39 (br s, 2H), 2.05 (br s, 2H), 1.43 (t, J = 7.0 Hz, 3H).
[0475] Example 16. N-{2,8-dimethylimidazo[1,2-a]pyrazin-6-yl}-4-ethoxy-2-(piperazin-1-yl)pyrimidine-5-carboxamide (Compound 16) [ka] Step 1: Synthesis of tert-butyl 4-(5-((2,8-dimethylimidazo[1,2-a]pyrazin-6-yl)carbamoyl)-4-ethoxypyrimidin-2-yl)piperazine-1-carboxylate A mixture of N-(2,8-dimethylimidazo[1,2-a]pyrazin-6-yl)-4-ethoxy-2-(methylsulfinyl)pyrimidine-5-carboxamide (80 mg, 0.21 mmol), tert-butyl piperazine-1-carboxylate (59 mg, 0.32 mmol), and K2CO3 (58 mg, 0.42 mmol) in MeCN (3 mL) was stirred at room temperature for 1 h. The solid was filtered, and the filtrate was concentrated. The residue was purified by silica gel column chromatography (1-10% MeOH in DCM). The product (95 mg, 90% yield) was obtained as a crude white solid. MS m / z (ESI): [M+H] + 497.5
[0476] Example 17. 2-{2,7-diazaspiro[3.5]nonan-2-yl}-N-{2,8-dimethylimidazo[1,2-a]pyrazin-6-yl}-4-ethoxypyrimidine-5-carboxamide (Compound 17) [ka] Step 1: Preparation of tert-butyl 2-(5-((2,8-dimethylimidazo[1,2-a]pyrazin-6-yl)carbamoyl)-4-ethoxypyrimidin-2-yl)-2,7-diazaspiro[3.5]nonane-7-carboxylate To a solution of N-(2,8-dimethylimidazo[1,2-a]pyrazin-6-yl)-4-ethoxy-2-(methylsulfinyl)pyrimidine-5-carboxamide (80 mg, 0.212 mmol) in ACN (8 mL) was added tert-butyl 2,7-diazaspiro[3.5]nonane-7-carboxylate (55 mg, 0.255 mmol) and KCO (59 mg, 0.424 mmol). The reaction mixture was stirred at room temperature for 1 hour. After concentration, the residue was purified by silica gel column chromatography (EA:PE=1:5) to give the title product (50 mg, Y: 44%) as a yellow solid. ESI-MS (M+H) + :528.3. 1 H NMR (400 MHz, DMSO-d6) δ 9.75 (s, 1H), 9.14 (s, 1H), 8.72 (s, 1H), 7.96 (s, 1H), 4.56 (d, J = 7.1 Hz, 2H), 3.87 (s, 4H), 3.22 (br s, 4H), 2.90 (s, 3H), 2.68 (s, 3H), 1.70 (br s, 4H), 1.47 (t, J = 7.0 Hz, 3H), 1.40 (s, 9H).
[0477] Step 2: Preparation of N-(2,8-dimethylimidazo[1,2-a]pyrazin-6-yl)-4-ethoxy-2-(2,7-diazaspiro[3.5]nonan-2-yl)pyrimidine-5-carboxamide TFA salt To a solution of tert-butyl 2-(5-((2,8-dimethylimidazo[1,2-a]pyrazin-6-yl)carbamoyl)-4-ethoxypyrimidin-2-yl)-2,7-diazaspiro[3.5]nonane-7-carboxylate (53 mg, 0.1 mmol) in DCM (10 mL) was added TFA (1 mL) at 0° C. The reaction mixture was stirred at room temperature for 1 h. After concentration, the residue was purified by preparative HPLC (0.05% TFA in MeCN / water) to give the title product (45 mg, Y: 80%) as a yellow solid. ESI-MS (M+H) + :437.0. 1 H NMR (400 MHz, DMSO-d6) δ 9.85 (s, 1H), 9.23 (s, 1H), 8.72 (s, 1H), 8.52 (br s, 2H), 8.06 (s, 1H), 4.56 (q, J = 7.1 Hz, 2H), 3.93 (s, 4H), 3.09 (s, 4H), 2.70 (s, 3H), 2.42 (s, 3H), 1.95 (s, 4H), 1.47 (t, J = 7.1 Hz, 3H).
[0478] Example 18. 2-{2,6-diazaspiro[3.3]heptan-2-yl}-N-{2,8-dimethylimidazo[1,2-a]pyrazin-6-yl}-4-ethoxypyrimidine-5-carboxamide (Compound 18) [ka] Step 1: Preparation of tert-butyl 6-(5-((2,8-dimethylimidazo[1,2-a]pyrazin-6-yl)carbamoyl)-4-ethoxypyrimidin-2-yl)-2,6-diazaspiro[3.3]heptane-2-carboxylate To a solution of N-(2,8-dimethylimidazo[1,2-a]pyrazin-6-yl)-4-ethoxy-2-(methylsulfinyl)pyrimidine-5-carboxamide (70 mg, 0.168 mmol) in ACN (3 mL) was added tert-butyl 2,6-diazaspiro[3.3]heptane-2-carboxylate (97 mg, 0.335 mmol) and KCO (70 mg, 0.504 mmol). The reaction mixture was stirred at room temperature for 2 hours. After concentration, the residue was purified by silica gel column chromatography (EA:PE=1:5) to give the title product (55 mg, Y: 65%) as a pale yellow solid. ESI-MS (M+H) + :509.2. 1 H NMR (400 MHz, DMSO-d6) δ 9.75 (s, 1H), 9.14 (s, 1H), 8.71 (s, 1H), 7.95 (s, 1H), 4.58 - 4.52 (m, 2H), 4.26 (s, 4H), 3.63 (s, 4H), 2.37 (s, 3H), 2.18 (s, 3H), 1.47 (t, J = 7.0 Hz, 3H), 1.38 (s, 9H).
[0479] Step 2: Preparation of N-(2,8-dimethylimidazo[1,2-a]pyrazin-6-yl)-4-ethoxy-2-(2,6-diazaspiro[3.3]heptan-2-yl)pyrimidine-5-carboxamide To a solution of tert-butyl 6-(5-((2,8-dimethylimidazo[1,2-a]pyrazin-6-yl)carbamoyl)-4-ethoxypyrimidin-2-yl)-2,6-diazaspiro[3.3]heptane-2-carboxylate (53 mg, 0.1 mmol) in DCM (10 mL) was added TFA (1 mL) at 0° C. The reaction mixture was stirred at room temperature for 1 h. After concentration, the residue was purified by preparative HPLC (0.05% TFA in MeCN / water) to give the title product (13.5 mg, Y: 20.7%) as a yellow solid. ESI-MS (M+H) + :409.2. 1H NMR (400 MHz, DMSO-d6) δ 9.86 (s, 1H), 9.22 (s, 1H), 8.72 (s, 1H), 8.63 (br s, 2H), 8.05 (s, 1H), 4.56 (q, J = 6.9 Hz, 2H), 4.31 (s, 4H), 4.19 (t, J = 5.9 Hz, 4H), 2.70 (s, 3H), 2.42 (s, 3H), 1.47 (t, J = 7.0 Hz, 3H).
[0480] Example 19. N-{2,8-dimethylimidazo[1,2-a]pyrazin-6-yl}-4-ethoxy-2-[(3S)-3-methylpiperazin-1-yl]pyrimidine-5-carboxamide (Compound 19) [ka] Step 1: Preparation of tert-butyl (S)-4-(5-((2,8-dimethylimidazo[1,2-a]pyrazin-6-yl)carbamoyl)-4-ethoxypyrimidin-2-yl)-2-methylpiperazine-1-carboxylate To a solution of N-(2,8-dimethylimidazo[1,2-a]pyrazin-6-yl)-4-ethoxy-2-(methylsulfinyl)pyrimidine-5-carboxamide (80 mg, 0.212 mmol) in ACN (8 mL) was added tert-butyl (S)-2-methylpiperazine-1-carboxylate (85 mg, 0.424 mmol) and K2CO3 (59 mg, 0.424 mmol). The reaction mixture was stirred at room temperature for 1 hour. After concentration, the residue was purified by silica gel column chromatography (EA:PE=1:5) to give the title product (75 mg, Y: 69%) as a yellow solid. ESI-MS (M+H) + :511.3.
[0481] Step 2: Preparation of (S)—N-(2,8-dimethylimidazo[1,2-a]pyrazin-6-yl)-4-ethoxy-2-(3-methylpiperazin-1-yl)pyrimidine-5-carboxamide TFA salt To a solution of tert-butyl (S)-4-(5-((2,8-dimethylimidazo[1,2-a]pyrazin-6-yl)carbamoyl)-4-ethoxypyrimidin-2-yl)-2-methylpiperazine-1-carboxylate (75 mg, 0.14 mmol) in DCM (5 mL) was added TFA (1 mL) at 0° C. The reaction mixture was stirred at room temperature for 1 h. After concentration, the residue was purified by preparative HPLC (0.05% TFA in MeCN / water) to give the title product (52 mg, Y: 72%) as a yellow solid. ESI-MS (M+H) + :411.2. 1 H NMR (400 MHz, DMSO) δ 9.90 (s, 1H), 9.23 (s, 2H), 8.90 (s, 1H), 8.78 (s, 1H), 8.06 (s, 1H), 4.68 (d, J = 12.8 Hz, 2H), 4.60 (q, J = 7.0 Hz, 2H), 3.40 - 3.36 (m, 3H), 3.24 - 3.04 (m, 2H), 2.71 (s, 3H), 2.42 (s, 3H), 1.48 (t, J = 7.0 Hz, 3H), 1.29 (d, J = 6.4 Hz, 3H).
[0482] Example 20. N-{2,8-dimethylimidazo[1,2-a]pyrazin-6-yl}-4-ethoxy-2-{octahydropyrrolo[3,4-c]pyrrol-2-yl}pyrimidine-5-carboxamide (Compound 20) [ka] Step 1: Preparation of tert-butyl 5-(5-((2,8-dimethylimidazo[1,2-a]pyrazin-6-yl)carbamoyl)-4-ethoxypyrimidin-2-yl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate To a solution of N-(2,8-dimethylimidazo[1,2-a]pyrazin-6-yl)-4-ethoxy-2-(methylsulfinyl)pyrimidine-5-carboxamide (80 mg, 0.212 mmol) in ACN (8 mL) was added tert-butyl hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate (90 mg, 0.424 mmol) and K2CO3 (59 mg, 0.424 mmol). The reaction mixture was stirred at room temperature for 1 hour. After concentration, the residue was purified by silica gel column chromatography (EA:PE=1:5) to give the title product (100 mg, Y: 90%) as a yellow solid. ESI-MS (M+H) + :523.3.
[0483] Step 2: Preparation of N-(2,8-dimethylimidazo[1,2-a]pyrazin-6-yl)-4-ethoxy-2-(hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)pyrimidine-5-carboxamide TFA salt To a solution of tert-butyl 5-(5-((2,8-dimethylimidazo[1,2-a]pyrazin-6-yl)carbamoyl)-4-ethoxypyrimidin-2-yl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate (52 mg, 0.11 mmol) in DCM (5 mL) was added TFA (1 mL) at 0° C. The reaction mixture was stirred at room temperature for 30 min. After concentration, the residue was purified by preparative HPLC (0.05% TFA in MeCN / water) to give the title product (32 mg, Y: 60%) as a yellow solid. ESI-MS (M+H) + :413.2. 1H NMR (400 MHz, DMSO) δ 9.86 (s, 1H), 9.24 (s, 1H), 9.00 (s, 2H), 8.76 (s, 1H), 8.07 (s, 1H), 4.60 (q, J = 7.0 Hz, 2H), 3.86 - 3.75 (m, 2H), 3.62 (d, J = 11.7 Hz, 2H), 3.45 (d, J = 4.9 Hz, 2H), 3.16 (br s, 4H), 2.71 (s, 3H), 2.43 (s, 4H), 1.49 (t, J = 7.0 Hz, 3H).
[0484] Example 21. N-{8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl}-2-(piperazin-1-yl)pyrimidine-5-carboxamide (Compound 21) [ka] Step 1: Synthesis of ethyl 2-(4-(tert-butoxycarbonyl)piperazin-1-yl)pyrimidine-5-carboxylate To a suspension of ethyl 2-chloropyrimidine-5-carboxylate (3.0 g, 16.3 mmol) and tert-butyl piperazine-1-carboxylate (3.3 g, 17.9 mmol) in 1,4-dixoane (30 mL) was added TEA (4.9 g, 48.9 mmol), and the reaction mixture was stirred for 16 hours at 60° C. After cooling to room temperature, the mixture was diluted with water (100 mL), filtered, and the filter cake was washed with water (50 mL) and dried to afford the crude title product (2.5 g, Y: 46%) as a white solid, which was used directly in the next step.
[0485] Step 2: Synthesis of 2-(4-(tert-butoxycarbonyl)piperazin-1-yl)pyrimidine-5-carboxylic acid To a mixture of ethyl 2-(4-(tert-butoxycarbonyl)piperazin-1-yl)pyrimidine-5-carboxylate (500 mg, 1.5 mmol) in MeOH (100 mL) and water (10 mL) was added LiOH (600 mg, 15 mmol). The reaction mixture was stirred at room temperature for 2 hours. After concentration, the residue was diluted with water (30 mL), adjusted to pH = 3, and the precipitate was filtered. The filter cake was washed with water (20 mL) and dried to give the title product (200 mg, Y: 43%) as a white solid. 1 H NMR (400 MHz, DMSO) δ 8.82 (s, 2H), 3.89 - 3.86 (m, 4H), 3.47 (d, J = 5.5 Hz, 4H), 1.47 (s, 9H).
[0486] Step 3: Synthesis of tert-butyl 4-(5-((8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)carbamoyl)pyrimidin-2-yl)piperazine-1-carboxylate To a solution of 2-(4-(tert-butoxycarbonyl)piperazin-1-yl)pyrimidine-5-carboxylic acid (200 mg, 0.65 mmol) in DMF (8 mL) was added HATU (250 mg, 0.8 mmol), DIEA (160 mg, 1.3 mmol), and the reaction mixture was stirred at room temperature for 30 minutes. 8-Fluoro-2-methylimidazo[1,2-a]pyridin-6-amine (165 mg, 1.0 mmol) was then added, and the reaction was stirred for an additional 2 hours. The mixture was diluted with water (50 mL), and the solid was filtered. The solid was washed with water and dried to give the title product (100 mg, Y: 23%) as a brown solid. ESI-MS: [M+H] + 456.5
[0487] Step 4: Synthesis of N-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(piperazin-1-yl)pyrimidine-5-carboxamide To a mixture of tert-butyl 4-(5-((8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)carbamoyl)pyrimidin-2-yl)piperazine-1-carboxylate (100 mg, 0.22 mmol) in DCM (3 mL) was added TFA (1.0 mL), and the reaction mixture was stirred at room temperature for 1 h. Concentrated, the residue was purified by preparative HPLC (MeCN / 0.05% NH3.HO in water) to give the title product (15 mg, yield: 9%) as a white solid. ESI-MS: [M+H] + 356.0 1 H NMR (400 MHz, DMSO) δ 10.14 (s, 1H), 9.03 (d, J = 1.5 Hz, 1H), 8.88 (s, 2H), 7.90 (d, J = 2.7 Hz, 1H), 7.26 (dd, J = 12.6, 1.6 Hz, 1H), 3.80 - 3.76 (m, 4H), 2.77 - 2.73 (m, 4H), 2.34 (s, 3H).
[0488] Example 22. N-{2,8-dimethylimidazo[1,2-a]pyrazin-6-yl}-4-methoxy-2-{octahydropyrrolo[3,4-c]pyrrol-2-yl}pyrimidine-5-carboxamide (Compound 22) [ka] Step 1: Preparation of tert-butyl 5-(5-((2,8-dimethylimidazo[1,2-a]pyrazin-6-yl)carbamoyl)-4-methoxypyrimidin-2-yl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate To a solution of N-(2,8-dimethylimidazo[1,2-a]pyrazin-6-yl)-4-ethoxy-2-(methylsulfinyl)pyrimidine-5-carboxamide (76 mg, 0.212 mmol) in ACN (8 mL) was added tert-butyl hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate (90 mg, 0.424 mmol) and K2CO3 (59 mg, 0.424 mmol). The reaction mixture was stirred at room temperature for 1 hour. After concentration, the residue was purified by silica gel column chromatography (EA:PE=1:5) to give the title product (51 mg, Y: 47%) as a yellow solid. ESI-MS (M+H) + :509.2.
[0489] Step 2: Preparation of N-(2,8-dimethylimidazo[1,2-a]pyrazin-6-yl)-2-(hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-4-methoxypyrimidine-5-carboxamide TFA salt To a solution of tert-butyl 5-(5-((2,8-dimethylimidazo[1,2-a]pyrazin-6-yl)carbamoyl)-4-methoxypyrimidin-2-yl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate (51 mg, 0.1 mmol) in DCM (5 mL) was added TFA (1 mL) at 0° C. The reaction mixture was stirred at room temperature for 30 min. After concentration, the residue was purified by preparative HPLC (0.05% TFA in MeCN / water) to give the title product (30 mg, Y: 57%) as a yellow solid. ESI-MS (M+H) + :409.2. 1 H NMR (400 MHz, MeOD-d4) δ 9.09 (s, 1H), 8.78 (s, 1H), 7.75 (s, 1H), 4.19 (s, 3H), 3.86 (d, J = 9.0 Hz, 2H), 3.56 (d, J = 10.6 Hz, 2H), 3.14 (dd, J = 11.2, 7.1 Hz, 2H), 3.00 (br s, 2H), 2.82 - 2.75 (m, 2H), 2.74 (s, 3H), 2.44 (s, 3H).
[0490] Example 25. 4-Ethoxy-N-(2-methyl-2H-indazol-5-yl)-2-(piperazin-1-yl)pyrimidine-5-carboxamide (Compound 25) [ka] Step 1: Preparation of 4-ethoxy-N-(2-methyl-2H-indazol-5-yl)-2-(methylthio)pyrimidine-5-carboxamide A mixture of 2-methyl-2H-indazol-5-amine (100 mg, 0.680 mmol), HATU (388 mg, 1.02 mmol), 4-ethoxy-2-(methylthio)pyrimidine-5-carboxylic acid (175 mg, 0.816 mmol), and DIEA (175 mg, 1.36 mmol) in DMF (5 mL) was stirred at room temperature for 2 h. The reaction mixture was diluted with water (30 mL), stirred at room temperature for 30 min, and the precipitate was filtered and concentrated in vacuo to give 4-ethoxy-N-(2-methyl-2H-indazol-5-yl)-2-(methylthio)pyrimidine-5-carboxamide (200 mg, 85.8% yield) as a yellow solid. 1 H NMR (400 MHz, DMSO-d6) δ 9.98 (s, 1H), 8.70 (s, 1H), 8.30 (s, 1H), 8.25 (s, 1H), 7.59 (d, J = 9.2 Hz, 1H), 7.30 (d, J = 9.2 Hz, 1H), 4.55 (q, J = 7.0 Hz, 2H), 4.15 (s, 3H), 2.58 (s, 3H), 1.42 (t, J = 7.0 Hz, 3H).ESI-MS (M+H) + :344.1
[0491] Step 2: Preparation of 4-ethoxy-N-(2-methyl-2H-indazol-5-yl)-2-(methylsulfinyl)pyrimidine-5-carboxamide To a solution of 4-ethoxy-N-(2-methyl-2H-indazol-5-yl)-2-(methylthio)pyrimidine-5-carboxamide (100 mg, 0.292 mmol) in DCM (5 ml) was added m-CPBA (78.8 mg, 0.321 mmol) at 0 °C, and the mixture was stirred at this temperature for 1 hour. Saturated NaHSO (10 mL) was added to the mixture, and the mixture was extracted with DCM (20 mL * 2). The combined organic layer was washed with brine (50 mL), filtered, and concentrated in vacuo to give 4-ethoxy-N-(2-methyl-2H-indazol-5-yl)-2-(methylsulfinyl)pyrimidine-5-carboxamide (120 mg, crude) as a yellow solid, which was used directly in the next step. ESI-MS: [M+H] + 360.1
[0492] Step 3: Preparation of tert-butyl 4-(4-ethoxy-5-((2-methyl-2H-indazol-5-yl)carbamoyl)pyrimidin-2-yl)piperazine-1-carboxylate To a solution of compound 4-ethoxy-N-(2-methyl-2H-indazol-5-yl)-2-(methylsulfinyl)pyrimidine-5-carboxamide (120 mg, 0.334 mmol) and tert-butyl piperazine-1-carboxylate (93.2 mg, 0.501 mmol) in CHCN (5 mL) was added KCO (92.2 mg, 0.668 mmol), and the reaction mixture was stirred for 2 hours at 50° C. The mixture was diluted with EA (80 mL), washed with water (20 mL) and brine (20 mL), dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by column chromatography (PE / EA=1:1) to give tert-butyl 4-(4-ethoxy-5-((2-methyl-2H-indazol-5-yl)carbamoyl)pyrimidin-2-yl)piperazine-1-carboxylate (100 mg, yield: 62.5%) as a yellow solid. 1H NMR (400 MHz, CDCl3) δ 9.41 (s, 1H), 9.05 (s, 1H), 8.42 (s, 1H), 7.85 (s, 1H), 7.65 (d, J = 9.1 Hz, 1H), 7.05 (d, J = 9.1 Hz, 1H), 4.60 (q, J = 7.0 Hz, 2H), 4.21 (s, 3H), 3.96 - 3.81 (m, 4H), 3.56 - 3.46 (m, 4H), 1.60 (t, J = 7.0 Hz, 3H), 1.50 (s, 9H).ESI-MS (M+H) + :482.3.
[0493] Step 4: N-(2,8-dimethylimidazo[1,2-a]pyrazin-6-yl)-2-(hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-4-hydroxypyrimidine-5-carboxamide hydrochloride To a solution of tert-butyl 4-(4-ethoxy-5-((2-methyl-2H-indazol-5-yl)carbamoyl)pyrimidin-2-yl)piperazine-1-carboxylate (100 mg, 0.208 mmol) in 1,4-dioxane (2 ml), 4 M HCl / dioxane (2 ml) was added and the mixture was stirred at room temperature for 2 hours. The precipitate was filtered and concentrated in vacuo to give 4-ethoxy-N-(2-methyl-2H-indazol-5-yl)-2-(piperazin-1-yl)pyrimidine-5-carboxamide hydrochloride (67 mg, yield: 71.3%) as a yellow solid. 1H NMR (400 MHz, DMSO-d6) δ 9.71 - 9.69 (m, 3H), 8.66 (s, 1H), 8.33 (s, 1H), 8.24 (s, 1H), 7.58 (d, J = 9.1 Hz, 1H), 7.33 (d, J = 9.1 ESI-MS: [M+H] + 382.2.
[0494] Example 26. 4-Ethoxy-N-(7-fluoro-2-methyl-2H-indazol-5-yl)-2-(piperazin-1-yl)pyrimidine-5-carboxamide (Compound 26) [ka] Step 1: Preparation of tert-butyl 4-4-ethoxy-5-[(7-fluoro-2-methyl-2H-indazol-5-yl)carbamoyl]pyrimidin-2-ylpiperazine-1-carboxylate tert-Butyl 4-(5-carbamoyl-4-ethoxypyrimidin-2-yl)piperazine-1-carboxylate (199.78 mg, 568.53 μmol), 5-bromo-7-fluoro-2-methyl-2H-indazole (130.22 mg, 568.53 μmol), tris((1E,4E)-1,5-diphenylpenta-1,4-dien-3-one)dipalladium (52.06 mg, 56.85 μmol), [5-(diphenylphosphanyl)-9,9-dimethyl-9H-xanthen-4-yl]diphenylphosphane (65.79 mg, 113.71 μmol), and cesium carbonate (555.71 mg, 1.71 mmol) were mixed in dioxane under an argon atmosphere. The reaction mixture was heated to 100° C. for 17 hours. The resulting mixture was evaporated under reduced pressure and purified by HPLC to give tert-butyl 4-4-ethoxy-5-[(7-fluoro-2-methyl-2H-indazol-5-yl)carbamoyl]pyrimidin-2-ylpiperazine-1-carboxylate (120.0 mg, Y: 42.3%). ESI-MS (M+H) + :500.4.
[0495] Step 2: Preparation of 4-ethoxy-N-(7-fluoro-2-methyl-2H-indazol-5-yl)-2-(piperazin-1-yl)pyrimidine-5-carboxamide Tert-butyl 4-4-ethoxy-5-[(7-fluoro-2-methyl-2H-indazol-5-yl)carbamoyl]pyrimidin-2-ylpiperazine-1-carboxylate (119.0 mg, 238.22 μmol) was dissolved in DCM (1 mL) and TFA (1 mL), and the reaction mixture was stirred overnight at room temperature. The resulting mixture was evaporated under reduced pressure and purified by HPLC to give pure 4-ethoxy-N-(7-fluoro-2-methyl-2H-indazol-5-yl)-2-(piperazin-1-yl)pyrimidine-5-carboxamide (79.1 mg, Y: 64.8%) as a TFA salt. ESI-MS (M+H) + :400.2. 1 H NMR (400 MHz, DMSO-d6) δ 9.62 (s, 1H), 8.78 (br s, 2H), 8.64 (s, 1H), 8.63 (s, 1H), 8.38 (s, 1H), 7.94 (s, 1H), 7.25 (d, J = 8 Hz, 1H), 4.51 (q, J = 7.2 Hz, 2H), 4.14 (s, 3H), 4.01-3.95 (m, 4H), 3.20-3.15 (m, 4H), 1.39 (t, J = 7.1 Hz, 3H).
[0496] Example 27. 4-Ethoxy-N-{8-methoxy-2-methylimidazo[1,2-a]pyridin-6-yl}-2-(piperazin-1-yl)pyrimidine-5-carboxamide (Compound 27) [ka] Step 1: Preparation of tert-butyl 4-[4-ethoxy-5-(8-methoxy-2-methylimidazo[1,2-a]pyridin-6-ylcarbamoyl)pyrimidin-2-yl]piperazine-1-carboxylate tert-butyl 4-(5-carbamoyl-4-ethoxypyrimidin-2-yl)piperazine-1-carboxylate (199.89 mg, 568.83 μmol), 6-Bromo-8-methoxy-2-methylimidazo[1,2-a]pyridine (137.14 mg, 568.83 μmol), tris((1E,4E)-1,5-diphenylpenta-1,4-dien-3-one)dipalladium (52.09 mg, 56.88 μmol), [5-(diphenylphosphanyl)-9,9-dimethyl-9H-xanthen-4-yl]diphenylphosphane (65.83 mg, 113.77 μmol), and cesium carbonate (556.01 mg, 1.71 mmol) were mixed in dioxane under an argon atmosphere. The reaction mixture was heated to 100° C. for 17 hours. The resulting mixture was evaporated under reduced pressure and purified by HPLC to give tert-butyl 4-[4-ethoxy-5-(8-methoxy-2-methylimidazo[1,2-a]pyridin-6-ylcarbamoyl)pyrimidin-2-yl]piperazine-1-carboxylate (200.0 mg, Y: 68.7%). ESI-MS (M+H) + :512.2. Step 2: Preparation of 4-ethoxy-N-8-methoxy-2-methylimidazo[1,2-a]pyridin-6-yl-2-(piperazin-1-yl)pyrimidine-5-carboxamide; trifluoroacetic acid tert-Butyl 4-[4-ethoxy-5-(8-methoxy-2-methylimidazo[1,2-a]pyridin-6-ylcarbamoyl)pyrimidin-2-yl]piperazine-1-carboxylate (99.3 mg, 194.11 μmol) was dissolved in DCM (1 mL) and TFA (1 mL), and the reaction mixture was stirred at room temperature overnight. The resulting mixture was evaporated under reduced pressure and purified by HPLC to give pure 4-ethoxy-N-8-methoxy-2-methylimidazo[1,2-a]pyridin-6-yl-2-(piperazin-1-yl)pyrimidine-5-carboxamide (84.4 mg, Y: 82.7%) as the TFA salt. ESI-MS (M+H) + :412.2. 1H NMR (400 MHz, DMSO-d6) 10.01 (s, 1H), 9.19 (s, 1H), 8.99 (br s, 2H), 8.63 (s, 1H), 8.14 (s, 1H), 7.41 (s, 1H), 4.51 (q, J = 7.2 Hz, 2H), 4.04 (s, 3H) 4.02 - 3.97 (m, 4H), 3.22-3.14 (m, 4H), 2.40 (s, 3H), 1.39 (t, J = 7.1 Hz, 3H).
[0497] Example 28. 4-Ethoxy-N-{2-methylimidazo[1,2-a]pyrazin-6-yl}-2-{octahydropyrrolo[3,4-c]pyrrol-2-yl}pyrimidine-5-carboxamide (Compound 28) [ka] Step 1: tert-Butyl 5-(4-ethoxy-5-((2-methylimidazo[1,2-a]pyrazin-6-yl)carbamoyl)pyrimidin-2-yl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate To a solution of 4-ethoxy-N-(2-methylimidazo[1,2-a]pyrazin-6-yl)-2-(methylsulfinyl)pyrimidine-5-carboxamide (100 mg, 0.278 mmol) in ACN (5 mL) was added tert-butyl hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate (117 mg, 0.56 mmol) and KCO (115 mg, 0.833 mmol). The reaction mixture was stirred at 50 °C for 3 h. After concentration, the residue was purified by preparative HPLC (0.05% HCl / CHCN in water) to give the product (60 mg, Y: 42.5%) as a yellow solid. ESI-MS (M+H) + :509.3. 1H NMR (400 MHz, CDCl3) δ 9.83 (s, 1H), 9.27 (d, J = 1.3 Hz, 1H), 9.01 (s, 1H), 8.74 (s, 1H), 7.47 (s, 1H), 4.66 (q, J = 7.1 Hz, 2H), 3.90 (br.s, 2H), 3.76 - 3.52 (m, 4H), 3.44 - 3.22 (m, 2H), 3.01 (br.s, 2H), 2.51 (s, 3H), 1.59 (t, J = 7.1 Hz, 3H), 1.46 (s, 9H).
[0498] Step 2: 4-Ethoxy-2-(hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-N-(2-methylimidazo[1,2-a]pyrazin-6-yl)pyrimidine-5-carboxamide hydrochloride To a solution of tert-butyl 5-(4-ethoxy-5-((2-methylimidazo[1,2-a]pyrazin-6-yl)carbamoyl)pyrimidin-2-yl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate (60 mg, 0.118 mmol) in EA (5 mL) was added HCl in EA (5 mL) at room temperature. The reaction mixture was stirred at room temperature for 1 h. The resulting mixture was concentrated and the crude was purified by preparative HPLC to give the title product (6 mg, Y: 12.4%) as hydrochloride as a yellow solid. ESI-MS (M+H) + :409.1. 1 H NMR (400 MHz, MeOD-d4) δ 9.29 - 9.25 (m, 1H), 8.84 - 8.80 (m, 1H), 8.68 (d, J = 1.5 Hz, 1H), 7.84 (s, 1H), 4.69 - 4.66 (m, 2H), 3.86 (br.s, 2H), 3.57 (d, J = 12.3 Hz, 2H), 3.19 - 3.12 (m, 2H), 3.01 (br.s, 2H), 2.80 (d, J = 11.0 Hz, 2H), 2.46 (s, 3H), 1.56 (t, J = 7.1 Hz, 3H). Example 29. Parallel synthesis of compounds 32-106 [ka]
[0499] To a mixture of 1 equivalent of ArSOMe (A) and 2 equivalents of amine (B) in 1 mL of NMP, 5.0 equivalents of *DIPEA were added. The reaction mixture was stirred at 100°C for 16 hours. After cooling to room temperature, the solvent was evaporated and 1 ml of cleavage cocktail** was added. The mixture was reacted for 4 hours and evaporated to dryness. The residue was dissolved in DMSO and subjected to HPLC purification***. *When Reagent 1 and / or Reagent 2 were used as salts, an additional amount of DIPEA (1.1 equivalents for each equivalent of acid) was added to the reaction mixture to convert the reagents to the free forms. **Cleavage cocktail was prepared by mixing TFA (92.5% v / v), water (5% v / v), and TIPS (2.5% v / v). *** The resulting solution was purified by HPLC using deionized water (phase A) and HPLC-grade acetonitrile (phase B) as eluents to give the final compound (D). In most cases, TFA was used as an additive. Instrument: Agilent 1260 Infinity system equipped with DAD and mass detector Column: Waters Sunfire C18 OBD Prep column, 100A, 5µm, 19mm x 100mm, with SunFire C18 Prep Guard cartridge, 100A, 10µm, 19mm x 10mm [Table 3-1] [Table 3-2] [Table 3-3] [Table 3-4] [Table 3-5] [Table 3-6] [Table 3-7] [Table 3-8] [Table 3-9] [Table 3-10] [Table 3-11] [Table 3-12] [Table 3-13]
[0500] Example 30. Parallel synthesis of compounds 107-248 [ka] To a mixture of 1 equivalent of ArSOMe (A) and 2 equivalents of amine (B) in 1 mL of NMP, 5.0 equivalents of *DIPEA were added. The reaction mixture was stirred at 100°C for 16 hours. After cooling to room temperature, the solvent was evaporated and 1 ml of cleavage cocktail** was added. The mixture was reacted for 4 hours and evaporated to dryness. The residue was dissolved in DMSO and subjected to HPLC purification***. *When Reagent 1 and / or Reagent 2 were used as salts, an additional amount of DIPEA (1.1 equivalents for each equivalent of acid) was added to the reaction mixture to convert the reagents to the free forms. **Cleavage cocktail was prepared by mixing TFA (92.5% v / v), water (5% v / v), and TIPS (2.5% v / v). *** The resulting solution was purified by HPLC using deionized water (phase A) and HPLC-grade acetonitrile (phase B) as eluents to give the final compound (D). In most cases, TFA was used as an additive. Instrument: Agilent 1260 Infinity system equipped with DAD and mass detector Column: Waters Sunfire C18 OBD Prep column, 100A, 5µm, 19mm x 100mm, with SunFire C18 Prep Guard cartridge, 100A, 10µm, 19mm x 10mm [Table 4-1] [Table 4-2] [Table 4-3] [Table 4-4] [Table 4-5] [Table 4-6] [Table 4-7] [Table 4-8] [Table 4-9] [Table 4-10] [Table 4-11] [Table 4-12] [Table 4-13] [Table 4-14] [Table 4-15] [Table 4-16] [Table 4-17] [Table 4-18] [Table 4-19] [Table 4-20] [Table 4-21] [Table 4-22] [Table 4-23] [Table 4-24] [Table 4-25] [Table 4-26]
[0501] Starting Material: Preparation of 2-(3-((tert-butoxycarbonyl)(methyl)amino)azetidin-1-yl)-4-ethoxypyrimidine-5-carboxylic acid [ka] Step 1: Ethyl 4-ethoxy-2-(methylthio)pyrimidine-5-carboxylate To a stirred solution of ethyl 4-chloro-2-(methylthio)pyrimidine-5-carboxylate (50 g, 215.0 mmol) in EtOH (500 mL) was added NaOEt (36.1 g, 645.0 mmol) under an argon atmosphere, and the mixture was stirred at room temperature for 5 hours. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was diluted with EtOAc and washed with brine. The organic layer was concentrated, and the residue was purified by silica gel column chromatography (PE / EA=4:1) to give ethyl 4-ethoxy-2-(methylthio)pyrimidine-5-carboxylate (43 g, Y: 83%) as a white solid. ESI-MS (M+H) + :243.3.
[0502] Step 2: Ethyl 4-ethoxy-2-(methylsulfinyl)pyrimidine-5-carboxylate To a stirred solution of ethyl 4-ethoxy-2-(methylthio)pyrimidine-5-carboxylate (20 g, 93.0 mmol) in DCM (200 mL) was added m-CPBA (16 g, 93.0 mmol) at 0 °C. The mixture was warmed to room temperature and stirred for 1 h. The reaction mixture was diluted with DCM (200 mL) and quenched with saturated NaSO (100 mL). The organic phase was washed with saturated sodium carbonate (200 mL) and dried over sodium sulfate. After concentration under reduced pressure, ethyl 4-ethoxy-2-(methylsulfinyl)pyrimidine-5-carboxylate (20 g, Y: 93%) was obtained as a white solid, which was used in the next step without further purification. ESI-MS (M+H) + :259.0. 1 H NMR (400 MHz, CDCl3) δ 9.06 (s, 1H), 4.66 (q, J = 7.1 Hz, 2H), 4.41 (q, J = 7.1 Hz, 2H), 2.98 (s, 3H), 1.48 (t, J = 7.1 Hz, 3H), 1.41 (t, J = 7.1 Hz, 3H).
[0503] Step 3: Synthesis of ethyl 2-(3-((tert-butoxycarbonyl)(methyl)amino)azetidin-1-yl)-4-ethoxypyrimidine-5-carboxylate To a stirred solution of ethyl 4-ethoxy-2-(methylsulfinyl)pyrimidine-5-carboxylate (3 g, 11.61 mmol) in MeCN (80 mL) was added tert-butyl azetidin-3-yl(methyl)carbamate hydrochloride (5.17 g, 23.23 mmol) and potassium carbonate (3.21 g, 23.23 mmol). The mixture was stirred at room temperature for 1 hour. After concentration, the residue was diluted with EA (200 mL), washed with water (150 mL), dried over sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column (PE:EA=2:1) to give the title product (2 g, Y: 45.28%) as a white solid. ESI-MS (M+H) + :381.2. 1 H NMR (400 MHz, CDCl3) δ 8.72 (s, 1H), 5.08 (br s, 1H), 4.46 (q, J = 7.1 Hz, 2H), 4.36 (t, J = 9.0 Hz, 2H), 4.29 (q, J = 7.1 Hz, 2H), 4.20 (d, J = 5.2 Hz, 2H), 3.01 (s, 3H), 1.47 (s, 9H), 1.42 (t, J = 7.1 Hz, 3H), 1.34 (t, J = 7.1 Hz, 3H).
[0504] Step 4: Synthesis of 2-(3-((tert-butoxycarbonyl)(methyl)amino)azetidin-1-yl)-4-ethoxypyrimidine-5-carboxylic acid To a solution of ethyl 2-(3-((tert-butoxycarbonyl)(methyl)amino)azetidin-1-yl)-4-ethoxypyrimidine-5-carboxylate (2 g, 5.26 mmol) in MeOH (20 mL) and HO (20 mL) was added LiOH (630 mg, 26.28 mmol) at room temperature. The reaction mixture was stirred at 50° C. overnight. After concentration, the residue was purified by reverse phase column (ACN in water, 50%) to give the title product (1 g, yield: 54%) as a white solid. ESI-MS (M+H) + :353.1. 1 H NMR (400 MHz, CDCl3) δ 8.65 (s, 1H), 5.19 - 4.70 (m, 3H), 4.60 (q, J = 7.0 Hz, 2H), 4.54 - 4.39 (m, 2H), 3.00 (s, 3H), 1.52 - 1.41 (m, 12H).
[0505] Starting Material: Preparation of 2-(3-((tert-butoxycarbonyl)(methyl)amino)pyrrolidin-1-yl)-4-ethoxypyrimidine-5-carboxylic acid. [ka] Step 1: Preparation of ethyl 2-(3-((tert-butoxycarbonyl)(methyl)amino)pyrrolidin-1-yl)-4-ethoxypyrimidine-5-carboxylate To a mixture of ethyl 4-ethoxy-2-(methylsulfinyl)pyrimidine-5-carboxylate (4.5 g, 22.50 mmol) and tert-butylmethyl(pyrrolidin-3-yl)carbamate (8.7 g, 33.75 mmol) in ACN (50 mL) was added K2CO3 (6.2 g, 45.00 mmol). The mixture was stirred at 50 °C for 2 h. The reaction was diluted with water (50 mL) and extracted with EA (80 mL × 3). The organic layer was washed with brine, dried over Na2SO4, and evaporated. The crude was purified by silica gel column chromatography (PE:EA = 6:1) to give the title product (6.5 g, 73.9% yield) as a white solid. ESI-MS (M+H) + :395.0.
[0506] Step 2: Preparation of 2-(3-((tert-butoxycarbonyl)(methyl)amino)pyrrolidin-1-yl)-4-ethoxypyrimidine-5-carboxylic acid To a mixture of ethyl 2-(3-((tert-butoxycarbonyl)(methyl)amino)pyrrolidin-1-yl)-4-ethoxypyrimidine-5-carboxylate (6.5 g, 16.5 mmol) in MeOH (100 mL) and HO (100 mL) was added LiOH (3.38 g, 82.5 mmol). The reaction solution was stirred at room temperature for 1 h. After concentration to remove most of the MeOH, the aqueous phase was adjusted to pH 5 and extracted with EA (80 mL × 3). The organic layer was washed with brine, dried over NaSO, filtered, and evaporated to give the title product (5.5 g, 91.7% yield) as a white solid. ESI-MS (M+H) + :367.3. 1 H NMR (400 MHz, DMSO-d6) δ 8.59 (s, 1H), 4.79 - 4.53 (m, 1H), 4.42 (q, J = 7.0 Hz, 2H), 3.78 - 3.67 (m, 2H), 3.51 - 3.37 (m, 2H), 2.77 - 2.73 (m, 3H), 2.13 - 2.05 (m, 2H), 1.42 (s, 9H), 1.33 (t, J = 7.0 Hz, 3H).
[0507] Preparation of 2-((1-(tert-butoxycarbonyl)piperidin-4-yl)amino)-4-ethoxypyrimidine-5-carboxylic acid. [ka] Step 1: Preparation of ethyl 2-((1-(tert-butoxycarbonyl)piperidin-4-yl)amino)-4-ethoxypyrimidine-5-carboxylate To a solution of ethyl 4-ethoxy-2-(methylsulfinyl)pyrimidine-5-carboxylate (5 g, 19.38 mmol) in CHCN (60 mL) was added KCO (5.34 g, 38.76 mmol) and tert-butyl 4-aminopiperidine-1-carboxylate (11.6 g, 58.14 mmol), and the mixture was stirred at 50 °C for 2 h. The reaction mixture was concentrated in vacuo to remove CHCN. The crude was diluted with water (30 mL) and extracted with EA (30 mL × 3). The organic layer was washed with brine, dried over NaSO, and concentrated in vacuo. The crude was purified by column chromatography (PE:EA = 5:1) to give the title compound (3 g, 39.4%) as a white solid. ESI-MS (M+H) + :395.2.
[0508] Step 2: Preparation of 2-((1-(tert-butoxycarbonyl)piperidin-4-yl)amino)-4-ethoxypyrimidine-5-carboxylic acid To a mixture of ethyl 2-((1-(tert-butoxycarbonyl)piperidin-4-yl)amino)-4-ethoxypyrimidine-5-carboxylate (3 g, 7.60 mmol) in THF:HO (10 mL:10 mL) was added LiOH (0.64 g, 15.20 mmol) and the mixture was stirred at 35° C. for 3 h. The reaction mixture was concentrated in vacuo to remove most of the THF. The mixture was adjusted to pH=5 with 1 M HCl. The precipitate was filtered to give the title product (2 g, 72%) as a white solid. ESI-MS (M+H) + :367.2.
[0509] Preparation of 2-((1-(tert-butoxycarbonyl)piperidin-4-yl)(methyl)amino)-4-methoxypyrimidine-5-carboxylic acid. [ka] Step 1: Preparation of ethyl 4-methoxy-2-(methylthio)pyrimidine-5-carboxylate To a solution of ethyl 4-chloro-2-(methylthio)pyrimidine-5-carboxylate (10 g, 0.043 mol) in MeOH (100 mL) was added NaOMe (2.56 g, 0.047 mol). The mixture was stirred at 0° C. for 1 h. The mixture was concentrated in vacuo to remove most of the MeOH. The crude was diluted with water (80 mL) and extracted with EA (100 mL×3). The organic layer was washed with brine, dried over Na2SO4, and concentrated in vacuo to give the title product (9.5 g, 0.97%) as a yellow solid. ESI-MS (M+H) + :229.1
[0510] Step 2: Preparation of ethyl 4-methoxy-2-(methylsulfinyl)pyrimidine-5-carboxylate To a solution of ethyl 4-methoxy-2-(methylthio)pyrimidine-5-carboxylate (9.5 g, 0.042 mol) in DCM (100 mL) was added m-CPBA (10.75 g, 0.060 mol). The mixture was stirred at room temperature for 1 h. The mixture was diluted with water (100 mL). The organic layer was washed with vinegar, dried over NaSO, and concentrated in vacuo to give the crude title product (9 g, 90%) as a white solid. ESI-MS (M+H): 245.1.
[0511] Step 3: Preparation of ethyl 2-((1-(tert-butoxycarbonyl)piperidin-4-yl)(methyl)amino)-4-methoxypyrimidine-5-carboxylate To a solution of ethyl 4-methoxy-2-(methylsulfinyl)pyrimidine-5-carboxylate (2 g, 8.20 mmol) in CHCN (30 mL) was added KCO (2.3 g, 16.40 mmol) and tert-butyl 4-methylpiperazine-1-carboxylate (2.6 g, 12.30 mol), and the mixture was stirred at 50 °C for 1 h. The reaction mixture was concentrated in vacuo to remove CHCN. The crude was diluted with water (30 mL) and extracted with EA (30 mL × 3). The organic layer was washed with brine, dried over NaSO, and concentrated in vacuo. The crude was purified by column chromatography (PE:EA = 5:1) to give the title compound (2.5 g, 78%) as a white solid. ESI-MS (M+H) + :395.3.
[0512] Step 4: Preparation of 2-((1-(tert-butoxycarbonyl)piperidin-4-yl)(methyl)amino)-4-methoxypyrimidine-5-carboxylic acid To a mixture of ethyl 2-((1-(tert-butoxycarbonyl)piperidin-4-yl)(methyl)amino)-4-methoxypyrimidine-5-carboxylate (2.5 g, 6.30 mmol) in THF:HO (10 mL:10 mL) was added LiOH (0.8 g, 18.90 mmol) and the mixture was stirred at 35° C. for 3 h. The reaction mixture was concentrated in vacuo to remove most of the THF. The mixture was adjusted to pH=5 with 1 M HCl. The precipitate was filtered and dried under vacuum to give the title product (1 g, 43.4%) as a white solid. ESI-MS (M+H) + :367.2.
[0513] Preparation of 2-((1-(tert-butoxycarbonyl)piperidin-4-yl)(methyl)amino)-4-methoxypyrimidine-5-carboxylic acid. [ka] Step 1: Preparation of ethyl 2-((1-(tert-butoxycarbonyl)piperidin-4-yl)(ethyl)amino)-4-ethoxypyrimidine-5-carboxylate To a mixture of ethyl 2-((1-(tert-butoxycarbonyl)piperidin-4-yl)amino)-4-ethoxypyrimidine-5-carboxylate (3 g, 7.60 mmol) in DMF (20 mL) was added NaH (0.64 g, 15.20 mmol) and CH3CHI (20 mL). The mixture was stirred at room temperature for 1 h. The mixture was diluted with water (50 mL) and extracted with EA (80 mL x 3). The organic layer was washed with brine, dried over Na2SO4 and concentrated in vacuo. The crude was purified by column chromatography (PE:EA = 5:1) to give the title compound (1.1 g, 34%) as a white solid. ESI-MS (M+H) + :423.3.
[0514] Step 2: Preparation of 2-((1-(tert-butoxycarbonyl)piperidin-4-yl)(ethyl)amino)-4-ethoxypyrimidine-5-carboxylic acid To a mixture of ethyl 2-((1-(tert-butoxycarbonyl)piperidin-4-yl)(ethyl)amino)-4-ethoxypyrimidine-5-carboxylate (1.1 g, 2.60 mmol) in THF:HO (10 mL:10 mL) was added LiOH (0.22 g, 5.20 mmol) and the mixture was stirred at 35° C. for 3 h. The reaction mixture was concentrated in vacuo to remove most of the THF. The mixture was adjusted to pH=5 with 1 M HCl. The precipitate was filtered and dried under vacuum to give the title product (450 mg, 44%) as a white solid. ESI-MS (M+H) + :395.2.
[0515] Starting Material: Preparation of 8-Fluoro-2-methylimidazo[1,2-a]pyridin-6-amine [ka] Step 1: 6-Bromo-8-fluoro-2-methylimidazo[1,2-a]pyridine A mixture of 5-bromo-3-fluoropyridin-2-amine (50 g, 263 mmol) and 1-bromopropan-2-one (89.5 g, 658 mmol) in EtOH (500 mL) was heated to 90 °C for 16 h. The reaction was cooled to room temperature, and the precipitated solid was collected by filtration and washed with EtOH. The cake was dissolved in HO, basified to pH 10 with NaCO, and the precipitated solid was collected by filtration, washed with HO, and dried in vacuo to give 6-bromo-8-fluoro-2-methylimidazo[1,2-a]pyridine (40 g, Y: 67%) as a white solid. ESI-MS (M+H) + :229.1, 231.1. 1 H NMR (400 MHz, DMSO-d6) δ 8.71 (d, J = 1.4 Hz, 1H), 7.82 - 7.73 (m, 1H), 7.38 (dd, J = 10.7, 1.5 Hz, 1H), 2.35 (d, J = 0.6 Hz, 3H).
[0516] Step 2: N-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-1,1-diphenylmethanimine A mixture of 6-bromo-8-fluoro-2-methylimidazo[1,2-a]pyridine (15 g, 65.8 mmol), diphenylmethanimine (12.5 g, 69.1 mmol), Pd(OAc) (1.48 g, 6.58 mmol), BINAP (8.2 g, 13.2 mmol), and CsCO (42.8 g, 131.6 mmol) in dioxane (150 mL) was purged with N three times at room temperature. The mixture was then heated at 115 °C for 16 h. The mixture was cooled to room temperature, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column (0-50% EA in PE) to give N-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-1,1-diphenylmethanimine (16 g, yield: 74%) as a light brown solid. ESI-MS (M+H) + :330.4. 1H NMR (400 MHz, DMSO-d6) δ 7.83 (d, J = 1.2 Hz, 1H), 7.68 (d, J = 7.3 Hz, 2H), 7.62 (d, J = 2.8 Hz, 1H), 7.56 (d, J = 7.2 Hz, 1H), 7.48 (t, J = 7.5 Hz, 2H), 7.43 - 7.35 (m, 3H), 7.24 - 7.21 (m, 2H), 6.65 - 6.63 (m, 1H), 2.27 (s, 3H).
[0517] Step 3: 8-Fluoro-2-methylimidazo[1,2-a]pyridin-6-amine To a solution of N-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-1,1-diphenylmethanimine (15 g, 45.6 mmol) in DCM (100 mL) was added HCl-dioxane (4 M, 22.8 mL, 91.2 mmol) at 0 °C. The mixture was stirred at room temperature for 16 h. After concentration, the residue was treated with EA. The residue was dissolved in HO and basified to pH 10 with NaCO. The precipitated solid was collected by filtration, washed with HO, and dried in vacuo to give 8-fluoro-2-methylimidazo[1,2-a]pyridin-6-amine (7.2 g, yield: 96%) as a yellow solid. ESI-MS (M+H) + :166.1. 1 H NMR (400 MHz, DMSO-d6) δ 8.04 (s, 1H), 7.85 (s, 1H), 7.38 (d, J = 12.3 Hz, 1H), 3.57 (s, 2H), 2.43 (s, 3H).
[0518] Starting material: Preparation of (R)-2-(3-((tert-butoxycarbonyl)(methyl)amino)pyrrolidin-1-yl)-4-ethoxypyrimidine-5-carboxylic acid. [ka] Step 1: Ethyl (R)-2-(3-((tert-butoxycarbonyl)(methyl)amino)pyrrolidin-1-yl)-4-ethoxypyrimidine-5-carboxylate To a stirred solution of ethyl 4-ethoxy-2-(methylsulfinyl)pyrimidine-5-carboxylate (20 g, 87 mmol) in MeCN (200 mL) was added tert-butyl (R)-methyl(pyrrolidin-3-yl)carbamate (17.4 g, 87 mmol) and potassium carbonate (23.6 g, 174 mmol). The mixture was stirred at 50° C. for 2 h. After concentration, the residue was treated with EA / water (300 mL, 1:1). The organic phase was separated, and the aqueous phase was extracted with EA (150 mL×3). The combined organics were dried over sodium sulfate. After concentration under reduced pressure, the crude product, ethyl (R)-2-(3-((tert-butoxycarbonyl)(methyl)amino)pyrrolidin-1-yl)-4-ethoxypyrimidine-5-carboxylate (28 g, Y: 92%), was obtained as a white solid, which was used in the next step without further purification. ESI-MS (M+H) + :395.5. 1 H NMR (400 MHz, CDCl3) δ 8.74 (s, 1H), 4.86 (br.s, 1H), 4.48 (q, J = 7.1 Hz, 2H), 4.29 (q, J = 7.1 Hz, 2H), 3.85 - 3.82 (m, 2H), 3.59 - 3.41 (m, 2H), 2.82 (s, 3H), 2.23 - 2.07 (m, 2H), 1.48 (s, 9H), 1.43 (t, J = 7.1 Hz, 3H), 1.34 (t, J = 7.1 Hz, 3H).
[0519] Step 2: (R)-2-(3-((tert-butoxycarbonyl)(methyl)amino)pyrrolidin-1-yl)-4-ethoxypyrimidine-5-carboxylic acid To a solution of ethyl (R)-2-(3-((tert-butoxycarbonyl)(methyl)amino)pyrrolidin-1-yl)-4-ethoxypyrimidine-5-carboxylate (28 g, 71.0 mmol) in THF (280 mL) and HO (28 ml), LiOH.HO (7.5 g, 177.5 mmol) was added. The reaction mixture was stirred at room temperature for 3 h. After concentration, the residue was diluted with water (100 mL) and the pH was adjusted to 5-6 with 1N aqueous HCl. A solid formed, which was collected by filtration and washed three times with water (50 mL × 3). The solid was dried under vacuum at 55 °C to give the title product (16 g, yield: 86%) as a yellow solid. ESI-MS (M+H) + :367.5. 1 H NMR (400 MHz, DMSO-d6) δ 12.16 (s, 1H), 8.60 (s, 1H), 4.67 (br.s, 1H), 4.42 (q, J = 7.0 Hz, 2H), 3.83 - 3.68 (m, 2H), 3.53 - 3.37 (m, 2H), 2.75 (s, 3H), 2.13 - 2.04 (m, 2H), 1.42 (s, 9H), 1.32 (t, J = 7.0 Hz, 3H).
[0520] Starting Material: Preparation of 4-ethoxy-N-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(methylsulfinyl)pyrimidine-5-carboxamide. [ka] Step 1: Preparation of 4-ethoxy-N-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(methylthio)pyrimidine-5-carboxamide To a solution of 4-ethoxy-2-(methylthio)pyrimidine-5-carboxylic acid (3.5 g, 14.52 mmol) in DMF (40 mL) was added DIEA (8.44 g, 58.09 mmol), HATU (8.14 g, 21.38 mmol), and 8-fluoro-2-methylimidazo[1,2-a]pyridin-6-amine (3.2 g, 17.42 mmol). The reaction mixture was stirred at 45 °C for 3 h. The mixture was diluted with water (200 mL). The precipitate was filtered, washed with water, and dried in vacuo to give the title product (3 g, 59.3%) as a black solid. ESI-MS (M+H) + :362.0.
[0521] Step 2: Preparation of 4-ethoxy-N-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(methylsulfinyl)pyrimidine-5-carboxamide To a solution of 4-ethoxy-N-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(methylthio)pyrimidine-5-carboxamide (1.00 g, 2.77 mmol) in DCM (10 mL) was added m-CPBA (0.71 g, 4.16 mmol). The mixture was stirred at room temperature for 1 hour. The mixture was extracted with water (30 mL x 3). The organic layer was washed with brine, dried over Na2SO4, and concentrated in vacuo to give the title product (1.0 g, 95.8%) as a white solid. ESI-MS (M+H) + :378.4.
[0522] Example 30. (S)-2-(3-((dimethylamino)methyl)piperidin-1-yl)-4-ethoxy-N-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)pyrimidine-5-carboxamide formate (Compound 250) [ka] Step 1: Preparation of tert-butyl (R)-3-formylpiperidine-1-carboxylate To a mixture of tert-butyl (R)-3-(hydroxymethyl)piperidine-1-carboxylate (4.0 g, 18.60 mmol) in DCM (20 mL) was added Dess-Martin reagent (500 mg, 2.90 mmol) at 0° C. The mixture was stirred at room temperature for 5 hours. The mixture was diluted with water (50 mL) and extracted with DCM (100 mL). The organic layer was washed with brine, dried over NaSO, and concentrated in vacuo. The crude was purified by silica gel column chromatography (PE:EA=5:1) to give the title product (2.8 g, 71.8%) as a yellow oil. 1 H NMR (400 MHz, CDCl3) δ 9.70 (s, 1H), 3.93 - 3.92 (m, 1H), 3.70 - 3.61 (m, 1H), 3.34 - 3.32 (m, 1H), 3.10 - 3.09 (m, 1H), 2.44 - 2.43 (m, 1H), 1.96 (d, J = 6.7 Hz, 1H), 1.68 - 1.66 (m, 2H), 1.52 - 1.51 (m, 1H), 1.46 (s, 9H).
[0523] Step 2: Preparation of tert-butyl (S)-3-((dimethylamino)methyl)piperidine-1-carboxylate To a mixture of tert-butyl (R)-3-formylpiperidine-1-carboxylate (1.0 g, 4.70 mmol) in DCM (10 mL) was added dimethylamine (0.21 mL, 0.42 mmol, 2 M in THF) and HOAc (115 mg, 1.4 mmol). The mixture was stirred at 50° C. for 1 h. Then NaBH(OAc) (36 mg, 0.571 mmol) was added, and the mixture was stirred at 50° C. for 2 h. The reaction mixture was diluted with water (50 mL) and extracted with EA (50 mL × 3). The organic layer was washed with brine, dried over NaSO, and concentrated in vacuo. The crude was purified by silica gel column chromatography (PE / EA = 5:1) to give the title product (400 mg, Y: 36.4%) as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 4.09 - 3.75 (m, 2H), 3.48 - 3.48 (m, 2H), 2.84 - 2.54 (m, 2H), 2.46 (s, 6H), 1.98 - 1.84 (m, 1H), 1.84 - 1.73 (m, 1H), 1.70 - 1.62 (m, 1H), 1.57 - 1.34 (m, 10H), 1.27 - 1.19 (m, 1H).
[0524] Step 3: Preparation of (R)-N,N-dimethyl-1-(piperidin-3-yl)methanamine hydrochloride To a solution of tert-butyl (S)-3-((dimethylamino)methyl)piperidine-1-carboxylate (400 mg, 1.65 mmol) in EA (5 mL) was added 3M HCl / EA (10 mL). The mixture was stirred at room temperature for 2 h. After concentration, the residue was diluted with water (20 mL) and extracted with EA (20 mL x 3). The aqueous phase was concentrated in vacuo and lyophilized to give the title product (250 mg, yield: 85.4%) as a yellow solid. ESI-MS (M+H) + :143.1.
[0525] Step 4: Preparation of (S)-2-(3-((dimethylamino)methyl)piperidin-1-yl)-4-ethoxy-N-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)pyrimidine-5-carboxamide formate To a mixture of (R)-N,N-dimethyl-1-(piperidin-3-yl)methanamine hydrochloride (250 mg, 1.40 mmol) in CHCN (3 mL) was added 4-ethoxy-N-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(methylsulfinyl)pyrimidine-5-carboxamide (80 mg, 0.39 mmol) and KCO (73 mg, 0.53 mmol). The mixture was stirred at 50 °C for 2 h. The mixture was diluted with HO (5 mL) and extracted with EA (10 mL × 3). The organic layer was concentrated in vacuo. The crude was purified by preparative HPLC (0.05% FA / ACN in water) to give the title product (18 mg, Y: 2.04%) as a yellow solid. ESI-MS (M+H) + :456.3. 1 H NMR (400 MHz, DMSO-d6) δ 9.56 (s, 1H), 9.07 (d, J = 1.4 Hz, 1H), 8.62 (s, 1H), 8.21 (s, 1H), 7.88 (d, J = 2.9 Hz, 1H), 7.21 (dd, J = 12.6, 1.4 Hz, 1H), 4.79 - 4.60 (m, 1H), 4.57 - 4.48 (m, 3H), 3.10 - 3.02 (m, 1H), 2.82 - 2.68 (m, 1H), 2.35 - 2.32 (m, 3H), 2.23 - 2.17 (m, 1H), 2.16 - 2.13 (m, 6H), 2.07 - 2.02 (m, 1H), 1.81 - 1.75 (m, 1H), 1.73 - 1.62 (m, 2H), 1.47 - 1.39 (m, 4H), 1.27 - 1.18 (m, 1H).
[0526] Example 31. N-(2,8-dimethylimidazo[1,2-a]pyrazin-6-yl)-4-ethoxy-2-(piperidin-4-ylamino)pyrimidine-5-carboxamide formate (Compound 251) [ka] Step 1: Preparation of tert-butyl 4-((5-((2,8-dimethylimidazo[1,2-a]pyrazin-6-yl)carbamoyl)-4-ethoxypyrimidin-2-yl)amino)piperidine-1-carboxylate To a mixture of 2-((1-(tert-butoxycarbonyl)piperidin-4-yl)amino)-4-ethoxypyrimidine-5-carboxylic acid (150 mg, 0.41 mmol) in DMF (5 mL) was added 2,8-dimethylimidazo[1,2-a]pyrazin-6-amine (67 mg, 0.41 mmol), HATU (234 mg, 0.61 mmol), and DIEA (159 mg, 1.23 mmol). The mixture was stirred at room temperature for 16 h. The mixture was diluted with HO (5 mL), and the precipitate was filtered and dried in vacuo to give the crude title product (150 mg, Y: 71.8%) as a yellow solid. ESI-MS (M+H) + :511.2.
[0527] Step 2: Preparation of N-(2,8-dimethylimidazo[1,2-a]pyrazin-6-yl)-4-ethoxy-2-(piperidin-4-ylamino)pyrimidine-5-carboxamide formate A mixture of tert-butyl 4-((5-((2,8-dimethylimidazo[1,2-a]pyrazin-6-yl)carbamoyl)-4-ethoxypyrimidin-2-yl)amino)piperidine-1-carboxylate (150 mg, 0.29 mmol) in 3M HCl / EA (5 mL) was stirred at room temperature for 2 h. The mixture was diluted with HO (5 mL) and extracted with EA (10 mL × 3). The aqueous layer was concentrated in vacuo and the residue was purified by preparative HPLC (0.05% FA / ACN in water) to give the title product (73 mg, 54.4%) as a yellow solid. ESI-MS (M+H + ):411.1. 1H NMR (400 MHz, DMSO-d6) δ 9.73 (d, J = 11.9 Hz, 1H), 9.14 (s, 1H), 8.71 (d, J = 7.6 Hz, 1H), 8.34 (s, 1H), 8.19 - 7.97 (m, 1H), 7.96 (s, 1H), 4.62 - 4.51 (m, 2H), 4.09 - 3.92 (m, 1H), 3.23 - 3.14 (m, 2H), 2.92 - 2.78 (m, 2H), 2.67 (s, 3H), 2.37 (s, 3H), 2.02 - 1.91 (m, 2H), 1.68 - 1.56 (m, 2H), 1.48 (s, 3H).
[0528] Example 32. 4-Ethoxy-2-(4-ethylpiperazin-1-yl)-N-(7-fluoro-2-methyl-2H-indazol-5-yl)pyrimidine-5-carboxamide hydrochloride (Compound 252) [ka] Step 1: Preparation of 4-ethoxy-2-(4-ethylpiperazin-1-yl)-N-(7-fluoro-2-methyl-2H-indazol-5-yl)pyrimidine-5-carboxamide hydrochloride To a mixture of 4-ethoxy-N-(7-fluoro-2-methyl-2H-indazol-5-yl)-2-(piperazin-1-yl)pyrimidine-5-carboxamide (80 mg, 0.2 mmol) and AcOH (36 mg, 0.6 mmol) in MeOH (10 mL) was added NaBHCN (63 mg, 1 mmol) and CHCHO (44 mg, 1 mmol). The mixture was stirred at room temperature for 5 hours. LCMS showed that the starting material was completely consumed. After filtration, the filtrate was concentrated in vacuo. The residue was purified by preparative HPLC (0.05% HCl / ACN in water) to give the title product (32.5 mg, Y: 35.1%) as a yellow solid. ESI-MS (M+H + ):397.1. 1H NMR (400 MHz, DMSO-d6) δ 11.01 (s, 1H), 9.71 (s, 1H), 8.68 (s, 1H), 8.42 (d, J = 2.8 Hz, 1H), 7.98 (s, 1H), 7.34 - 7.27 (m, 1H), 4.81 - 4.74 (m, 2H), 4.54 - 4.52 (m, 2H), 4.18 (s, 3H), 3.59 - 3.46 (m, 4H), 3.19 - 3.11 (m, 2H), 3.08 - 2.97 (m, 2H), 1.44 (t, J = 7.0 Hz, 3H), 1.28 (t, J = 7.3 Hz, 3H).
[0529] Example 33. N-(2,8-dimethylimidazo[1,2-a]pyrazin-6-yl)-4-methoxy-2-(methyl(piperidin-4-yl)amino)pyrimidine-5-carboxamide formate (Compound 253) [ka] Step 1: Preparation of tert-butyl 4-((5-((2,8-dimethylimidazo[1,2-a]pyrazin-6-yl)carbamoyl)-4-methoxypyrimidin-2-yl)(methyl)amino)piperidine-1-carboxylate To a mixture of 2-((1-(tert-butoxycarbonyl)piperidin-4-yl)(methyl)amino)-4-methoxypyrimidine-5-carboxylic acid (150 mg, 0.41 mmol) in DMF (5 mL) was added 2,8-dimethylimidazo[1,2-a]pyrazin-6-amine (67 mg, 0.41 mmol), HATU (234 mg, 0.61 mmol), and DIEA (159 mg, 1.23 mmol). The mixture was stirred at room temperature for 16 h. The mixture was diluted with HO (5 mL), and the precipitate was filtered and dried in vacuo to give the crude title product (150 mg, Y: 71.8%) as a yellow solid. ESI-MS (M+H) + :511.2. 1H NMR (400 MHz, DMSO-d6) δ 9.61 (s, 1H), 9.16 (s, 1H), 8.74 (s, 1H), 7.95 (s, 1H), 4.92 - 4.56 (m, 1H), 4.11 (s, 3H), 4.08 - 4.02 (m, 1H), 3.28 - 3.24 (m, 1H), 3.07 (s, 3H), 2.93 - 2.77 (m, 2H), 2.69 (s, 3H), 2.38 (s, 3H), 1.72 - 1.60 (m, 4H), 1.42 (s, 9H).
[0530] Step 2: Preparation of N-(2,8-dimethylimidazo[1,2-a]pyrazin-6-yl)-4-methoxy-2-(methyl(piperidin-4-yl)amino)pyrimidine-5-carboxamide formate A mixture of tert-butyl 4-((5-((2,8-dimethylimidazo[1,2-a]pyrazin-6-yl)carbamoyl)-4-methoxypyrimidin-2-yl)(methyl)amino)piperidine-1-carboxylate (150 mg, 0.29 mmol) in 3M HCl / EA (5 mL) was stirred at room temperature for 2 h. The mixture was diluted with HO (5 mL) and extracted with EA (10 mL × 3). The aqueous layer was concentrated in vacuo and the residue was purified by preparative HPLC (0.05% FA / ACN in water) to give the title product (40 mg, 29.8%) as a yellow solid. ESI-MS (M+H + ):411.2. 1 H NMR (400 MHz, DMSO-d6) δ 9.61 (s, 1H), 9.16 (s, 1H), 8.74 (s, 1H), 8.32 (s, 1H), 7.95 (s, 1H), 4.89 - 4.62 (m, 1H), 4.11 (s, 3H), 3.18 (d, J = 11.2 Hz, 2H), 3.08 (s, 3H), 2.77 (t, J = 11.8 Hz, 2H), 2.69 (s, 3H), 2.38 (s, 3H), 1.86 - 1.67 (m, 4H).
[0531] Example 34. 4-Ethoxy-N-(7-fluoro-2-methyl-2H-indazol-5-yl)-2-(3-(methylamino)azetidin-1-yl)pyrimidine-5-carboxamide hydrochloride (Compound 254) [ka] Step 1: Synthesis of tert-butyl (1-(4-ethoxy-5-((7-fluoro-2-methyl-2H-indazol-5-yl)carbamoyl)pyrimidin-2-yl)azetidin-3-yl)(methyl)carbamate A solution of 2-(3-(tert-butoxycarbonyl)(methyl)amino)azetidin-1-yl)-4-ethoxypyrimidine-5-carboxylic acid (200 mg, 0.57 mmol), 7-fluoro-2-methyl-2H-indazol-5-amine (94 mg, 0.57 mmol), HATU (324 mg, 0.85 mmol), and DIEA (293 mg, 2.27 mmol) in DMF (5 mL) was stirred at 45° C. for 1 h. The reaction mixture was purified by reverse-phase column (ACN in water, 70%, 1% FA) to give the title product (130 mg, Y: 46%) as a white solid. ESI-MS (M+H) + :500.3.
[0532] Step 2: Synthesis of 4-ethoxy-N-(7-fluoro-2-methyl-2H-indazol-5-yl)-2-(3-(methylamino)azetidin-1-yl)pyrimidine-5-carboxamide hydrochloride A solution of tert-butyl (1-(4-ethoxy-5-((7-fluoro-2-methyl-2H-indazol-5-yl)carbamoyl)pyrimidin-2-yl)azetidin-3-yl)(methyl)carbamate (130 mg, 0.26 mmol) in DCM (3 mL) and TFA (1 mL) was stirred at room temperature for 1 h. After concentration, the residue was purified by preparative HPLC (0.05% HCl in MeCN / water, 35%) to give the title product (70 mg, Y: 62%) as a white solid. ESI-MS (M+H) + :400.2. 1H NMR (400 MHz, MeOD-d4) δ 8.68 (s, 1H), 8.30 (d, J = 2.5 Hz, 1H), 7.93 (s, 1H), 7.27 (d, J = 11.9 Hz, 1H), 4.75 - 4.70 (m, 4H), 4.55 (dd, J = 11.1, 4.0 Hz, 2H), 4.37 - 4.30 (m, 1H), 4.23 (s, 3H), 2.80 (s, 3H), 1.56 (t, J = 7.1 Hz, 3H).
[0533] Example 35. 4-Ethoxy-N-(2-methyl-2H-indazol-5-yl)-2-(3-(methylamino)azetidin-1-yl)pyrimidine-5-carboxamide (Compound 255) [ka] Step 1: Synthesis of tert-butyl (1-(4-ethoxy-5-((2-methyl-2H-indazol-5-yl)carbamoyl)pyrimidin-2-yl)azetidin-3-yl)(methyl)carbamate A solution of 2-(3-((tert-butoxycarbonyl)(methyl)amino)azetidin-1-yl)-4-ethoxypyrimidine-5-carboxylic acid (200 mg, 0.57 mmol), 2-methyl-2H-indazol-5-amine (84 mg, 0.57 mmol), HATU (324 mg, 0.85 mmol), and DIEA (293 mg, 2.27 mmol) in DMF (5 mL) was stirred at 45° C. for 1 h. After concentration, the residue was purified by reverse-phase column (0.1% FA / CH3CN in water) to give the title product (100 mg, Y: 37%) as a white solid. ESI-MS (M+H) + :482.3. 1H NMR (400 MHz, DMSO-d6) δ 9.59 (s, 1H), 8.63 (s, 1H), 8.28 (s, 1H), 8.23 (s, 1H), 7.57 (d, J = 9.1 Hz, 1H), 7.27 (d, J = 9.2 Hz, 1H), 4.87 (br s, 1H), 4.52 (q, J = 7.0 Hz, 2H), 4.30 (t, J = 8.9 Hz, 2H), 4.18 (dd, J = 9.8, 6.0 Hz, 2H), 4.14 (s, 3H), 2.88 (s, 3H), 1.44 (t, J = 7.1 Hz, 3H), 1.41 (s, 9H).
[0534] Step 2: Synthesis of 4-ethoxy-N-(2-methyl-2H-indazol-5-yl)-2-(3-(methylamino)azetidin-1-yl)pyrimidine-5-carboxamide A solution of tert-butyl (1-(4-ethoxy-5-((2-methyl-2H-indazol-5-yl)carbamoyl)pyrimidin-2-yl)azetidin-3-yl)(methyl)carbamate (130 mg, 0.26 mmol) in DCM (3 mL) and TFA (1 mL) was stirred at room temperature for 1 h. After concentration, the residue was purified by preparative HPLC (MeCN in water, 45%, 0.1% NH4OH) to give the title product (60 mg, Y: 76%) as a white solid. ESI-MS (M+H) + :382.2. 1 H NMR (400 MHz, DMSO d6) δ 9.56 (s, 1H), 8.61 (s, 1H), 8.27 - 8.24 (m, 2H), 7.55 (s, 1H), 7.25 (s, 1H), 4.50 (br s, 2H), 4.17 - 4.14 (m, 5H), 3.80 (br s, 2H), 3.59 (br s, 1H), 2.26 (s, 3H), 1.45 (s, 3H).
[0535] Example 36. 4-Ethoxy-2-(methyl(piperidin-4-yl)amino)-N-(2-methylimidazo[1,2-a]pyrazin-6-yl)pyrimidine-5-carboxamide (Compound 256) [ka] Step 1: Preparation of tert-butyl 4-((5-((2,8-dimethylimidazo[1,2-a]pyrazin-6-yl)carbamoyl)-4-ethoxypyrimidin-2-yl)(methyl)amino)piperidine-1-carboxylate To a mixture of 2-((1-(tert-butoxycarbonyl)piperidin-4-yl)(methyl)amino)-4-ethoxypyrimidine-5-carboxylic acid (150 mg, 0.39 mmol) in DMF (5 mL) was added HATU (120 mg, 0.30 mmol), DIEA (136 mg, 1.00 mmol), and 2-methylimidazo[1,2-a]pyrazin-6-amine (46 mg, 0.30 mmol). The mixture was stirred at 45° C. for 16 h. The mixture was diluted with water (20 mL) and extracted with EA (20 mL×3). The organic layer was washed with brine, dried over NaSO, and concentrated in vacuo to give the title product (100 mg, 74.63%) as a yellow solid, which was used in the next step without further purification. ESI-MS (M+H) + :511.3.
[0536] Step 2: Preparation of 4-ethoxy-2-(methyl(piperidin-4-yl)amino)-N-(2-methylimidazo[1,2-a]pyrazin-6-yl)pyrimidine-5-carboxamide To a mixture of tert-butyl 4-((4-ethoxy-5-((2-methylimidazo[1,2-a]pyrazin-6-yl)carbamoyl)pyrimidin-2-yl)(methyl)amino)piperidine-1-carboxylate (100 mg, 0.20 mmol) in EA (3 mL) was added 3 M HCl / EA (3 mL). The mixture was stirred at room temperature for 2 h. The mixture was concentrated in vacuo. The residue was purified by preparative HPLC (0.05% NH3·H2O / CH3CN in water) to give the title product (12 mg, Y: 14.92%) as a yellow solid. ESI-MS (M+H + ):411.1. 1 H NMR (400 MHz, MeOD-d4) δ 9.30 (d, J = 1.3 Hz, 1H), 8.87 (s, 1H), 8.70 (s, 1H), 7.85 (s, 1H), 4.68 (q, J = 7.0 Hz, 2H), 3.48- 3.47 (m, 1H), 3.18 - 3.17 (m, 2H), 3.13 (s, 3H), 2.75 (t, J = 11.1 Hz, 2H), 2.47 (s, 3H), 1.88 - 1.79 (m, 2H), 1.75 - 1.74 (m, 2H), 1.57 (t, J = 7.1 Hz, 3H).
[0537] Example 37. 4-Methoxy-2-(methyl(piperidin-4-yl)amino)-N-(2-methylimidazo[1,2-a]pyrazin-6-yl)pyrimidine-5-carboxamide formate (Compound 257) [ka] Step 1: Preparation of tert-butyl 4-((4-methoxy-5-((2-methylimidazo[1,2-a]pyrazin-6-yl)carbamoyl)pyrimidin-2-yl)(methyl)amino)piperidine-1-carboxylate To a mixture of 2-((1-(tert-butoxycarbonyl)piperidin-4-yl)(methyl)amino)-4-methoxypyrimidine-5-carboxylic acid (50 mg, 0.137 mmol) in DMF (3 mL) was added HATU (62 mg, 0.164 mmol), DIEA (70 mg, 0.546 mmol), and 2-methylimidazo[1,2-a]pyrazin-6-amine (30 mg, 0.205 mmol). The mixture was stirred at 45° C. for 3 h. The reaction mixture was diluted with water (20 mL) and extracted with EA (30 mL×2). The organic phase was washed with brine, dried over sodium sulfate, and concentrated to give the title product (50 mg, 68%) as a yellow solid. ESI-MS (M+H) + :497.1.
[0538] Step 2: Preparation of 4-methoxy-2-(methyl(piperidin-4-yl)amino)-N-(2-methylimidazo[1,2-a]pyrazin-6-yl)pyrimidine-5-carboxamide formate To a mixture of tert-butyl 4-((4-methoxy-5-((2-methylimidazo[1,2-a]pyrazin-6-yl)carbamoyl)pyrimidin-2-yl)(methyl)amino)piperidine-1-carboxylate (50 mg, 0.101 mmol) in EA (2 mL) was added 3M HCl / EA (2 mL). The mixture was stirred at room temperature for 2 h. The mixture was concentrated in vacuo and the residue was purified by preparative HPLC (0.05% FA / ACN in water) to give the title product (3 mg, Y: 6.74%) as a yellow solid. ESI-MS (M+H) + :397.1. 1 H NMR (400 MHz, MeOD-d4) δ 9.32 (s, 1H), 8.88 (s, 1H), 8.71 (s, 1H), 8.53 (s, 1H), 7.86 (s, 1H), 5.05 - 4.93 (m, 1H), 4.22 (s, 3H), 3.49 - 3.45 (m, 2H), 3.18 (s, 3H), 3.14 - 3.07 (m, 2H), 2.48 (s, 3H), 2.07 - 1.93 (m, 4H).
[0539] Example 38. 4-Ethoxy-2-(ethyl(piperidin-4-yl)amino)-N-(7-fluoro-2-methyl-2H-indazol-5-yl)pyrimidine-5-carboxamide formate (Compound 258) [ka] Step 1: Preparation of tert-butyl 4-((4-ethoxy-5-((7-fluoro-2-methyl-2H-indazol-5-yl)carbamoyl)pyrimidin-2-yl)(ethyl)amino)piperidine-1-carboxylate To a mixture of 2-((1-(tert-butoxycarbonyl)piperidin-4-yl)(ethyl)amino)-4-ethoxypyrimidine-5-carboxylic acid (50 mg, 0.13 mmol) in DMF (5 mL) was added 7-fluoro-2-methyl-2H-indazol-5-amine (21 mg, 0.13 mmol), HATU (145 mg, 0.38 mmol), and DIEA (82 mg, 0.64 mmol). The mixture was stirred at room temperature for 24 hours. The mixture was diluted with HO (5 mL). The precipitate was filtered and dried in vacuo to give the crude title product (50 mg, Y: 36.4%) as a yellow solid. ESI-MS (M+H) + :542.2. 1 H NMR (400 MHz, DMSO-d6) δ 9.61 (s, 1H), 8.64 (s, 1H), 8.41 (d, J = 2.7 Hz, 1H), 7.98 (s, 1H), 7.30 (d, J = 13.3 Hz, 1H), 4.56 - 4.48 (m, 2H), 4.18 (s, 3H), 4.14 - 4.03 (m, 2H), 3.60 - 3.49 (m, 2H), 2.92 - 2.70 (m, 3H), 1.83 - 1.60 (m, 4H), 1.48 - 1.37 (m, 12H), 1.18 (s, 3H).
[0540] Step 2: Preparation of 4-ethoxy-2-(ethyl(piperidin-4-yl)amino)-N-(7-fluoro-2-methyl-2H-indazol-5-yl)pyrimidine-5-carboxamide formate A mixture of tert-butyl 4-((4-ethoxy-5-((7-fluoro-2-methyl-2H-indazol-5-yl)carbamoyl)pyrimidin-2-yl)(ethyl)amino)piperidine-1-carboxylate (100 mg, 0.19 mmol) in 3M HCl / EA (5 mL) was stirred at room temperature for 2 h. The mixture was diluted with HO (5 mL) and extracted with EA (10 mL x 3), the aqueous layer was concentrated in vacuo, and the residue was purified by preparative HPLC (0.05% FA / ACN in water) to give the title product (16 mg, 17.8%) as a yellow solid. ESI-MS (M+H + ):442.2. 1 H NMR (400 MHz, MeOD-d4) δ 8.80 (s, 1H), 8.54 (s, 1H), 8.25 (s, 1H), 7.88 (s, 1H), 7.23 (d, J = 12.4 Hz, 1H), 4.85 - 4.79 (m, 1H), 4.69 - 4.61 (m, 2H), 4.22 (s, 3H), 3.69 - 3.61 (m, 2H), 3.50 (d, J = 12.6 Hz, 2H), 3.12 (t, J = 13.8 Hz, 2H), 2.21 - 2.05 (m, 2H), 2.05 - 1.97 (m, 2H), 1.56 (t, J = 7.0 Hz, 3H), 1.32 - 1.24 (m, 3H).
[0541] Example 39. 4-Ethoxy-N-(7-fluoro-2-methyl-2H-indazol-5-yl)-2-(4-methylpiperazin-1-yl)pyrimidine-5-carboxamide formate (Compound 259) [ka] Step 1: Preparation of 4-ethoxy-N-(7-fluoro-2-methyl-2H-indazol-5-yl)-2-(4-methylpiperazin-1-yl)pyrimidine-5-carboxamide formate A mixture of 6-ethoxy-2-methyl-N-(6-(piperazin-1-yl)pyridazin-3-yl)-2H-pyrazolo[3,4-b]pyridine-5-carboxamide (50 mg, 0.13 mmol), AcOH (23 mg, 0.38 mmol) in MeOH (10 mL) was treated with NaBHCN (40 mg, 0.63 mmol) and (HCl) n (20 mg, 0.63 mmol) was added. The mixture was stirred at 50° C. for 5 hours. It was filtered and the filtrate was concentrated in vacuo. The residue was purified by preparative HPLC (0.05% FA / ACN in water) to give the title product (16 mg, Y: 27.9%) as a yellow solid. ESI-MS (M+H + ):414.1. 1 H NMR (400 MHz, MeOD-d4) δ 8.80 (s, 1H), 8.32 (s, 1H), 8.26 - 8.23 (m, 1H), 7.88 (d, J = 1.4 Hz, 1H), 7.22 (dd, J = 12.7, 1.5 Hz, 1H), 4.63 (q, J = 7.1 Hz, 2H), 4.22 (s, 3H), 4.06 - 3.99 (m, 4H), 2.85 - 2.80 (m, 4H), 2.57 (s, 3H), 1.55 (t, J = 7.1 Hz, 3H).
[0542] Example 40. 4-Ethoxy-2-(ethyl(piperidin-4-yl)amino)-N-(8-methoxy-2-methylimidazo[1,2-a]pyridin-6-yl)pyrimidine-5-carboxamide formate (Compound 260) [ka] Step 1: Preparation of N-(8-methoxy-2-methylimidazo[1,2-a]pyridin-6-yl)-1,1-diphenylmethanimine To a mixture of 6-bromo-8-methoxy-2-methylimidazo[1,2-a]pyridine (6.8 g, 28.33 mmol) and diphenylmethanimine (5.6 g, 31.17 mmol) in 1,4-dioxane (250 mL) was added BINAP (3.53 g, 0.56 mmol), Pd(OAc) (636 mg, 0.28 mmol), and CsCO (18.5 g, 0.057 mol). The reaction solution was stirred at 100 °C for 16 h. The reaction mixture was diluted with HO (50 mL) and extracted with EA (85 mL × 3). The organic layer was washed with brine, dried over NaSO, and evaporated. The crude was purified by silica gel column chromatography (PE:EA = 3:1) to give the title product (6.8 g, 70.4%) as a yellow solid. ESI-MS (M+H) + :342.2. 1 H NMR (400 MHz, CDCl3) δ 7.77 - 7.72 (m, 2H), 7.51 - 7.46 (m, 1H), 7.44 - 7.39 (m, 2H), 7.35 - 7.29 (m, 3H), 7.23 (d, J = 1.6 Hz, 1H), 7.20 - 7.16 (m, 2H), 7.14 - 7.10 (m, 1H), 5.96 (d, J = 1.5 Hz, 1H), 3.71 (s, 3H), 2.38 (s, 3H).
[0543] Step 2: Preparation of 7-fluoro-2-methyl-2H-indazol-5-amine hydrochloride A mixture of N-(8-methoxy-2-methylimidazo[1,2-a]pyridin-6-yl)-1,1-diphenylmethanimine (6.8 g, 19.88 mmol) in 3M HCl / EA (80 mL) was stirred at room temperature for 2 h. The reaction was diluted with HO (30 mL) and extracted with EA (30 mL). The aqueous layer was purified by reverse-phase column (0.05% NH in water.HO / CHCN) to give the title product (4.2 g, 98.8%) as a yellow solid. ESI-MS (M+H) + :178.2. 1H NMR (400 MHz, DMSO-d6) δ 8.04 - 7.92 (m, 1H), 7.88 - 7.64 (m, 1H), 7.15 - 6.95 (m, 1H), 4.01 (s, 3H), 2.39 (s, 3H).
[0544] Step 3: Preparation of tert-butyl 4-((4-ethoxy-5-((8-methoxy-2-methylimidazo[1,2-a]pyridin-6-yl)carbamoyl)pyrimidin-2-yl)(ethyl)amino)piperidine-1-carboxylate To a mixture of 2-((1-(tert-butoxycarbonyl)piperidin-4-yl)(ethyl)amino)-4-ethoxypyrimidine-5-carboxylic acid (50 mg, 0.12 mmol) in DMF (5 mL) was added 7-fluoro-2-methyl-2H-indazol-5-amine (45 mg, 0.25 mmol), HATU (145 mg, 0.38 mmol), and DIEA (82 mg, 0.63 mmol). The mixture was stirred at room temperature for 3 hours. The mixture was poured into HO (5 mL), and the precipitate was filtered and concentrated in vacuo to give the crude title product (30 mg, 42.7%) as a yellow solid. ESI-MS (M+H) + :554.2.
[0545] Step 4: Preparation of 4-ethoxy-2-(ethyl(piperidin-4-yl)amino)-N-(8-methoxy-2-methylimidazo[1,2-a]pyridin-6-yl)pyrimidine-5-carboxamide formate A mixture of tert-butyl 4-((4-ethoxy-5-((8-methoxy-2-methylimidazo[1,2-a]pyridin-6-yl)carbamoyl)pyrimidin-2-yl)(ethyl)amino)piperidine-1-carboxylate (60 mg, 0.11 mmol) in 3 M HCl / EA (3 mL) was stirred at room temperature for 1 h. The mixture was diluted with HO (5 mL) and extracted with EA (10 mL). The aqueous layer was concentrated in vacuo and purified by preparative HPLC (0.05% FA / ACN in water) to give the title product (9 mg, 16.6%) as a yellow solid. ESI-MS (M+H) + :454.2.1 H NMR (400 MHz, DMSO-d6) δ 9.54 (s, 1H), 8.82 (s, 1H), 8.63 (s, 1H), 8.29 (s, 1H), 7.69 (s, 1H), 6.66 (s, 1H), 5.00 - 4.46 (m, 3H), 3.92 (s, 3H), 3.65 - 3.47 (m, 2H), 3.33 (d, J = 10.7 Hz, 2H), 2.97 (t, J = 12.0 Hz, 2H), 2.29 (s, 3H), 2.03 (d, J = 11.1 Hz, 2H), 1.88 - 1.73 (m, 2H), 1.45 (t, J = 7.0 Hz, 3H), 1.20 (s, 3H).
[0546] Example 41. (S)-4-Ethoxy-N-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(3-(methylamino)pyrrolidin-1-yl)pyrimidine-5-carboxamide formate (Compound 261) [ka] Step 1: Preparation of tert-butyl (S)-(1-(4-ethoxy-5-((8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)carbamoyl)pyrimidin-2-yl)pyrrolidin-3-yl)(methyl)carbamate To a mixture of 4-ethoxy-N-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(methylsulfinyl)pyrimidine-5-carboxamide (500 mg, 1.33 mmol) in MeCN (15 mL) was added KCO (366 mg, 2.66 mmol) and tert-butyl (S)-methyl(pyrrolidin-3-yl)carbamate (400 mg, 2.00 mmol). The mixture was stirred at 50 °C for 1 hour. The mixture was filtered, and the filtrate was concentrated. The residue was purified by silica gel column chromatography (PE:EA = 1:2) to give the title product (400 mg, 58.7%) as an off-white solid. ESI-MS (M+H) + :514.2.
[0547] Step 2: Preparation of (S)-4-ethoxy-N-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(3-(methylamino)pyrrolidin-1-yl)pyrimidine-5-carboxamide formate A mixture of tert-butyl (S)-(1-(4-ethoxy-5-((8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)carbamoyl)pyrimidin-2-yl)pyrrolidin-3-yl)(methyl)carbamate (400 mg, 0.78 mmol) in 3M HCl / EA (15 mL) was stirred at room temperature for 2 hours. The mixture was concentrated in vacuo, and the residue was purified by preparative HPLC (0.05% FA / ACN in water) to give the title product (250 mg, Y: 69%) as an off-white solid. ESI-MS (M+H + ):414.1. 1 H NMR (400 MHz, DMSO-d6) δ 9.55 (s, 1H), 9.06 (d, J = 1.1 Hz, 1H), 8.63 (s, 1H), 8.30 (s, 1H), 7.87 (d, J = 2.6 Hz, 1H), 7.20 (dd, J = 12.5, 1.2 Hz, 1H), 4.60 - 4.49 (m, 2H), 3.75 - 3.64 (m, 2H), 3.61 - 3.44 (m, 3H), 2.42 (s, 3H), 2.33 (s, 3H), 2.22 - 2.12 (m, 1H), 2.03 - 1.90 (m, 1H), 1.45 (t, J = 7.0 Hz, 3H).
[0548] Example 42. (R)-4-Ethoxy-N-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(3-(methylamino)pyrrolidin-1-yl)pyrimidine-5-carboxamide formate (Compound 262) [ka] Step 1: Preparation of tert-butyl (R)-(1-(4-ethoxy-5-((8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)carbamoyl)pyrimidin-2-yl)pyrrolidin-3-yl)(methyl)carbamate To a mixture of (R)-2-(3-((tert-butoxycarbonyl)(methyl)amino)pyrrolidin-1-yl)-4-ethoxypyrimidine-5-carboxylic acid (500 mg, 1.37 mmol) in DMF (5 mL) was added 8-fluoro-2-methylimidazo[1,2-a]pyridin-6-amine (225 mg, 1.37 mmol), HATU (779 mg, 2.05 mmol), and DIEA (881 mg, 6.83 mmol). The mixture was stirred at room temperature for 16 hours. The mixture was diluted with water. The precipitate was filtered and dried in vacuo to give the crude title product (500 mg, Y: 71.3%) as a yellow solid. ESI-MS (M+H) + :514.1
[0549] Step 2: Preparation of (R)-4-ethoxy-N-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(3-(methylamino)pyrrolidin-1-yl)pyrimidine-5-carboxamide formate A mixture of tert-butyl (R)-(1-(4-ethoxy-5-((8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)carbamoyl)pyrimidin-2-yl)pyrrolidin-3-yl)(methyl)carbamate (500 mg, 0.98 mmol) in 3M HCl / EA (5 mL) was stirred at room temperature for 2 hours. The mixture was diluted with HO (5 mL) and extracted with EA (10 mL x 3). The aqueous layer was concentrated in vacuo, and the residue was purified by preparative HPLC (0.05% FA / ACN in water) to give the title product (300 mg, Y: 67.1%) as a yellow solid. ESI-MS (M+H + ):414.1. 1H NMR (400 MHz, DMSO-d6) δ 9.57 (s, 1H), 9.07 (s, 1H), 8.64 (s, 1H), 8.25 (s, 1H), 7.88 (d, J = 2.7 Hz, 1H), 7.22 (d, J = 12.5 Hz, 1H), 4.55 (q, J = 7.0 Hz, 2H), 3.77 - 3.64 (m, 2H), 3.61 - 3.49 (m, 3H), 2.43 (s, 3H), 2.33 (s, 3H), 2.22 - 2.13 (m, 1H), 2.04 - 1.93 (m, 1H), 1.44 (t, J = 7.0 Hz, 3H).
[0550] Example 43. 4-Ethoxy-N-(7-fluoro-2-methyl-2H-indazol-5-yl)-2-(3-(methylamino)pyrrolidin-1-yl)pyrimidine-5-carboxamide formate (Compound 263) [ka] Step 1: Preparation of tert-butyl (1-(4-ethoxy-5-((7-fluoro-2-methyl-2H-indazol-5-yl)carbamoyl)pyrimidin-2-yl)pyrrolidin-3-yl)(methyl)carbamate To a mixture of 2-(3-((tert-butoxycarbonyl)(methyl)amino)pyrrolidin-1-yl)-4-ethoxypyrimidine-5-carboxylic acid (100 mg, 0.27 mmol) in DMF (3 mL) was added 7-fluoro-2-methyl-2H-indazol-5-amine (45 mg, 0.27 mmol), HATU (155 mg, 0.4 mmol), and DIEA (176 mg, 1.35 mmol). The mixture was stirred at room temperature for 2 hours. The mixture was diluted with HO (5 mL), and the precipitate was filtered and dried in vacuo to give the title product (80 mg, crude) as a yellow solid. ESI-MS (M+H) + :514.3.
[0551] Step 2: Preparation of 4-ethoxy-N-(7-fluoro-2-methyl-2H-indazol-5-yl)-2-(3-(methylamino)pyrrolidin-1-yl)pyrimidine-5-carboxamide formate A mixture of tert-butyl (1-(4-ethoxy-5-((7-fluoro-2-methyl-2H-indazol-5-yl)carbamoyl)pyrimidin-2-yl)pyrrolidin-3-yl)(methyl)carbamate (80 mg, 0.16 mmol) in 3M HCl / EA (3 mL) was stirred at room temperature for 1 hour. The mixture was concentrated in vacuo, and the residue was purified by preparative HPLC (0.05% FA / ACN in water) to give the title product (12 mg, Y: 16.4%) as a yellow solid. ESI-MS (M+H + ):414.5. 1 H NMR (400 MHz, MeOD-d4) δ 8.80 (s, 1H), 8.47 (s, 2H), 8.25 (d, J = 2.6 Hz, 1H), 7.89 (s, 1H), 7.23 (d, J = 12.8 Hz, 1H), 4.67 (q, J = 7.1 Hz, 2H), 4.22 (s, 3H), 4.02 - 3.95 (m, 1H), 3.90 - 3.73 (m, 4H), 2.74 (s, 3H), 2.52 - 2.43 (m, 1H), 2.26 - 2.16 (m, 1H), 1.56 (t, J = 7.1 Hz, 3H).
[0552] Example 44. (R)-4-Ethoxy-N-(7-fluoro-2-methyl-2H-indazol-5-yl)-2-(3-methylpiperazin-1-yl)pyrimidine-5-carboxamide formic acid (Compound 264) [ka] Step 1: tert-butyl (R)-4-(4-ethoxy-5-((7-fluoro-2-methyl-2H-indazol-5-yl)carbamoyl)pyrimidin-2-yl)-2-methylpiperazine-1-carboxylate To a solution of 4-ethoxy-N-(7-fluoro-2-methyl-2H-indazol-5-yl)-2-(methylsulfinyl)pyrimidine-5-carboxamide (300.0 mg, 0.794 mmol) and tert-butyl (R)-2-methylpiperazine-1-carboxylate (160.0 mg, 0.80 mmol) in CHCN (5 mL) was added KCO (219.0 mg, 1.588 mmol), and the reaction mixture was stirred at 50 °C for 1 h. The mixture was diluted with EA (20 mL), washed with water (10 mL) and brine (20 mL), dried over sodium sulfate, filtered, and concentrated in vacuo to give the crude title product (300.0 mg, yield: 73.4%) as a yellow solid. ESI-MS (M+H) + :514.3.
[0553] Step 2: (R)-4-Ethoxy-N-(7-fluoro-2-methyl-2H-indazol-5-yl)-2-(3-methylpiperazin-1-yl)pyrimidine-5-carboxamide formic acid To a solution of tert-butyl (R)-4-(4-ethoxy-5-((7-fluoro-2-methyl-2H-indazol-5-yl)carbamoyl)pyrimidin-2-yl)-2-methylpiperazine-1-carboxylate (100 mg, 0.194 mmol) in DCM (2 mL) was added a solution of 4 M HCl in 1,4-dioxane (1 mL), and the mixture was stirred at room temperature for 2 h. The precipitate was filtered and concentrated in vacuo. The residue was purified by C18 chromatography using 0.05% FA in water (0 to 100% in a 40 min gradient) to give the title product (10.53 mg, yield: 12.5%) as a yellow solid. 1H NMR (400 MHz, DMSO-d6) δ 9.59 (s, 1H), 8.63 (s, 1H), 8.41 (d, J = 2.4 Hz, 1H), 8.21 (s, 1H), 7.97 (s, 1H), 7.28 (d, J = 13.1 Hz, 1H), 4.54 - 4.48 (m, 4H), 4.17 (s, 3H), 2.97 - 2.93 (m, 2H), 2.77 - 2.55 (m, 3H), 1.44 (t, J = 7.0 Hz, 3H), 1.05 (d, J = 5.9 Hz, 3H).ESI-MS:[M+H] + =414.1.
[0554] Example 45. 2-(3,3-Dimethylpiperazin-1-yl)-4-ethoxy-N-(7-fluoro-2-methyl-2H-indazol-5-yl)pyrimidine-5-carboxamide (Compound 265) [ka] Step 1: tert-butyl 4-(4-ethoxy-5-((7-fluoro-2-methyl-2H-indazol-5-yl)carbamoyl)pyrimidin-2-yl)-2,2-dimethylpiperazine-1-carboxylate To a solution of 4-ethoxy-N-(7-fluoro-2-methyl-2H-indazol-5-yl)-2-(methylsulfinyl)pyrimidine-5-carboxamide (140.0 mg, 0.371 mmol) and tert-butyl 2,2-dimethylpiperazine-1-carboxylate (94.0 mg, 0.43 mmol) in CHCN (5 mL) was added KCO (120.0 mg, 1.2 mmol), and the reaction mixture was stirred at 50 °C for 1 h. The mixture was diluted with EA (20 mL), washed with water (10 mL) and brine (20 mL), dried over sodium sulfate, filtered, and concentrated in vacuo to give the crude title product (130.0 mg, 66.42%) as a yellow solid. The crude product was used in the next step without further purification. ESI-MS (M+H) + :528.3.
[0555] Step 2: 2-(3,3-dimethylpiperazin-1-yl)-4-ethoxy-N-(7-fluoro-2-methyl-2H-indazol-5-yl)pyrimidine-5-carboxamide To a solution of tert-butyl 4-(4-ethoxy-5-((7-fluoro-2-methyl-2H-indazol-5-yl)carbamoyl)pyrimidin-2-yl)-2,2-dimethylpiperazine-1-carboxylate (130 mg, 0.246 mmol) in DCM (2 mL) was added 4 M HCl in 1,4-dioxane (2 mL), and the mixture was stirred at room temperature for 2 h. The mixture was concentrated in vacuo. The residue was purified by C18 chromatography using 0.01% FA in water (0 to 100% in a 40 min gradient) to give the title product (16.54 mg, yield: 15.57%) as a yellow solid. 1H NMR (400 MHz, DMSO-d6) δ 9.60 (s, 1H), 8.62 (d, J = 6.7 Hz, 1H), 8.41 (d, J = 2.7 Hz, 1H), 8.20 (s, 1H), 7.96 (s, 1H), 7.28 (d, J = 13.3 Hz, 1H), 4.49 (q, J = 6.7 Hz, 2H), 4.17 (s, 3H), 3.80 (br s, 2H), 3.64 (s, 3H), 2.87 (br s, 2H), 1.43 (t, J = 7.0 Hz, 3H), 1.08 (s, 6H).ESI-MS:[M+H] + :428.2.
[0556] Example 46. N-(2,8-dimethylimidazo[1,2-a]pyrazin-6-yl)-4-methoxy-2-(piperidin-4-ylamino)pyrimidine-5-carboxamide formic acid (Compound 266) [ka] Step 1: Preparation of tert-butyl 4-((5-((2,8-dimethylimidazo[1,2-a]pyrazin-6-yl)carbamoyl)-4-methoxypyrimidin-2-yl)amino)piperidine-1-carboxylate To a mixture of 2-((1-(tert-butoxycarbonyl)piperidin-4-yl)amino)-4-methoxypyrimidine-5-carboxylic acid (100 mg, 0.284 mmol) in DMF (3 mL) was added HATU (130 mg, 0.341 mmol), DIEA (147 mg, 1.136 mmol), and 2,8-dimethylimidazo[1,2-a]pyrazin-6-amine (76 mg, 0.426 mmol). The mixture was stirred at 45° C. for 3 h. The reaction mixture was diluted with HO (20 mL) and extracted with EA (30 mL×2). The organic phase was washed with brine, dried over sodium sulfate, and concentrated to give the title product (50 mg, 35%) as a brown solid, which was used in the next step without further purification. ESI-MS (M+H) + :497.3.
[0557] Step 2: Preparation of N-(2,8-dimethylimidazo[1,2-a]pyrazin-6-yl)-4-methoxy-2-(piperidin-4-ylamino)pyrimidine-5-carboxamide formic acid To a mixture of tert-butyl 4-((5-((2,8-dimethylimidazo[1,2-a]pyrazin-6-yl)carbamoyl)-4-methoxypyrimidin-2-yl)amino)piperidine-1-carboxylate (50 mg, 0.101 mmol) in EA (2 mL) was added EA / HCl (2 mL). The mixture was stirred at room temperature for 2 h. The mixture was concentrated in vacuo and the residue was purified by preparative HPLC (0.05% FA / ACN in water) to give the title product (9 mg, Y: 20%) as a white solid. ESI-MS (M+H) + :397.1. 1 H NMR (400 MHz, MeOD-d4) δ 9.12 (s, 1H), 8.80 (s, 1H), 8.53 (s, 1H, HCO2H), 7.76 (s, 1H), 4.22 - 4.15 (m, 3H), 3.54 - 3.38 (m, 3H), 3.20 - 3.11 (m, 2H), 2.75 (s, 3H), 2.45 (s, 3H), 2.30 - 2.21 (m, 2H), 1.88 - 1.75 (m, 2H).
[0558] Example 47. 4-Ethoxy-2-(ethyl(piperidin-4-yl)amino)-N-(2-methylimidazo[1,2-a]pyrazin-6-yl)pyrimidine-5-carboxamide formic acid (Compound 267) [ka] Step 1: Preparation of tert-butyl 4-((4-ethoxy-5-((2-methylimidazo[1,2-a]pyrazin-6-yl)carbamoyl)pyrimidin-2-yl)(ethyl)amino)piperidine-1-carboxylate To a mixture of 2-((1-(tert-butoxycarbonyl)piperidin-4-yl)(ethyl)amino)-4-ethoxypyrimidine-5-carboxylic acid (100 mg, 0.253 mmol) in DMF (3 mL) was added HATU (116 mg, 0.304 mmol), DIEA (131 mg, 1.02 mmol), and 2-methylimidazo[1,2-a]pyrazin-6-amine (56 mg, 0.381 mmol). The mixture was stirred at 45 °C for 3 h. The reaction was diluted with HO (20 mL) and extracted with EA (30 mL × 2). The organic phase was washed with brine, dried over sodium sulfate, and concentrated to give the title product (100 mg, 75%) as a brown solid, which was used in the next step without further purification. ESI-MS (M+H) + :525.3.
[0559] Step 2: Preparation of 4-ethoxy-2-(ethyl(piperidin-4-yl)amino)-N-(2-methylimidazo[1,2-a]pyrazin-6-yl)pyrimidine-5-carboxamide formic acid To a mixture of tert-butyl 4-((4-ethoxy-5-((2-methylimidazo[1,2-a]pyrazin-6-yl)carbamoyl)pyrimidin-2-yl)(ethyl)amino)piperidine-1-carboxylate (100 mg, 0.191 mmol) in EA (3 mL) was added 3 M HCl / EA (3 mL). The mixture was stirred at room temperature for 2 h. The mixture was concentrated in vacuo and the residue was purified by preparative HPLC (0.05% FA / ACN in water) to give the title product (18 mg, Y: 22%) as a yellow solid. ESI-MS (M+H) + :425.1. 1 H NMR (400 MHz, DMSO-d6) δ 9.79 (s, 1H), 9.32 (s, 1H), 8.82 - 8.80 (m, 2H), 8.34 (s, 1H), 8.02 (s, 1H), 4.94 - 4.69 (m, 1H), 4.59 (q, J = 7.0 Hz, 2H), 3.61 - 3.52 (m, 2H), 3.25 - 3.16 (m, 2H), 2.77 (t, J = 11.6 Hz, 2H), 2.40 (s, 3H), 1.90 - 1.69 (m, 4H), 1.48 (t, J = 7.0Hz, 3H), 1.24 - 1.13 (m, 3H).
[0560] Example 48. 4-Ethoxy-N-(2-methylimidazo[1,2-a]pyrazin-6-yl)-2-(piperidin-4-ylamino)pyrimidine-5-carboxamide formate (Compound 268) [ka] Step 1: Preparation of tert-butyl 4-((4-ethoxy-5-((2-methylimidazo[1,2-a]pyrazin-6-yl)carbamoyl)pyrimidin-2-yl)amino)piperidine-1-carboxylate To a mixture of 2-((1-(tert-butoxycarbonyl)piperidin-4-yl)amino)-4-ethoxypyrimidine-5-carboxylic acid (100 mg, 0.273 mmol) in DMF (3 mL) was added HATU (125 mg, 0.328 mmol), DIEA (141 mg, 1.09 mmol), and 2-methylimidazo[1,2-a]pyrazin-6-amine (61 mg, 0.410 mmol). The mixture was stirred at 45° C. for 3 h. The reaction mixture was diluted with HO (20 mL) and extracted with EA (30 mL×2). The organic phase was washed with brine, dried over sodium sulfate, and concentrated to give the title product (50 mg, 37%) as a brown solid. ESI-MS (M+H) + :497.3.
[0561] Step 2: Preparation of 4-ethoxy-N-(2-methylimidazo[1,2-a]pyrazin-6-yl)-2-(piperidin-4-ylamino)pyrimidine-5-carboxamide formate To a mixture of tert-butyl 4-((4-ethoxy-5-((2-methylimidazo[1,2-a]pyrazin-6-yl)carbamoyl)pyrimidin-2-yl)amino)piperidine-1-carboxylate (50 mg, 0.1 mmol) in EA (2 mL) was added 3 M HCl / EA (2 mL). The mixture was stirred at room temperature for 2 h. The mixture was concentrated in vacuo and the residue was purified by preparative HPLC (0.05% FA / ACN in water) to give the title product (8 mg, Y: 14.3%) as a white solid. ESI-MS (M+H) + :397.1. 1 H NMR (400 MHz, MeOD-d4) δ 9.32 (s, 1H), 8.83 (s, 1H), 8.72 (s, 1H), 8.52 (s, 1H), 7.89 (s, 1H), 4.18 - 4.11 (m, 1H), 3.46 - 3.36 (m, 4H), 3.13 - 3.06 (m, 2H), 2.47 (s, 3H), 2.24 - 2.18 (m, 2H), 1.83 - 1.75 (m, 2H), 1.58 - 1.53 (m, 3H).
[0562] Example 49. 2-(3-(dimethylamino)pyrrolidin-1-yl)-4-ethoxy-N-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)pyrimidine-5-carboxamide (Compound 269) [ka] Step 1: Prep...
Claims
1. A compound of formula (I), [Formula 1] or a pharma- ceutically acceptable salt, solvate, or prodrug thereof, wherein A is a saturated or partially unsaturated monocyclic, bicyclic, or tricyclic 4-14 membered heterocycloalkyl or NR 1 R 2 wherein the heterocycloalkyl contains 1 or 2 nitrogen ring atoms and 1, 2, 3, or 4 R 6 optionally replaced by R 1 is a -(CH) group of 4 to 14 ring atoms, including at least one nitrogen ring atom and 0 to 2 additional ring heteroatoms independently selected from N, O, and S; 2 ) 0-2 -heterocycloalkyl, R 1 1, 2, 3, or 4 R 6 optionally replaced by R 2 is hydrogen, C 1-7 Alkyl, or C 3-8 is cycloalkyl, R 3 But, Halo, C 1-7 Alkyl, OR 5 , N(R 5 ) 2 , C 3-8 cycloalkyl, or heterocycloalkyl; R 4 is an aryl or bicyclic 9-membered heteroaryl containing 2, 3, or 4 heteroatoms independently selected from N, O, and S; R 4 1, 2, or 3 R 7 optionally replaced by Each R 5 But independently, C 1-7 Alkyl, C 1-7 Haloalkyl, C 3-8 cycloalkyl, or heterocycloalkyl; Each R 6 are independently hydroxy, halogen, C 1-7Alkyl, -(CH 2 ) 0-3 -NR a R b , C 1-7 Heteroalkyl, -(CH 2 ) 0-3 -C 3-8 Cycloalkyl, -NR'-(CH 2 ) 0-3 -C 3-8 Cycloalkyl, -(CH 2 ) 0-3 -heterocycloalkyl, -C(O)-heterocycloalkyl, or -O-heterocycloalkyl, where alkyl is selected from 1 to 4 independently selected halogen, OH, or C 1-7 cycloalkyl and heterocycloalkyl are optionally substituted with 1 to 4 independently selected C 1-7 optionally substituted with alkyl, halogen, or OH; Or two R's 6 together to form an oxo (=O) or Or two R's 6 Together, C 1-7 forming an alkylene to form a ring, Each R' is hydrogen or C 1-7 is alkyl, Each R 7 But independently, halo, cyano, C 1-7 Alkyl, C 1-7 Haloalkyl, C 1-7 Alkoxy, C 1-7 Haloalkoxy, or C 3-8 cycloalkyl, 1-7 The alkyl is optionally substituted with OH; Each R a However, independently, H, C 1-7 Alkyl, C 1-7 Haloalkyl, or C 3-8 is cycloalkyl, Each R b However, independently, H, C 1-7 Alkyl, C 1-7 Haloalkyl, or C 3-8The compound, or a pharma- ceutically acceptable salt, solvate, or prodrug thereof, wherein:
2. A compound of formula (I), [Case 2] or a pharma- ceutically acceptable salt, solvate, or prodrug thereof, wherein A is a saturated or partially unsaturated monocyclic or bicyclic 4-11 membered nitrogen-containing heterocycloalkyl or NR 1 R 2 wherein the nitrogen-containing heterocycloalkyl contains 1 or 2 nitrogen ring atoms and 1, 2, 3, or 4 R 6 optionally replaced by R 1 1, 2, 3, or 4 R 6 is a heterocycloalkyl containing one nitrogen ring atom, optionally substituted with R 2 is hydrogen, C 1-7 Alkyl, or C 3-8 is cycloalkyl, R 3 But, C 1-7 Alkyl, OR 5 , N(R 5 ) 2 , C 3-8 cycloalkyl, or heterocycloalkyl; R 4 is a bicyclic 9-membered heteroaryl containing 2, 3, or 4 heteroatoms independently selected from N and O; R 4 1, 2, or 3 R 7 optionally replaced by Each R 5 But independently, C 1-7 Alkyl, C 1-7 Haloalkyl, C 3-8 cycloalkyl, or heterocycloalkyl; Each R 6 are independently hydroxy, halogen, C 1-7 Alkyl, -(CH 2 ) 0-3 -NR a R b , C 1-7 Heteroalkyl, -(CH 2 ) 0-3 -C 3-8 Cycloalkyl, -NR'-(CH 2 ) 0-3 -C 3-8 Cycloalkyl, -(CH 2 ) 0-3 -heterocycloalkyl, -C(O)-heterocycloalkyl, or -O-heterocycloalkyl, where alkyl is selected from 1 to 4 independently selected halogen, OH, or C 1-7 cycloalkyl and heterocycloalkyl are optionally substituted with 1 to 4 independently selected C 1-7 optionally substituted with alkyl, halogen, or OH; Or two R's 6 together to form an oxo (=O) or Or two R's 6 Together, C 1-7 forming an alkylene to form a ring, Each R' is hydrogen or C 1-7 is alkyl, Each R 7 But independently, Halo, C 1-7 Alkyl, C 1-7 Haloalkyl, C 1-7 Alkoxy, or C 1-7 is haloalkoxy; Each R a However, independently, H, C 1-7 Alkyl, C 1-7 Haloalkyl, or C 3-8 is cycloalkyl, Each R b However, independently, H, C 1-7 Alkyl, C 1-7 Haloalkyl, or C 3-8 The compound, or a pharma- ceutically acceptable salt, solvate, or prodrug thereof, wherein: R is cycloalkyl;
3. The compound is a compound of formula (Ia) [C3] 3. The compound of claim 1 or 2, which is: or a pharma- ceutically acceptable salt, solvate, or prodrug thereof.
4. 4. The compound of claim 3, wherein A is a saturated or partially unsaturated monocyclic or bicyclic 4-11 membered nitrogen-containing heterocycloalkyl, and A is bonded through the nitrogen of said heterocycloalkyl.
5. The compound is a compound of formula (Ib) [C4] 3. The compound of claim 1 or 2, which is: or a pharma- ceutically acceptable salt, solvate, or prodrug thereof.
6. 6. The compound of claim 5, wherein A is a saturated or partially unsaturated monocyclic or bicyclic 4-11 membered nitrogen-containing heterocycloalkyl, and A is bonded through the nitrogen of said heterocycloalkyl.
7. The compound is a compound of formula (Ic) [C5] 3. The compound of claim 1 or 2, which is: or a pharma- ceutically acceptable salt, solvate, or prodrug thereof.
8. 8. The compound of claim 7, wherein A is a saturated or partially unsaturated monocyclic or bicyclic 4-11 membered nitrogen-containing heterocycloalkyl, and A is bonded through the nitrogen of said heterocycloalkyl.
9. The compound is a compound of formula (Ic) [C6] 3. The compound of claim 1 or 2, which is: or a pharma- ceutically acceptable salt, solvate, or prodrug thereof.
10. 10. The compound of claim 9, wherein A is a saturated or partially unsaturated monocyclic or bicyclic 4-11 membered nitrogen-containing heterocycloalkyl, and A is bonded through the nitrogen of said heterocycloalkyl.
11. A is a 4-11 membered nitrogen-containing heterocycloalkyl containing 1 or 2 nitrogen ring atoms and 0-2 additional ring heteroatoms selected from O and S, and 1, 2, 3, or 4 R 6 optionally replaced by Each R 6 But independently, C 1-7 Alkyl, -(CH 2 ) 0-3 -NR a R b , C 3-8 Cycloalkyl, heterocycloalkyl, and / or two R 6 Together, C 1-7 forming an alkylene to form a ring, Each R a are independently H or C 1-7 is alkyl, Each R b are independently H or C 1-7 The compound according to any one of claims 1 to 10, which is alkyl.
12. Each R 6 But independently, C 1-7 alkyl, heterocycloalkyl, or two R 6 Together, C 1-7 The compound according to any one of claims 1 to 11, wherein the alkylenes are combined to form a ring.
13. Each R 6 are independently methyl, ethyl, isopropyl, methoxy-azetidinyl, or pyrrolidinyl, or two R 6 The compound according to any one of claims 1 to 12, wherein together they form an ethylene or propylene ring.
14. Each R 6 are independently -(CH 2 ) 0-3 -NR a R b The compound according to any one of claims 1 to 13,
15. R a is H, and R b But, C 1-7 The compound according to any one of claims 1 to 14, which is alkyl.
16. R a and R b Each independently, C 1-7 The compound according to any one of claims 1 to 14, which is alkyl.
17. R a and R b The compound of any one of claims 1 to 14, wherein each is independently H.
18. R 6 is -NH(CH 3 ), -N(CH 3 ) 2 , -NH(CH 2 CH 3 ), -CH 2 NH (CH 3 ), or -CH 2 N (CH 3 ) 2 The compound according to any one of claims 1 to 17,
19. R 6 is -NH(CH 3 19. The compound according to any one of claims 1 to 18, wherein
20. R 6 But -N(CH 3 ) 2 The compound according to any one of claims 1 to 18,
21. R 6 is -NH(CH 2 CH 319. The compound according to any one of claims 1 to 18, wherein
22. R 6 But -CH 2 NH (CH 3 19. The compound according to any one of claims 1 to 18, wherein
23. R 6 But -CH 2 N (CH 3 ) 2 The compound according to any one of claims 1 to 18,
24. A, [C7] and Y is absent, N or CH; R 9 is hydrogen, C 1-7 Alkyl, or (CH 2 ) m -NR 14 R 15 and R 10 is optionally substituted with hydrogen or one or more halo 1-7 is alkyl, R 11 is optionally substituted with hydrogen or one or more halo 1-7 is alkyl, R 12 is optionally substituted with hydrogen or one or more halo 1-7 is alkyl, R 13 is optionally substituted with hydrogen or one or more halo 1-7 is alkyl, Each R 14 and R 15 are independently hydrogen, C 1-7 Alkyl, and C 3-8 is cycloalkyl, n is 0, 1, or 2; m is 0, 1, or 2; Or R 9 and R 10Together, C 1-7 forming an alkylene to form a ring, or Or R 9 and R 12 Together, C 1-7 forming an alkylene to form a ring, or Or R 10 and R 11 Together, C 2-7 Forming an alkylene ring, or 1-7 forming a 4-6 membered heterocycloalkyl optionally substituted with alkyl; Or R 10 and R 12 Together, C 1-7 Forming an alkylene ring, or 1-7 forming a 4-6 membered heterocycloalkyl optionally substituted with alkyl; Or R 10 and R 14 Together, C 1-7 forming an alkylene to form a ring, or Or R 12 and R 13 Together, C 2-7 forming an alkylene to form a ring, or Or R 12 and R 14 Together, C 1-7 forming an alkylene to form a ring, or Or R 14 and R 15 Together, C 2-7 The compound according to any one of claims 1 to 23, wherein the alkylenes are combined to form a ring.
25. 25. The compound of claim 24, wherein Y is N.
26. Y is CH and R 9 However, (CH 2 ) m -NR 14 R 15 25. The compound of claim 24, wherein
27. R 9 is -NH(CH 3 ), -N(CH 3 ) 2 , -NH(CH 2 CH 3 ), -CH 2 NH (CH 3 ), or -CH 2 N (CH 3 ) 2 The compound according to any one of claims 24 to 26,
28. The compound according to any one of claims 24 to 27, wherein n is 1.
29. R 9 The compound of any one of claims 24 to 28, wherein is hydrogen, pyrrolidinyl, or methoxy-azetidinyl.
30. R 10 The compound according to any one of claims 24 to 29, wherein is hydrogen, methyl, ethyl, or isopropyl.
31. R 11 The compound according to any one of claims 24 to 30, wherein is hydrogen or methyl.
32. R 12 The compound according to any one of claims 24 to 31, wherein is hydrogen or methyl.
33. R 13 The compound according to any one of claims 24 to 32, wherein is hydrogen.
34. R 9 and R 10 The compound according to any one of claims 24 to 33, wherein together they form a propylene ring.
35. R 10 and R 11 taken together to form an ethylene ring.
36. R 14 and R 15 taken together to form a propylene or butylene to form a ring.
37. A, [C8] Wherein R 9 , R 10 , R 11 , R 12 , and R 13 is as defined in any one of the preceding claims, and each R 16 are independently hydrogen or C 1-7 alkyl, each p is 0, 1, or 2, each o is 0, 1, or 2, and each A is one or two R 6 37. The compound of any one of claims 1 to 36, optionally substituted with:
38. A, [C9] Wherein R 9 , R 10 , R 11 , R 12 , and R 13 is as defined in any one of the preceding claims, and each R 16 are independently hydrogen or C 1-7 alkyl, each p is 0, 1, or 2, each o is 0, 1, or 2, and each A is one or two R 6 37. The compound of any one of claims 1 to 36, optionally substituted with:
39. A is piperazinyl, diazepanyl, octahydropyrrolopyrazinyl, diazaspirooctanyl, pyrrolidinyl, octahydropyrrolopyrroyl, diazaspirononanyl, diazaspiroheptanyl, or diazabicyclooctanyl, and piperazinyl, diazepanyl, octahydropyrrolopyrazinyl, diazaspirooctanyl, pyrrolidinyl, octahydropyrrolopyrroyl, diazaspirononanyl, diazaspiroheptanyl, or diazabicyclooctanyl each independently represents one, two, three, or four R 6 37. The compound of any one of claims 1 to 36, optionally substituted with:
40. A is NR 1 R 2 The compound according to any one of claims 1 to 36,
41. A, [C10] The compound according to any one of claims 1 to 36,
42. A, [C11] The compound according to any one of claims 1 to 36,
43. A, [C12] The compound according to any one of claims 1 to 36,
44. R 3 But, OR 5 The compound according to any one of claims 1 to 43,
45. R 3 The compound of any one of claims 1 to 43, wherein is methoxy, ethoxy, or n-propoxy.
46. R 3 The compound according to any one of claims 1 to 43, wherein is methoxy.
47. R 3 The compound according to any one of claims 1 to 43, wherein is ethoxy.
48. R 4 is a bicyclic 9-membered heteroaryl containing two heteroatoms independently selected from N and O; R 4 1, 2, or 3 R 7 48. The compound of any one of claims 1 to 47, optionally substituted with:
49. R 4 is a bicyclic 9-membered heteroaryl containing two heteroatoms independently selected from N and O; R 4 , 1 or 2 R 7 48. The compound of any one of claims 1 to 47, substituted with:
50. R 4 but, [C13] The compound according to any one of claims 1 to 47,
51. R 4 but, [C14] The compound according to any one of claims 1 to 47,
52. R 4 but, [C15] The compound according to any one of claims 1 to 47,
53. R 4 is selected from imidazo[1,2-a]pyrazine, benzo[d]oxazole, or imidazo[1,2-a]pyrazine, each of which has 1, 2, 3, or 4 R 7 48. The compound of any one of claims 1 to 47, optionally substituted with
54. R 4 but, [C16] The compound according to any one of claims 1 to 52,
55. R 4 but, [C17] The compound according to any one of claims 1 to 52,
56. R 4 but, [C18] The compound according to any one of claims 1 to 55,
57. 57. The compound according to any one of claims 1 to 56, selected from the compounds in Table 1.
58. 60. A compound according to any one of claims 1 to 57, or a pharma- ceutically acceptable salt, solvate, or prodrug thereof, for use as a small molecule splicing modulator.
59. 60. A pharmaceutical composition comprising a compound according to any one of claims 1 to 58, or a pharma- ceutically acceptable salt, solvate, or prodrug thereof, and one or more pharma- ceutically acceptable excipients.
60. 60. A method for treating a disorder associated with a nucleotide repeat expansion, comprising administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 58 or a pharmaceutical composition according to claim 59.
61. 61. The method of claim 60, wherein the nucleotide repeat expansion comprises a nucleotide sequence that is repeated two or more times, the nucleotide sequence being selected from the group consisting of CAG, CAG / CTG, GCG, GCN, CGG, CCG, CCCCGCCCCGCG, GCA, GGGGCC, CTG, GAA, ATTCT, TGGAA, GGCCTG, AAGGG, CCCTCT, ATTTT / ATTTC, and CCCTCT.
62. 61. The method of claim 60, wherein the nucleotide repeat expansion comprises a trinucleotide sequence that is repeated two or more times, and the trinucleotide sequence is selected from the group consisting of CAG, CTG, CGG, and GCN.
63. A method of treating a disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound according to any one of claims 1 to 58 or a pharmaceutical composition according to claim 59, wherein the disease is selected from the group consisting of dentatorubral-pallidoluysian atrophy, Huntington's disease, spinal-bulbar muscular atrophy, SCA1 (Spinocerebellar ataxia type 1), SCA2 (Spinocerebellar ataxia type 2), SCA3 (Spinocerebellar ataxia type 3 or Machado-Joseph disease), SCA6 (Spinocerebellar ataxia type 6), SCA7 (Spinocerebellar ataxia type 7), SCA12 (Spinocerebellar ataxia type 8), SCA13 (Spinocerebellar ataxia type 9), SCA14 (Spinocerebellar ataxia type 14), SCA15 (Spinocerebellar ataxia type 15), SCA16 (Spinocerebellar ataxia type 16), SCA17 (Spinocerebellar ataxia type 17), SCA18 (Spinocerebellar ataxia type 19), SCA19 (Spinocerebellar ataxia type 21), SCA20 (Spinocerebellar ataxia type 22), SCA21 (Spinocerebellar ataxia type 23), SCA22 (Spinocerebellar ataxia type 24), SCA23 (Spinocerebellar ataxia type 25), SCA24 (Spinocerebellar ataxia type 26), SCA25 (Spinocerebellar ataxia type 27), SCA26 (Spinocerebellar ataxia type 28), SCA27 (Spinocerebellar ataxia type 29), SCA28 (Spinocerebellar ataxia type 29), S ataxia type 12), SCA17 (spinocerebellar ataxia type 17), FRAXA (fragile X syndrome), FXTAS (fragile X-associated tremor / ataxia syndrome), FRAXE (fragile XE mental retardation), Baratela-Scott syndrome, FRDA (Friedreich ataxia), DM1 (myotonic dystrophy type 1), DM2 (myotonic dystrophy type 2), SCA8 (spinocerebellar ataxia type 8), Fuchs endothelial corneal dystrophy, Desbuquois dysplasia, amyotrophic lateral sclerosis, and frontotemporal dementia.
64. 60. A method of treating a disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1 to 58 or a pharmaceutical composition of claim 59, wherein the disease is Huntington's disease.
65. 60. A method of treating a disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound according to any one of claims 1 to 58 or a pharmaceutical composition according to claim 59, wherein the disease is myotonic dystrophy.
66. 60. A method of treating a disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound according to any one of claims 1 to 58 or a pharmaceutical composition according to claim 59, wherein the disease is FRAXA (Fragile X syndrome), FXTAS (Fragile X-associated tremor / ataxia syndrome), or FRAXE (Fragile XE mental retardation).
